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ABSTRACT 
To prevent further incidences of human immunodeficiency virus type 1 (HIV-1), pre-exposure 
prophylaxis (PrEP) is effective at inhibiting infection in high-risk populations; however, PrEP 
efficacy is correlated with adherence. Currently, the only approved PrEP regimen requires taking 
daily pills. To improve adherence, rilpivirine (RPV), a non-nucleoside reverse transcriptase 
inhibitor approved for antiretroviral therapy, has been developed into an injectable long-acting 
nanoparticle formula (RPV LA). RPV LA provides a depot of drug for sustained release and 
monthly dosing instead of daily pills. A concern with using approved antiretroviral drugs for 
both therapy and PrEP is the selection of drug-resistant mutations that may confer cross-
resistance to multiple drugs. This issue has public health relevance, as individuals with cross-
resistant mutations will have limited therapy options and could transmit drug-resistant virus to 
others. To study HIV-1 resistance to RPV in the context of PrEP, we treated macaques and 
humanized mice with RPV LA and characterized selection of drug-resistant virus and the ability 
to prevent mucosal transmission of drug-resistant HIV-1, respectively. We found that RPV LA 
monotherapy in macaques selected for transient low-level RPV-resistant mutations. We also 
found that RPV LA prevented vaginal transmission of HIV-1 with low- but not high-level 
resistance in a concentration dependent manner. Similar to macaques, we found no evidence of 
consistent resistance selection in breakthrough infections in mice. Together, these animal models 
HIV-1 RESISTANCE TO RILPIVIRINE IN THE CONTEXT OF PRE-EXPOSURE 
PROPHYLAXIS 
 
Kevin Patrick Melody, PhD 
University of Pittsburgh, 2017
 
v 
indicate the risk of resistance selection by RPV LA is low; however, the in vivo protective 
concentration of RPV LA should be better defined before Phase 3 clinical trials to measure 
efficacy. To counter HIV-1 drug resistance, new antiretroviral compounds must be developed. 
We studied three experimental RPV analogs and found that one compound selected for a novel 
combination of two mutations in reverse transcriptase. Together the mutations conferred cross-
resistance to all approved NNRTIs; however, hypersusceptibility to several non-NNRTI drugs 
was observed. This indicates that the analog has a novel interaction with HIV-1 reverse 
transcriptase that could be exploited to design better antiretroviral compounds.  
vi 
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1.0  INTRODUCTION 
It is estimated that 36.7 million people are infected by human immunodeficiency virus type 1 
(HIV-1), with 2.1 million new infections occurring in 2015 (1). Since the discovery of HIV-1, 
the World Health Organization (WHO) estimates that over 70 million infections and 35 million 
deaths can be attributed to the virus (2). HIV-1 was discovered and named in the 1980s after 
healthy young adult men became sick and died from opportunistic infections typically controlled 
by a normal immune system (3-8). This condition is acquired immunodeficiency syndrome 
(AIDS) and is defined by a HIV-1 infection plus cluster of differentiation 4 (CD4) positive cell 
counts of less than 200 cells/μl of blood and/or the presence of opportunistic infections including 
but not limited to pneumocystis pneumonia, tuberculosis, or Kaposi sarcoma (9). HIV-1 is a 
human-specific lentivirus that is transmitted via blood-to-blood contact (needle sharing, 
transfusions, or birth) or exposure to body fluids (genital secretions, breast feeding) with the 
primary transmission route being sexual intercourse (10). There is no cure for HIV-1, and 
individuals who become infected require life-long combination antiretroviral therapy (ART) to 
suppress virus replication, else untreated HIV-1 infection predominantly leads to AIDS. 
There is also no approved vaccine to prevent HIV-1 infection because Phase III clinical 
trials have failed to demonstrate efficacy (11, 12) or showed modest protection (13), the 
correlates of which are still being explored to improve future vaccination strategies. In the 
absence of a vaccine, pre-exposure prophylaxis (PrEP) with United States (US) Food and Drug 
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Administration (FDA)-approved antiretroviral drugs is shown to be effective at preventing HIV-
1 infection (Table 1). Currently, the only approved PrEP is daily oral Truvada, a co-formulated 
pill of the FDA-approved antiretroviral drugs emtricitabine (FTC) and tenofovir (TFV); 
however, global approval of Truvada is limited. Despite the significant reductions in HIV-1 
infections reported in Truvada groups in most PrEP studies, the biggest barrier to efficacy is 
adherence, as highlighted by lack of protection in study participants not taking their pills in two 
clinical trials (14, 15).  
To improve PrEP adherence, rilpivirine (RPV), an antiretroviral drug approved for ART, 
was formulated into a long-acting injectable nanoparticle formulation. Long-acting injectable 
drugs administered by healthcare providers eliminate daily dosing and allow for accurate 
adherence monitoring. Despite the benefits of injectable PrEP, employing the same antiretroviral 
drugs (i.e., Truvada or RPV) for both ART and PrEP raises concerns for development or 
transmission of drug-resistant HIV-1 isolates in newly infected individuals on PrEP. 
Consequently, drug-resistant HIV-1 can limit future therapy options as mutations may confer 
cross-resistance to other drugs within the same class (16).  
To assess the concern of HIV-1 cross-resistance from PrEP, the theme of this dissertation 
is to understand the effects of HIV-1 resistance to RPV, either long-acting RPV (RPV LA) or 
novel RPV analogs. Specifically, in vivo models were employed to study the development of 
drug resistance and inhibition of HIV-1 transmission by RPV LA, while cell cultures were used 
to determine the genotypic and phenotypic resistance profiles of novel RPV analogs. This 
research aims to bridge the knowledge gap between in vitro and in vivo systems to guide future 
work in HIV-1 prophylaxis.  
  
  3 
Table 1. Clinical trials with FDA-approved antiretroviral drugs for HIV-1 PrEP 
Trial name Study 
population 
Study design Risk reduction in 
intent-to-treat 
population 
Risk reduction 
in adherent 
population 
Ref. 
iPrEx MSM, 
transgender 
women 
daily oral 
FTC/TFV or 
placebo 
44% 92% (17) 
      
CAPRISA 
004 
Women intercourse-
dependent TFV 
gel or placebo 
39% 54% (18) 
      
FEM-PrEP Women daily oral 
FTC/TFV or 
placebo 
No reduction Failure due to 
<40% 
adherence 
(14) 
      
Partners 
PrEP 
Serodiscordant 
couples 
daily oral TFV, 
FTC/TFV, or 
placebo 
67% (TFV) 
75% (FTC/TFV) 
86% (TFV) 
90% 
(FTC/TFV) 
(19) 
      
TDF2 Serodiscordant 
couples 
daily oral 
FTC/TFV or 
placebo 
62% 78% 
 
(20) 
      
Bangkok 
Tenofovir 
Study 
IDU daily oral TFV 
or placebo 
48.9% 74% (21) 
      
VOICE Women daily oral TFV, 
FTC/TFV, or 
placebo,  
TFV gel or 
placebo gel 
-49% (TFV pill) 
-4% (FTC/TFV pill) 
15% (TFV gel) 
Failure due to 
<30% 
adherence 
(15) 
      
iPERGAY MSM intercourse-
dependent oral 
FTC/TFV or 
placebo 
82% Not reported (22) 
      
PROUD MSM daily oral 
FTC/TFV 
immediate or 
delayed 
86% (immediate) Not Reported (23) 
IDU, injection drug users; MSM, men who have sex with men; FTC, emtricitabine; TFV, 
tenofovir 
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1.1 HIV-1, DRUGS, AND RESISTANCE 
HIV-1 is a lentivirus of the Retroviridae family and has a positive sense, single-stranded 
ribonucleic acid (RNA) genome. As a retrovirus, HIV-1 enters a cell, reverse transcribes its RNA 
genome into double-stranded deoxyribonucleic acid (DNA), and then integrates its DNA into the 
host cell genome to complete the infection cycle. In addition, host cell transcription and 
translation of the integrated viral DNA is essential for production of new virions. HIV-1 
antiretroviral drugs target various stages of the HIV-1 cycle to block infection and production of 
new virus; however, HIV-1 replication is an error-prone process that can lead to mutations that 
confer drug resistance, which abrogates ART usefulness.  
1.1.1 The HIV-1 replication cycle  
The HIV-1 genome consists of nine genes contained within approximately 1x104 bases of RNA 
that codes for structural, enzymatic, envelope, and accessory proteins essential to infection, 
replication, and pathogenesis (Figure 1). HIV-1 begins its infection cycle when the virus binds to 
a receptor on a target cell via viral envelope (Env) proteins. Glycosylated Env proteins 
(consisting of gp120 and gp41 subunits) on the virion bind to CD4 molecules (24-26), the 
primary receptor of HIV-1 that can be found on T cells, monocytes, macrophages, and dendritic 
cells. Interaction of gp120 and CD4 results in the reconfiguration of variable loops in gp120 that 
also allows binding to target cell co-receptors (27), primarily the chemokine receptors C-C 
chemokine receptor type 5 (CCR5) or C-X-C chemokine receptor type 4 (CXCR4) (28-30). 
Conformation changes in gp120 from these host cell interactions exposes gp41, which facilitates 
fusion of the virus and target cell membranes and entry of the virus core into the target cell (31).  
  5 
 
Figure 1. The RNA genome of HIV-1. 
HIV-1 utilizes overlapping coding regions in three reading frames to minimize the size of its 
genome. HIV-1 has three genes, gag (blue), pol (yellow), and env (red) that code for 
polyproteins. Gag encodes the matrix (MA), capsid (CA), nucleocapsid (NC), and p6 proteins 
that form a protective layer around the genome and accessory proteins and guide the formation 
of new virions. The pol region codes for protease (PR), reverse transcriptase (RT), and integrase 
(IN), which are responsible for cleavage of polyproteins, transcription of viral RNA into DNA, 
and integration of viral DNA into the host genome, respectively. Env encodes the gp120 and 
gp41 proteins that create glycosylated heterotrimers necessary for host cell receptor binding and 
cell entry. Vif, Vpr, Vpu, Tat, Rev, and Nef are accessory proteins that modulate the host cell 
environment to counter antiviral defenses, activate transcription of viral DNA, and export viral 
RNA. The reading frames for this figure are based on the HIV-1NL4-BAL sequence. 
 
The virus core is composed of capsid proteins, encoded in the gag gene, that form a 
protective shell around the viral genome and enzymes (32-35). Upon entry into a host cell, the 
core will destabilize and shed capsid proteins in a process called uncoating that is important for 
viral infectivity (36, 37). The extent of uncoating between entry and integration is debated, but 
core destabilization begins early post-entry (38, 39) and reverse transcription occurs concurrently 
with uncoating (36, 37).  
A hallmark of retroviruses is reverse transcriptase (RT), which is the enzyme responsible 
for converting the viral single-stranded RNA genome into a double-stranded DNA genome using 
host cell deoxynucleoside triphosphates (dNTPs) (40, 41). HIV-1 RT is a heterodimeric enzyme 
made of two subunits, p66 and p51, where p51 is a truncated version of p66 and lacks the 
ribonuclease H domain (42-46). Synthesis of viral DNA (vDNA) occurs through the enzymatic 
activity of p66, while p51 provides structural stability (42, 47-49). Thus, RT possesses multiple 
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enzymatic functions for conversion of single-stranded RNA into single-stranded DNA (RNA-
dependent DNA polymerase), conversion of single-stranded DNA into double-stranded DNA 
(DNA-dependent DNA polymerase), and the removal of RNA bases from the RNA-DNA duplex 
(ribonuclease H) (42-46). Reverse transcription products are detectable in CD4+ T cells within 4 
hours post-infection with peak double-stranded DNA production after 12 hours (50). 
At the completion of reverse transcription, the reverse transcription complex will 
transition into a pre-integration complex (PIC). The PIC is composed of the newly reverse 
transcribed vDNA genome, capsid, integrase, and host cell nuclear import factors (51-53). After 
the PIC crosses the nuclear membrane, integrase performs 3’ endonuclease processing of the 
vDNA, bind the vDNA and host cell DNA, nick the host cell DNA, and catalyze the ligation of 
virus to host DNA (54, 55). Host enzymes repair the DNA gaps to create the provirus (56, 57), 
which is the stable integrated genome of the HIV-1 virus that is replicated by the host cell. 
Capsid is also associated with integration as studies show capsid-host factor interactions for 
targeting the integration of HIV-1 DNA to sites of active replication (58, 59), thus increasing the 
chances of transcription of HIV-1 genes. 
To produce new virions for continuation of the infection cycle, the HIV-1 provirus 
requires host cell polymerases to produce nascent genomic viral RNA (vRNA) and messenger 
RNA (mRNA). Host cell transcription factors bind to the 5’ long terminal repeat, the de facto 
promoter region of HIV-1, to begin transcription of the provirus (60-63). During early 
transcription, replication of the provirus is limited to the regulatory proteins Tat and Rev (64, 
65). Tat proteins bind to the transactivation-response (TAR) region (66-68) and recruits the 
positive transcription elongation factor complex to promote quick and efficient transcription of 
HIV-1 RNA products (69-72). Without the Tat-TAR interaction, HIV-1 transcription stalls early 
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in the genome (73). HIV-1 transcription involves the production of both spliced and unspliced 
RNA elements (74). Spliced products include mRNA for Tat, Rev, and Nef, and these transcripts 
are safely transported out of the nucleus through normal export channels. To avoid degradation 
by host cell enzymes, unspliced RNA, such as the nascent genome, gag, gag-pol, env, and some 
accessory proteins, requires the viral protein Rev for nuclear export. Rev binds to the Rev 
response element found in the Env coding region of unspliced vRNA (75-78) and interacts with 
nuclear pore proteins via a nuclear export signal for safe trafficking of the viral transcripts out of 
the nucleus and into the cytoplasm (79-81).  
 After translation of viral mRNA, HIV-1 proteins must coalesce at the cell membrane for 
proper virion formation and release from the host cell to complete the replication cycle. The Gag 
polyprotein consists of matrix, capsid, and nucleocapsid domains and recruits Env and binds the 
genomic vRNA. The Gag-Pol polyprotein contains the same domains along with the protease, 
RT, and integrase domains. Localization signals in the matrix domain target the transport of 
these polyproteins to the host cell membrane (82), and domains in nucleocapsid recognize and 
selectively bind HIV-1 genomic vRNA to ensure packaging of the correct RNA species (83, 84). 
Host cell granules deliver Env to the cell membrane in a less constitutive manor than Gag and 
Gag-Pol (85). At the host cell membrane, viral structural proteins multimerize at lipid rafts to 
begin the budding process (86-91). Immature virions made of viral proteins and host cell 
membrane moieties are released from the host cell through the action of host endosomal sorting 
complexes required for transport system (92). Within the nascent virion, viral protease cleaves 
Gag and Gag-Pol polyproteins to trigger conformation changes necessary for proper core 
formation and enzyme functions (33, 93-95), thus creating mature, infectious virions and 
completing the virus replication cycle (Figure 2). 
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Figure 2. Structure of a mature HIV-1 virion. 
Nucleocapsid (NC) forms a protective layer around the genome, while capsid (CA) forms a shell 
around the genome and viral enzymes (protease (PR), reverse transcriptase (RT), and integrase 
(IN)) and accessory proteins (Vpr, Vif, Vpu, and Nef) necessary for maturation and infection. 
Matrix (MA) binds to lipids in the host cell membrane, which become part of the virion 
membrane as the virus buds. Extracellular envelope proteins (gp120 and gp41) are anchored in 
the membrane for recognition of target cell receptors and membrane fusion for virus entry.  
 
 
Throughout the replication cycle, the host cell has a variety of antiviral defenses, but 
three specialized viral accessory proteins, Vif, Vpu, and Nef, aid in host cell immune evasion 
and increased pathogenesis. Vif is responsible for binding to apolipoprotein B mRNA editing 
enzyme catalytic polypeptide-like 3 (APOBEC3) enzymes and targeting them to cellular 
ubiquitin ligases for destruction (96). APOBEC3 proteins are RNA editing enzymes from the 
APOBEC cytidine deaminase family and can be packaged into virions during nascent virus 
formation (97). The enzymes deaminate deoxycytidine to create deoxyuridine during first-strand 
complementary DNA (cDNA) synthesis of reverse transcription, resulting in G-to-A 
hypermutations that are often lethal to the virus (98, 99). Vpu is a multi-functional protein that 1) 
binds to CD4 within the endoplasmic reticulum, thus leading to CD4 degradation via 
proteasomes and allowing proper processing of Env (100-103) and 2) allows virion budding by 
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antagonizing tetherin, a protein that binds to the virus membrane to prevent release from the host 
cell (104-107). The third accessory protein, Nef, is also multi-functional. It induces surface CD4 
endocytosis by binding to a cytoplasmic domain on CD4 and targeting it for degradation (108, 
109). Nef also causes the endocytosis and lysosomal breakdown of MHC class I and class II 
molecules (110-113), which prevents proper cytotoxic T cell response to infected cells (114) and 
potentially interferes with antigen presentation and helper T cell stimulation (112), respectively. 
Additionally, Nef removes SERINC3 and SERINC5 proteins from the cell surface to prevent 
these molecules from incorporating into virions and inhibiting fusion (115, 116). The loss of any 
of these accessory proteins diminishes HIV-1 pathogenesis in vivo (111, 117-119). 
1.1.2 HIV-1 pathogenesis 
The primary targets of HIV-1 infection are CD4+ T cells, which have an essential role in host 
adaptive immunity. There are a variety of CD4+ T cells with distinct functions differentiated by 
gene expression and cytokine release; however, the overall purpose of these cells is to regulate 
the adaptive immune response to protect the host from foreign bodies, including viruses. HIV-1 
targets these cells through their cell surface expression of CD4 and the chemokine co-receptors, 
CCR5 and CXCR4, as discussed above. While HIV-1 mainly targets CD4+ T cells, the virus can 
also productively infect macrophages and dendritic cells (120-126), which also express CD4 
(127). Subsequent infection and long-term loss of immune cells serve to deregulate the host 
immune system and can lead to infection by opportunistic pathogens and the development of 
AIDS.  
Infection of the host begins with transmission of HIV-1. The primary route of infection is 
through sexual contact, mainly the female and male genital tracts, and rates of transmission vary 
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depending on exposure route (10). It is estimated that <1% of HIV-1 exposure events in the 
female or male genital tract lead to an infection, but probability of rectal transmission is 
estimated as high as 5% due to differences in cell layers and microenvironment (10). Because 
HIV-1 is a bloodborne pathogen, transmission probabilities are highest for direct blood contact 
and range from 5-20% or 0.6-95% during pregnancy/birth and direct blood exposure (needles or 
transfusion), respectively (10). Initial infection is usually attributed to a single founder virus 
(128-133). However, multiple isolates can infect an individual at one time and may be dependent 
on virus inoculum, exposure route, and host environment factors (134-139). For mucosal 
transmission, activated CCR5+ CD4+ T cells are the initial targets of HIV-1 infection (133, 137, 
140-145) and are found in high numbers at mucosal exposure sites (146-150), including the gut-
associated lymphoid tissue (GALT), which is the largest reservoir of lymphocytes in the human 
body (151). It is proposed that a specific subset of pro-inflammatory CD4+ cells, called Th17 
helper cells, are the first T cells infected by HIV-1 (152-155). In time, HIV-1 evolves the ability 
to also target CXCR4-expressing T cells, which is linked to increased infectivity and 
pathogenicity (156-158). Although, macrophages and dendritic cells can be infected by HIV-1, 
they are not considered major players during transmission and acute infection (143, 145). Newly 
infected cells migrate to target-rich lymph tissues (e.g. lymph nodes (LN)) where the virus can 
be further disseminated (159), thus exponentially increasing the number of infected cells.  
Migration of HIV-1+ cells from the site of exposure can lead to systemic spread of the 
infection, setting off the events that lead to AIDS (Figure 3). Plasma viremia reaches a peak 
approximately three weeks post-infection and is followed by a drop to a viral set-point as the 
adaptive immune system responds to counter virus replication (160-162). The period of 
seroconversion and establishment of a viral set-point is known as clinical latency, where an 
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individual is asymptomatic but the virus is replicating and transmissible to others, and can last 
for years. The viral set-point is a near steady longitudinal concentration of detectable vRNA 
copies in the plasma, and higher plasma viremia is associated with clinical progression to AIDS 
(163-167). However, viremia is not an absolute predictor (168) and progression to AIDS is a 
long-term multifactorial event involving viremia, immune response, and CD4+ lymphocyte 
maintenance (163, 165, 166, 169-172). Early signs of HIV-1 infection can be asymptomatic or 
manifest as a range from general malaise and flu-like symptoms to rashes and unexplained 
weight loss usually within 4 weeks of infection (9). However, the pathogenic hallmark of HIV-1 
infection is the systemic depletion of CD4+ T cells (3-5, 173), particularly in the GALT (174, 
175), that leads to disruption of immune homeostasis. This depletion of immune cells is a result 
of cytotoxicity from HIV-1 production (173), apoptosis or pyroptosis of infected and uninfected 
neighboring cells (176, 177), and killing of infected cells by cytotoxic immune cells, such as 
cluster of differentiation 8 (CD8) positive T cells and natural killer (NK) cells (178, 179). 
Damage to the gut epithelial barrier caused by HIV-1 infection and T cell loss leads to microbial 
translocation (180-182), and the systemic spread of gut microbe products that further perturb the 
immune system and cause pathogenicity (183-185). HIV-1 infection is also associated with 
progressive neurocognitive decline associated with infected macrophages (186-189) and brain 
atrophy from inflammation and damage to glial cells (190).  
HIV-1 is constantly evolving to escape cytotoxic lymphocyte and antibody pressure (191-
197), and will eventually cause enough systemic damage to create an immunocompromised 
environment ideal for invasion by opportunistic pathogens that are normally controlled by a 
healthy immune system. Such opportunistic infections that led to the discovery of AIDS include 
Pneumocystis jiroveci (formerly P. carinii) pneumonia, chronic herpes lesions, and Kaposi’s 
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sarcoma (3-5). Most HIV-1+ individuals will progress to AIDS in approximately 10 years after 
infection (198) unless they adhere to an ART regimen that successfully suppresses viremia. ART 
can significantly delay the onset of AIDS and increases life expectancy of HIV-1+ persons (199). 
 
Figure 3. Progression of HIV-1 pathogenesis. 
HIV-1 viremia (red) peaks within weeks of infection. During this primary infection, CCR5+CD4+ 
cells are preferentially depleted (blue line) but partially rebound as immune functions develop to 
suppress viremia. The viral set-point and clinical latency occur through a balance of virus 
replication and immune function. Without ART to suppress viral replication, CD4+ cells will 
continuously decline due to virus replication until the immune system is compromised to the 
point that opportunistic infections occur and lead to mortality. Throughout infection, HIV-1 
mutates to escape immune pressure and can develop affinity for CXCR4+CD4+ T cells, which is 
associated with increased pathogenicity. Figure reproduced and adapted with permission from 
Pantaleo et al. 1993 (200), © Massachusetts Medical Society, and Facui & Desrosiers 1997 and 
Swanstrom & Coffin 2012 (201, 202), © Cold Spring Harbor Press. 
 
 
Only one person has been cured of HIV-1. The Berlin patient (named because of the 
location of successful treatment) was treated with multiple rounds of chemotherapy for acute 
myeloid leukemia and received an allogeneic stem-cell transplant with donor tissue screened for 
the HIV-1-resistant delta32 CCR5 allele (203). This allele contains a 32-base pair deletion that 
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results in a non-functioning CCR5 co-receptor that inhibits cell entry and infection by CCR5-
tropic HIV-1 isolates and delays progression to AIDS (204-206). To date, the Berlin patient has 
undetectable HIV-1 in the absence of ART; however, this success has not been recapitulated in 
other persons (207) and is not feasible on a global scale. Until a practical cure is discovered, it is 
crucial to block the HIV-1 infection cycle with ART for HIV-1+ individuals and promote 
effective prophylactic methods to prevent transmission of HIV-1 to uninfected individuals. 
1.1.3 HIV-1 antiretroviral therapy 
Disruption of any of the steps in the HIV-1 replication cycle can reduce or abolish infection. 
Because HIV-1 RT, integrase, and protease are not expressed in host cells, these enzymes 
essential to virus replication are ideal targets for antiretroviral drugs. Currently, there are 25 
FDA-approved drugs that target four steps of the HIV-1 infection cycle (Figure 4): entry, reverse 
transcription, integration, and protease cleavage. Most of these drugs directly bind to their target 
HIV-1 protein to inhibit proper function.  
There are two FDA-approved drugs for inhibiting HIV-1 cell entry, enfuvirtide (T-20) 
and maraviroc (MVC). T-20 is a 36 amino acid peptide that interacts with the gp41 subunit of 
HIV-1 Env to prevent fusion of the virus and host cell membranes (208, 209). Alternatively, 
MVC binds to host cell CCR5 proteins and inhibits gp120 binding; however, the drug is not 
effective against HIV-1 isolates with CXCR4 tropism (210). MVC is the only FDA-approved 
HIV-1 drug that targets a non-viral protein. Although both drugs were effective in clinical trials 
(211, 212); they are not recommended for first-line ART because T-20 requires twice daily 
injections and is the most expensive therapy, while MVC also requires twice-daily dosing and 
tropism testing (213). 
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Figure 4. FDA-approved antiretroviral drugs and their targets. 
Twenty-five drugs that inhibit five steps of the HIV-1 infection cycle are clinically available for 
the treatment of HIV-1+ individuals. 
 
The most commonly prescribed drugs for ART include two classes of RT inhibitors 
known as nucleoside reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse 
transcriptase inhibitors (NNRTI). While both drugs target the same step of the HIV-1 infection 
cycle, their mechanisms of action are distinct. NRTIs were the first drug class approved for HIV-
1+ individuals, and they work by resembling dNTPs but lack a 3’ hydroxyl group necessary for 
DNA elongation. These drugs are phosphorylated within a cell and compete with natural dNTPs 
for insertion into nascent DNA strands by RT, thus NRTIs are competitive inhibitors and their 
incorporation results in DNA chain termination and abortive reverse transcription products (214, 
215). Conversely, NNRTIs are allosteric inhibitors that hinder RT function by binding directly to 
RT but not in an active site. These drugs bind with high specificity to a hydrophobic region in 
HIV-1 RT known as the NNRTI-binding pocket, which is approximately 10 angstroms from the 
RT polymerase active site (49, 216-218). NNRTIs cause a structural shift in RT that affects the 
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alignment of the primer terminus and the polymerase active site, thus inhibiting the chemical 
step of nucleotide transfer (219-221). A dual combination of NRTIs (abacavir and lamivudine or 
FTC and TFV) forms the backbone for all first-line and most alternative recommended ART 
regimens in the US (213); however, the NNRTIs efavirenz (EFV) and RPV are reserved for 
alternative first-line options because of central nervous system side effects (EFV), reduced 
efficacy based on dose (RPV), single mutation resistance profiles (both), and increasing 
prevalence of resistance mutations within HIV-1+ populations (both) (213).  
 Integrase inhibitors are the newest class of drugs approved by the FDA for ART. There 
are three clinically available integrase inhibitors that bind directly to the enzyme to prevent 
strand transfer of the viral genome to the host DNA (222, 223). An advantage of integrase 
inhibitors over RT inhibitors is the larger window of time for them to be transported into a cell to 
be effective, as integration does not begin until approximately 8 hours post-entry (50). However, 
these drugs are only functional after integrase complexes with HIV-1 DNA (222). Due to the 
potency and tolerability of integrase inhibitors, all three are recommended as first-line HIV-1 
therapy in combination with NRTIs in the US (213).  
The fourth and largest class of antiretroviral drugs is the protease inhibitors. These drugs 
bind to the catalytic domain of protease and prevent Gag and Gag-Pol polyprotein cleavage that 
is necessary for viral maturation and infectivity (94, 95). Most protease inhibitors have peptide-
like centers that allow direct interaction with the catalytic aspartic acid residues of HIV-1 
protease (224, 225). However, this class of antiretrovirals is only effective in cells where HIV-1 
has integrated and begun to produce new virions. Of the eight approved protease inhibitors, 
darunavir in combination with two NRTIs is recommend for first-line therapy, and atazanavir 
and lopinavir with two NRTIs are recommended for alternative starting regimens; however, 
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protease inhibitors require a booster drug, ritonavir, and tend to be more toxic than integrase and 
RT inhibitors (213).  
In 2015, WHO revised global guidelines on ART and now recommends that all HIV-1+ 
individuals should receive ART regardless of CD4+ cell counts (226). Previous guidelines 
recommended ART for all HIV-1+ children regardless of CD4 T cell count and adults with  <350 
CD4+ cells/ml or AIDS-related conditions because of improved development and less clinical 
events in children (227-230) and reduced mortality in adults (231). However, the new 
recommendations are based on more recent data that show reduction in transmission and better 
clinical outcomes if ART is started immediately rather than until AIDS occurs (232-236). These 
studies comparing early versus deferred ART showed significant reductions in HIV-1-related 
clinical events (232-236), a decrease in mortality (233, 234), and a 96% drop in transmission 
within serodiscordant couples (232, 237) in cohorts that received immediate ART. Thus, 
immediate therapy leads to earlier suppression of HIV-1 viremia and better conservation of the 
immune system, which results in reductions in transmission and adverse clinical events.   
1.1.4 HIV-1 resistance selection 
The HIV-1 replication cycle is a dynamic process that involves virus proteins as well as 
dependence on host cell factors that can each exert distinctive rates of mutagenesis. The high 
mutation and turnover rates of HIV-1 virions lead to genetic variation that can create drug-
resistant mutations (DRMs) within the viral quasispecies, the heterogeneous virus population 
detectable in each infected individual. DRMs can lead to HIV-1 replication in the presence of 
ART, thus causing therapy failure and increasing the probability of drug-resistant virus 
transmission (238).  
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To complete a replication cycle, HIV-1 requires RT to transcribe viral genomic RNA to 
DNA, and host RNA polymerase II (Pol II) to synthesize proviral DNA into viral genomic and 
mRNA. The function of these two enzymes can introduce mutations into the HIV-1 genome. The 
mutation rate of RT in various biochemical and cell culture assays is estimated to range from 10-4 
to 10-6 bases per replication cycle (239-245). Mutations caused by RT arise from mismatched 
base substitutions, base deletions or insertions, and frameshift from enzyme slippage in 
homopolymeric regions (241, 242, 246, 247). HIV-1 RT lacks the proofreading capability to fix 
errors generated during reverse transcription (239, 240) and is considered the driving force 
behind HIV-1 mutagenesis (243, 246). The exact contribution of human RNA Pol II to HIV-1 
mutation rates is unknown, but RNA Pol II has proofreading capabilities suggesting its role in 
generating mutations would be significantly lower than RT (246, 248).  
Because an infectious HIV-1 virion contains two separate strands of RNA, there is 
potential for RT to produce mutations through genomic hybridization. Recombination of HIV-1 
genomes occurs via strand displacement during reverse transcription when RT switches from one 
RNA strand to another (249, 250). Should a cell be infected with multiple subtypes of HIV-1 
(discussed in the proceeding section), it is possible for nascent virions to package heterologous 
genomes that could recombine to create a novel infectious isolate referred to as a unique or 
circulating recombinant form (CRF) (251). High rates of recombination are described in cell 
lines (252, 253); however, in vitro recombination in primary T cells and macrophages is reported 
to average 1.5 and 6.2 events per 1,000 bases (245). The higher recombination rate in 
macrophages is attributed to lower dNTPs pools (254), which prompts increased DNA synthesis 
pausing, strand transfer efficiency, and template switching (255-257). Thus, HIV-1 RT 
influences HIV-1 evolution through infidelity and recombination.   
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As mentioned before, the APOBEC3 family of proteins can also contribute to HIV-1 
mutagenesis; however, controversy remains as to the contribution of APOBEC3-mediated viral 
mutagenesis to HIV-1 pathogenesis in humans (258, 259). If unimpeded, the direct contribution 
of APOBEC3 proteins to drug resistance is likely low due to the high mutation rates and 
tendency to generate replication incompetent virus (98, 99, 260). APOBEC3 proteins have been 
estimated to contribute 10- to 100-fold more mutations than RT (258), but the frequency of 
sublethal mutations is >6-log less than the mutation rate of RT (259). APOBEC3 activity can be 
reduced by interaction with Vif, thus decreasing the number of APOBEC3-driven mutations and 
replication-incompetent genomes (261). Hence, APOBEC3 proteins can influence HIV-1 
evolution. Interestingly, APOBEC3G activity was shown to prime the quasispecies for easier 
selection of the M184I RT resistance mutation through recombination (262); although, 
APOBEC3 hypermutations are not associated with increases in recombination rates (259). 
The most significant factor associated with HIV-1 evolution and DRM development is 
the high turnover rate of the virus. The production of new virions has been estimated to be 
approximately 1010 virions per day with half the plasma viral population turning over nearly 
every six hours (263). At its lowest estimated fidelity, RT could generate one base change per 
viral genome per replication cycle. Combined with the production rate of new virions, each base 
of the HIV-1 genome could change >10,000 times a day (264). Because of rapid mutation and 
high turnover rates, the virus quasispecies within an individual is estimated to be 3,000 
generations removed from its founding sequence after a decade (264). Thus, the longer an 
individual has unchecked virus replication, the larger the genetic variation and the greater the 
likelihood of developing DRMs, particularly in replication competent proviruses. 
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1.1.5 HIV-1 resistance and antiretroviral therapy 
HIV-1 can develop DRMs that reduce susceptibility to all approved antiretroviral drugs (16). 
Because antiretroviral drugs within the same class tend to bind to the same regions of their 
respective targets, DRMs reduce drug binding and can lead to cross-resistance of several or all 
drugs of the same class. Such cross-resistant patterns lead to limited therapy options in HIV-1+ 
individuals who acquire or develop these mutations through transmission or evolution, 
respectively. For example, single amino acid changes in the NNRTI-binding pocket such as 
K103N or G190S confer high-level resistance to both EFV and nevirapine (NVP) with no change 
in susceptibility to RPV or etravirine (ETR) (265). However, four mutations in RT, L100I, 
K101P, G190E, and M230L are considered to have clinically relevant resistance to all four FDA-
approved NNRTIs (16, 266). Similarly, mutations at positions T69 and Q151 in RT, or at Q148 
in integrase reduce the utility of all NRTIs and integrase inhibitors, respectively (16, 266). MVC 
is the exception in that HIV-1 can develop mutations to allow binding in the presence of the drug 
or evolve the preference for an alternative co-receptor (e.g. CXCR4) (267). 
Despite access to anti-HIV-1 drugs since the late 1980s, treatment failure due to 
replication of drug resistant virus was noted in individuals taking single drug regimens, or 
monotherapy (268-270). To prevent resistance selection, the current practice of combination 
ART (formerly referred to as HAART: Highly Active Antiretroviral Therapy) replaced 
monotherapy in 1996 as clinical data in individuals on a multi-drug regimen showed better 
viremia suppression (271-274), immune cell recovery (271-273, 275), and reduced resistance 
selection (272, 273, 276). Therefore, it is imperative that HIV-1+ individuals adhere to a lifetime 
regimen of three to four drugs from at least two antiretroviral drug classes for successful viremia 
suppression.  
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Because of its high mutation rate, decades of replication before the advent of ART, and 
global compartmentalization, HIV-1 group M has evolved into nine distinct subtypes and dozens 
of CRFs (277). CRFs are a result of infection by more than one HIV-1 subtype and genetic 
recombination that creates a virus with a mixed subtype genome (278-280). Nearly 50% of the 
global HIV-1+ population is infected with subtype C virus, predominantly in southern Africa and 
Middle East nations (281); however, the majority of antiretroviral drug development uses 
subtype B HIV-1, which is most prevalent in the US and Western Europe (281). This means the 
differences between subtypes may affect the global utility of antiretroviral drugs.  
Genetic drift and recombination can lead to polymorphisms, which are different amino 
acids that are prevalent at the same position within a population, and can influence drug 
resistance. Between subtypes, 53% of the entire protease and 48% of the first half of the RT 
coding region are polymorphic in untreated individuals (282). Although most DRMs are similar 
across subtypes (282), polymorphisms at positions associated with HIV-1 drug resistance could 
lead to suboptimal therapy in non-B dominant areas. For example, the E138A RT mutation is 
associated with RPV resistance (16, 265, 283) and is significantly more prevalent in untreated 
individuals infected with subtype C than subtype B virus (284). Consequently, RPV may not be 
as effective in areas where subtype C HIV-1 is prevalent, as using the drug could lead to 
treatment failure in individuals with the mutation.  
Despite the benefits of ART and increasing improvements in global ART coverage (1), 
there is a global increase in drug-resistant HIV-1 prevalence (285). Subsequently, geographic 
regions with higher treatment rates could see a shift towards drug-resistant polymorphisms if the 
drugs are not utilized properly. ART could lead to increased DRM prevalence by mutations from 
suboptimal therapy pressure and drug-resistant HIV-1 transmission to uninfected persons. Thus, 
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it is imperative to continually develop novel, potent, and safe drugs and therapy combinations 
that can counter HIV-1 with currently known DRMs and any unique resistant mutations that 
arise to future drugs.  
1.1.6 Rilpivirine 
RPV is a diarylpyrimidine small molecule that belongs to the NNRTI class of antiretroviral drugs 
(Figure 5) and was approved by the FDA for ART in 2011. RPV is the most potent FDA-       
approved NNRTI to date with in vitro effective concentrations to prevent 50% infection (EC50) 
ranging from 0.06-1.01 nM against primary and laboratory HIV-1 isolates and displays no loss of 
susceptibility against resistance mutations associated with the first generation NNRTIs, EFV and 
NVP (265, 286, 287). RPV potency is accredited to amino linker bonds, which provide flexibility 
to reposition the drug within the NNRTI-binding pocket, and the cyanovinyl group that binds a 
hydrophobic tunnel between the NNRTI-binding pocket and the dNTP-binding cleft (286, 288, 
289). The cyanovinyl group is unique to RPV and not found on the other clinically relevant 
diarylpyrimidines, ETR and dapivirine (DAP) (286).  
Results from clinical trials showed RPV to be non-inferior to EFV in reducing plasma 
viremia in HIV-1-infected participants on combination ART (290-293). However, RPV was 
tolerated better, caused significantly less side effects, and predominantly selected different 
resistance mutations than EFV (292-295). The selection of distinct resistance mutations without 
cross-resistance to EFV suggests that HIV-1+ individuals would be able to continue with 
NNRTIs as part of their ART regimen should DRMs develop to either drug. In the US, RPV in 
combination with Truvada is recommended as an alternative first-line ART regimen because of 
increased failure in individuals with plasma viremia >1x105 RNA copies/ml (213, 292). 
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Figure 5. Chemical structures of clinically relevant NNRTIs. 
EFV, NVP, ETR, and RPV are all FDA-approved NNRTIs for antiretroviral therapy. DAP and 
MIV-150 are not currently approved for clinical use. However, DAP formulated in an 
intravaginal ring is shown to protect against vaginal HIV-1 transmission. MIV-150 as part of a 
multi-functional vaginal gel for PrEP is in safety trials. 
 
1.1.7 HIV-1 resistance to RPV 
As previously discussed, HIV-1 can develop mutations that reduce the potency of antiretroviral 
drugs, some of which can confer cross-resistance to multiple compounds. Because all NNRTIs 
target the same hydrophobic region of RT (49, 216, 217, 286), DRMs within and around the 
NNRTI-binding pocket reduce the ability of the drug class to inhibit HIV-1 replication through a 
reduction in enzyme-drug interactions (296-302). The NNRTI-binding pocket is considered to 
encompass positions L100, K101, K103, V106, T107, V108, V179, Y181, Y188, V189, G190, 
F227, W229, L234, P236, and Y318 of p66 and E138 of p51 (49, 216), and clinically relevant 
mutations to FDA-approved NNRTIs include V90I, A98G, L100I, K101E/H/P, K103N/S, 
V106A/I/M, V108I, E138A/G/K/Q/R, V179D/F/L/T, Y181C/I/V, Y188C/H/L, G190A/S, 
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H221Y, P225H, F227C, M230I/L (16). For example, the more rigid first generation NNRTIs 
EFV and NVP predominantly have reduced ability to occupy the NNRTI-binding pocket in the 
presence of DRMs, such as K103N and Y181C. The K103N mutation in RT results in the 
formation of hydrogen bonds between N103 and Y188 and water molecules that 1) essentially 
block drug access to the NNRTI-binding pocket (296) or 2) result in less drastic conformation 
changes in drug-bound RT (297). In Y181C RT, NVP loses ring-stacking interactions in the 
mutant enzyme, which decreases binding affinity (298). However, the different side chain 
interactions and structural flexibility of RPV (and diarylpyrimidines) allows the drug to 
reposition within mutant RT and maintain inhibitory activity against viruses with DRMs that 
confer resistance to EFV and NVP (265, 286, 288).  
Although most NNRTI-associated resistance mutations require only one base change 
(303), RPV is considered to have a higher genetic barrier to resistance than first generation 
NNRTIs. The genetic barrier to resistance is defined as the number of mutations needed to confer 
resistance to a drug, and the decrease in drug susceptibility from a single amino acid mutation is 
less pronounced for RPV than EFV or NVP (265). For example, K103N is the dominant 
mutation selected in adults failing EFV and NVP therapy (304, 305), but is not selected by RPV 
and does not confer resistance (265, 306). RPV predominantly selects for E138K (265, 295, 
307). In an in vitro drug susceptibility assay, HIV-1 with K103N showed a >30-fold decrease in 
susceptibility to EFV and NVP, while E138K and many other drug-resistant HIV-1 clones 
showed an approximate 3-fold or less decrease in susceptibility to RPV (265). Theoretically, 
high enough concentrations of RPV should still suppress virus with DRMs conferring low-level 
resistance as opposed to EFV and NVP, which tend to select for resistance mutations that display 
substantial changes in susceptibility. Known single amino acid mutations that confer >10-fold 
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reduction in susceptibility to RPV are K101P, Y181I, and Y181V, which all require two base 
changes; else, HIV-1 requires more than one known drug-resistant mutation for high-level 
resistance to RPV (265). This resistance phenomenon is a hallmark of diarylpyrimidines and was 
also noted with ETR (308).  
In cell culture and RPV clinical trials, E138K, K101E, and Y181C were the most 
commonly selected DRMs (265, 283, 295, 306). The linker groups of RPV form H-bonds with 
K101 of the p66 subunit and E138 of the p51 subunit of RT, allowing the drug to bind to the 
virus enzyme and hinder reverse transcription (288, 289). Mutations at these positions break a 
salt bridge that links the RT subunits (300) and creates a wider gap in the NNRTI-binding pocket 
that reduces RPV binding stability (301, 302). Mutations at the Y181 position result in a loss of 
stacking interaction between the tyrosine group of RT and the dimethylphenyl ring of RPV, 
again reducing binding of RPV (288). However, the flexibility of RPV allows the molecule to 
shift within RT to create or maintain other interactions with the enzyme, which accounts for the 
low-level of resistance conferred by many mutations in the NNRTI-binding pocket region. In the 
case of Y181C, the ring moiety of RPV can alternatively interact with the tyrosine residue at 
position 183 to maintain its ability to bind and inhibit RT function, though reduced (288). The 
RT-binding locations and shifting rings of RPV are critical for potency and why first-generation 
NNRTI-associated DRMs confer little to no reduction in susceptibility to the drug. The 
resistance mechanisms conferred by other RPV-associated mutations have not yet been explored. 
As of this writing, half of the clinically relevant RPV-associated mutations are associated 
with DRM transmission but only K101E and Y181C are found in >5% of the treatment-
experienced HIV-1+ population, while all RPV-associated DRMs are reported in <0.5% of 
treatment-naïve populations (266, 309). The global distribution of RPV DRMs is varied, with 
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Europe and Latin America having the highest prevalence of RPV resistance populations at 3.2% 
and 3.6%, respectively (310). However, drug-resistant polymorphisms at the E138 position are 
found in 6.1%, 5.1%, and 3.3% of individuals infected with subtypes C, F, and A, respectively 
(310). While E138 mutations currently have an overall low global prevalence, Y181C is the 
second most prevalent NNRTI-resistant mutation worldwide with 17.5% prevalence in ART-
experience populations (285). Combined, these data indicate that RPV must be used with caution 
in certain geographic regions or in patients infected with particular HIV-1 subtypes.  
If RPV use becomes more common, it is likely the prevalence of associated resistance 
mutations will also increase and potentially reduce the efficacy of RPV to be effective against 
HIV-1. Despite a restricted ART recommendation, the favorable potency, safety, and tolerability 
profile of RPV is why it was chosen for development as a long-acting injectable PrEP agent 
(311, 312). The use of FDA-approved drugs for both ART and PrEP brings into question the 
effects of PrEP on resistance selection and DRM transmission. However, a reduction in use of 
NNRTIs for ART, as recommended by US guidelines (213), could eventually reduce prevalence 
and incidence of NNRTI-resistant infections, thus alleviating the concern with drug-resistant 
HIV-1 transmission. This would allow RPV to remain a viable PrEP option should it be shown 
effective in animal models and clinical trials.  
1.2 PRE-EXPOSURE PROPHYLAXIS 
PrEP is the use of antiretroviral drugs by uninfected individuals to prevent HIV-1 transmission 
by providing localized or systemic drug concentrations prior to virus exposure. Effective drug 
concentrations at sites of exposure, particularly mucosal tissues, should entirely block infection 
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or avert spread of a founder population of HIV-1-infected cells. In clinical trials, either daily oral 
TFV or Truvada was found to significantly prevent HIV-1 infection in high-risk populations 
including men and transgender women who have sex with men (MSM) (17, 23), serodiscordant 
couples (19), young heterosexual adults in an area of high HIV-1 prevalence (20), and injection 
drug users (21) (Table 1). Similarly, significant protection has been shown with intercourse-
dependent Truvada (22) and 1% TFV topical gel (18) (Table 1). At the time of this writing, only 
daily oral Truvada for PrEP is available in high-risk populations, but global availability is 
limited. Despite the success of Truvada PrEP in clinical trials, adherence, resistance selection, 
resistance transmission, and long-term use of drugs by HIV-1- individuals are areas of concern. 
1.2.1 HIV-1 PrEP 
There are 25 approved antiretroviral drugs and countless analogs and experimental compounds 
that could be chosen for PrEP. The cost and time to properly evaluate a fraction of these 
candidates would require vast resources and would significantly delay control of the HIV-1 
pandemic. Therefore, drugs already approved for clinical use are more likely to be accepted as 
PrEP because of known safety, tolerability, resistance, and efficacy profiles, which entails years 
of thorough study and large-scale clinical trials before approval. For example, Truvada was an 
excellent candidate for PrEP because of good bioavailability of the active metabolites, a well-
established safety profile, and lack of interaction with non-HIV-1 therapies relevant to other 
conditions/diseases (17). The NRTIs in Truvada, FTC and TFV, mimic separate dNTPs (cytidine 
and adenosine, respectively) and select for distinct resistance mutations (313, 314), indicating a 
therapeutic effect could be maintained should an individual acquire a single DRM while on 
PrEP. Of importance, animal models showed successful prevention of HIV-1 infection by 
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Truvada PrEP (315, 316), providing in vivo evidence of PrEP utility prior to initiating clinical 
trials.  
To test the efficacy of daily oral Truvada as PrEP, thousands of individuals from several 
nations participated in multiple randomized, blinded, and placebo-controlled clinical trials. The 
rates of protection within the total populations were 44%, 62%, and 75% in MSM, sexually 
active adults, and serodiscordant couples, respectively (17, 19, 20). When the efficacy data for 
these trials were adjusted to analyze participants with detectable drug concentrations, HIV-1 
prevention was >75% for adherent individuals. Even if drug was detected in treated individuals 
who became infected, the concentrations were significantly lower than those of matched 
uninfected persons (17, 20). Comparison of TFV concentrations and protection in Truvada 
clinical trials indicates that plasma TFV concentrations of ~50 ng/ml estimates a 50% risk 
reduction in HIV-1 infection (317) and specifies an obtainable, protective concentration in 
individuals. The success of Truvada PrEP is a much-needed boon for HIV-1 prevention, and 
different compounds and delivery modalities are being explored to increase PrEP options. 
Similar to ART, development of DRMs is a concern for PrEP efficiency. Individuals who 
are HIV-1+ at initiation or become infected while on PrEP will essentially be treated with mono- 
or dual therapy, which could select for drug resistance similar to what occurred in the 1980s and 
early 1990s prior to the initiation of pre-combination ART. PrEP-turned-therapy and DRM 
selection raises the issue of cross-resistance and limited ART options; however, resistance 
selection in individuals adherent to Truvada was low. Follow-up analyses of seroconverters in 
the TDF2 and iPrEx trials revealed no selection of DRMs if the individuals were infected after 
initiating PrEP (318, 319); however, 4.8% and 3.3% of infected participants in the Partners PrEP 
study developed a resistant mutation as a result of Truvada or TFV PrEP, respectively (320). 
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These results indicate that selection of drug resistance during Truvada PrEP is low if one is 
infected after initiating PrEP. Yet, the resistance outcome was different, though rare, for persons 
who received PrEP when already infected with HIV-1. One of three participants retrospectively 
found to be infected at the start of the TDF2 study developed mutations resistant to both drugs 
(318), while 25% of HIV-1+ participants with undetected infection given PrEP in the Partners 
trial developed DRMs (320). Two participants in the iPrEx trial were retrospectively discovered 
to be HIV-1+ prior to enrollment, and the data indicate that FTC exposure selected M184I/V 
mutations quickly (319). Although the data sets are small, it appears the risk of developing 
resistance as a result of PrEP is unlikely if the infection occurs after starting PrEP. However, the 
individuals in these trials were closely monitored. In a clinical setting, the amount of time before 
detection of HIV-1 infections in PrEP users may allow more time for selection of DRMs.  
While efficacy and low resistance selection for daily oral Truvada PrEP has been 
observed, adherence is the largest barrier to PrEP effectiveness and should be addressed to 
reduce the global burden of HIV-1. Daily oral PrEP was ineffective in two studies, the FEM-
PrEP and VOICE trials, as no difference in infection rates was exhibited between treatment and 
placebo groups (14, 15). The entire FEM-PrEP and the single drug arms of VOICE were halted 
early because of such discouraging results. Despite greater than 85% adherence based on product 
return and self-reporting, <40% of participants were actually found to be adherent based on 
plasma drug concentrations in both trials. Follow-up interviews revealed that poor adherence was 
associated with low risk perception (321) and fear of side effects, real or imagined (322). 
Although adherence measured by plasma drug concentrations never matched rates of self-
reporting or product count monitoring in any Truvada clinical trial (14, 15, 17, 19, 20), 
adherence in the successful trials was considerably higher. In the iPrEx trial, age and higher 
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education levels were positively correlated with adherence (323). Similarly, increased age was 
also positively correlated with adherence in the Bangkok Tenofovir (21) and VOICE (15) trials. 
These results suggest maturity and experience as key factors for adherence; however, with 
increased implementation of PrEP strategies and proper education and outreach, it is expected 
that adherence will increase for future product use (324). 
To address daily adherence issues with PrEP, alternative regimens such as intermittent 
oral pills, topical gels, and intravaginal rings (IVRs) have been investigated, but not yet 
approved. In the iPERGAY trial, intercourse-driven oral Truvada use rather than daily pills led to 
an 82% reduction in HIV-1 infections in a MSM population (22). These results indicate that 
intermittent oral dosing may alleviate adherence problems, as users would take PrEP only during 
times of sexual activity, thus assuaging fears of potential long-term side effects from daily use.  
Microbicide gels provide localized concentrations of anti-HIV-1 compounds and were 
originally proposed as intercourse-driven PrEP controlled by women (325). The CAPRISA 004 
trial explored the use of an intercourse-dependent 1% TFV vaginal gel as PrEP and reported a 
39% reduction in HIV-1 infections in the overall treated group, but a 54% reduction in women 
who were adherent to the product (18). Conversely, no difference in HIV-1 transmission between 
gel or placebo groups was reported in the VOICE study because of poor adherence (15). Several 
other microbicide trials explored the use of carrageenan-based gels, Carraguard and PRO2000 
(326-328); the surfactant C31G (329); and the acidic Buffergel (328) and all of them failed to 
show efficacy or were associated with increased infection risk (330, 331). Microbicide gels are 
not limited to vaginal formulations, as rectal gels with TFV or an experimental NNRTI are 
shown to be safe and tolerable in both men and women (332-334).  
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Another female-driven PrEP strategy is the IVR, which provides a solid substrate for 
localized long-term drug release with intermittent replacement and have been prescribed for 
contraception and hormone replacement for decades (335). An IVR containing the NNRTI DAP 
showed similar results to 1% TFV topical gel, leading to 37% and 56% lower incidences of HIV-
1 transmission among the total and adherent treated populations, respectively (336). A second 
DAP IVR clinical trial showed 31% lower incidence of HIV-1 in the DAP group; however, there 
was no correlation between adherence and increased protection (337). Women would apply the 
IVR and replace as necessary to maintain vaginal drug concentrations, thus eliminating concerns 
of missed daily doses. Despite promising results, intermittent pills, microbicide gels, and IVR 
strategies are still user-driven and cannot guarantee adherence. 
New long-acting injectable formulas of antiretroviral drugs such as the NNRTI RPV or 
the integrase inhibitor cabotegravir (CAB) have been developed for PrEP and have favorable 
safety and dosing profiles (338-340). Long-acting injectable formulations are designed 
specifically for intermittent use and provide sustained systemic release of drugs instead of 
localized concentrations, like topical gels or IVRs. This strategy has been successful in fields 
such as cancer treatment, contraception, hormone replacement, and psychiatry (341-344). Long-
acting injectable PrEP benefits from the elimination of user responsibility for daily or event-
driven dosing and administration and adherence monitoring by healthcare providers. Opinions on 
taking injectable drugs as PrEP are positive in target populations, such as MSM and high-risk 
women (345, 346); however, long-acting PrEP has not been tested in efficacy trials at the time of 
this writing.  
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1.2.2 RPV LA as PrEP 
Because of its aforementioned potency and safety profiles, RPV is the most appropriate clinically 
approved NNRTI for PrEP (312). RPV has been formulated as a long-acting injectable designed 
to provide a depot of drug that is released systemically over time for monthly dosing and better 
adherence. RPV LA is prepared by wet-milling irradiated RPV with a surfactant (polxamer 338) 
in an aqueous environment to obtain a nanoparticle suspension with an average particle size of 
200 nm (311, 312, 347). Chelating and isotonifying agents and a phosphate buffer are then added 
to preserve the product for long-term refrigerated storage (312).  
 Phase I clinical trials showed that RPV LA is safe and tolerable with reported low-grade 
adverse events such as rash, stiffness, and injection site pain and swelling (338, 340, 348). In one 
clinical trial, pharmacokinetic (PK) analysis of plasma RPV in women administered a single 300, 
600, or 1,200 mg intramuscular (IM) injection displayed a dose-dependent effect on plasma and 
vaginal tissue drug disposition (338). Maximal plasma drug concentrations in women averaged 
160 ng/ml at 6 days post-injection in the 1,200 mg group and were sustained to 83 ng/ml by 28 
days post-injection for a calculated half-life of 38 days (338). The ratio of drug concentrations in 
cervicovaginal lavages and vaginal tissues versus plasma at 28 days post-injection averaged 1.0 
and 0.8, respectively (338). The decay of lavage and plasma drug concentrations mirrored each 
other; however, vaginal tissue-to-plasma ratios increased as tissue drug concentrations remained 
steady (300 mg and 600 mg) or increased (1,200 mg) indicating that RPV may concentrate in 
vaginal tissue, while it is metabolized in plasma (338). In the same study, a population of men 
was given a 600 mg IM injection of RV LA. Average plasma RPV concentrations were higher in 
men at all time points than women given the same dose, but displayed a nine day shorter half-life 
indicating gender difference in metabolism (338). Male rectal tissue-to-plasma ratios of RPV 
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averaged 0.9 at 2 weeks post-injection (338), suggesting that plasma RPV concentrations could 
be used as a surrogate measurement for rectal drug concentrations. Data from all participants 
administered the 600 mg dose suggests that RPV penetrates rectal tissue better than vaginal 
tissue as concentrations in rectal tissue were 3-fold higher one week post-injection (338), a 
characteristic of RPV LA that has been confirmed in explant models (348, 349). Although a 
minimal in vivo RPV protective concentration for RPV LA has not been defined to date, the 
authors reference a protein-adjusted effective concentration to prevent 90% (PAEC90) value of 
12.1 ng/ml and propose this as a baseline measurement as a protective threshold (338). Overall, 
the authors demonstrated systemic distribution of RPV and deposition in sites relevant to HIV-1 
exposure at concentrations above the theoretical protective concentration.  
A second RPV LA clinical trial corroborates the dose-dependent plasma drug 
concentrations reported by Jackson et al. (338) and outlined a potential dosing strategy of 
priming with a 1,200 mg IM injection followed by monthly 600 mg injections (340). This dosing 
regimen was tolerable, maintained drug concentrations above the proposed protective 12.1 ng/ml 
PAEC90 value, and revealed a consistent peak and trough of plasma RPV concentrations 
maintained within a 50-80 ng/ml range (340), the minimum effective range reported in oral RPV 
trials (338). Current methods of measuring RPV account for total drug concentrations and not 
free/active drug. Like most NNRTIs, RPV is highly protein bound (265, 350) and reported drug 
concentrations are not an accurate representation of available active drug. While the results of 
both studies support testing of a monthly 1,200 mg RPV LA dosing strategy for PrEP, it is 
crucial to determine in vivo protective concentrations of RPV and the feasibility of providing 
these thresholds in humans. 
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To understand RPV penetration and protection in mucosal tissues, human tissue explant 
models were used to determine protective ranges of RPV ex vivo. Ectocervical and colon 
explants revealed that RPV concentrates more readily in colonic versus female genital tract 
tissue (348, 349). In one study, tissues were incubated in media containing RPV before exposure 
to HIV-1, and the colonic explants exhibited significantly higher RPV absorption than 
ectocervical explants, which absorbed <10% of the input drug (349). The effective concentration 
to prevent 90% infection (EC90) for RPV in the ectocervix and colon explants was approximately 
99 and 16 ng/ml, respectively, thus displaying a 6-fold difference in concentrations needed for 
protection between the tissue compartments (349). A second study used explants taken from 
RPV LA-treated individuals and found that RPV concentrates in rectal tissue up to 2.5-fold more 
than matched vaginal and cervical tissues (348). However, this study reported an EC90 value of 
91 ng/ml in rectal tissues sampled 14 days post-injection and no protective correlate in cervical 
or vaginal tissues, which suggests that a 1,200 mg dose of RPV LA may not be effective (348). If 
these explant results are applied to reported human RPV tissue concentrations (338), RPV LA 
should provide protection from rectal exposure, suggesting that RPV LA may not be an ideal 
PrEP candidate for women at risk of HIV-1 infection via vaginal exposure. The explant models 
further emphasize the need for careful characterization of the in vivo protective concentrations of 
RPV LA, which appear to be unique to specific tissue compartments.  
Along with mucosal tissue penetration and protective concentration concerns with RPV 
LA, cold storage, shipping chains, and a long detectable pharmacologic tail have brought into 
question the practicality of the PrEP agent. A single 1,200 mg dose of RPV LA provides 
concentrations of drug that are still detectable nearly 170 days post-dosing; however, after 40 
days post-dosing, the drug concentrations remain just above the aforementioned theoretical 
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protective concentration (338, 348). This long detectable tail of RPV is a problem because low 
drug concentrations could be ideal for resistance selection should a user stop receiving RPV LA 
and then become infected with HIV-1. Such resistance selection did occur in one individual that 
received a single 300 mg dose of RPV LA in the SSAT 040 trial and became infected during the 
tail phase when RPV concentrations hovered near the 12.1 ng/ml EC90 for over 200 days (351). 
Using a sensitive sequencing technique, the RPV-associated mutation K101E was detected in 
approximately 20% of the viral population 70 days after infection (351). Although this is a 
singular event, it shows that resistance selection can occur during RPV LA monotherapy.  
Currently, a phase II clinical trial is underway to explore the safety and tolerability of 
repeated 1,200 mg IM doses of RPV LA administered to low-risk HIV-1- females every 8 weeks 
for 52 weeks (https://clinicaltrials.gov; NCT02165202). Given the scope of the trial, the supply 
chain issues may be addressed; however, questions with protective thresholds and waning RPV 
concentrations should be answered before RPV LA is moved into large scale Phase III trials. 
1.2.3 Transmission of drug resistance 
While resistance selection during PrEP appears to be limited based on results from clinical trials, 
the question of the ability of PrEP to prevent transmission of drug-resistant HIV-1 still remains. 
The global rollout of ART is necessary for the control of HIV-1 viremia and reduction of 
incidences (232, 237); however, increased ART coverage positively correlates with prevalence 
of drug resistance (352, 353). According to a meta-analysis, overall drug-resistant HIV-1 
prevalence has increased in Sub-Saharan Africa, Latin America, North America, and upper 
income Asian regions since the scale-up of ART; however, prevalence of NNRTI-associated 
DRMs and odds of drug-resistant virus transmission is increasing in every global region (285). 
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Because drug-resistant HIV-1 can be transmitted, global surveillance of specific mutations that 
are associated with virologic failure was initiated (309, 354). The four criteria for inclusion as a 
surveillance resistance mutation are: 1) the mutation must be associated with drug resistance and 
recognized on multiple expert lists of resistance mutations; 2) the mutation should be non-
polymorphic, nor occur at highly polymorphic sites; 3) the mutation must show resistance across 
the most common subtypes of HIV-1; and 4) the list should be simple and exclude very rare 
mutations (354). Currently there are 34 NRTI, 19 NNRTI, 40 protease, and 17 integrase-
associated surveillance mutations (http://hivdb.stanford.edu/pages/surveillance.html). A concern 
is that PrEP will not inhibit transmission of drug-resistant HIV-1; therefore, the continued scale-
up of ART combined with PrEP availability could push the global HIV-1 population towards 
drug-resistant genotypes. 
Because of cross-resistance between currently approved drugs, transmission of resistant 
virus could limit therapy options of newly infected individuals and reduce PrEP options for 
serodiscordant partners. Of the oral Truvada clinical trials, only one participant from the Partners 
PrEP study was reported to have acquired a transmitted drug-resistant infection, which contained 
NRTI- and NNRTI-associated mutations (320); however, this participant was considered non-
adherent to the regimen, so PrEP failure may not have been to blame. Thus far, two case studies 
have reported transmission of multi-drug-resistant HIV-1 in individuals adherent to Truvada 
PrEP (355, 356). In both cases, FTC-associated and NNRTI-associated DRMs were detected, 
including E138Q (355) and Y181C (356). Both E138Q and Y181C confer resistance all NNRTIs 
(265), thus limiting the utility of an NNRTI-containing ART regimen in these individuals. No 
resistance was reported in the intermittent Truvada (22) or 1% TFV gel (18) trials. In the 
ASPIRE study, DRM transmission occurred in clinical trial participants using DAP IVRs. 
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Similar prevalence of DRMs were reported between newly infected individuals in the placebo 
and treatment DAP IVR groups (336), and population sequencing results suggest that these 
seroconverters acquired NNRTI-associated DRMs through transmission (357). In contrast, the 
development of a DAP-associated DRM, E138A, was more frequent in the treated group versus 
the placebo in the Ring Study (337). 
Transmission of drug-resistant HIV-1 is detected at rates between 2.8-11.5% and is 
associated with ART use and geographic region (285). NRTI-associated mutations account for 
the majority of transmissions, and the likelihood of acquiring resistant virus to multiple drug 
classes decreases by at least 4-fold per additional class (285), suggesting the case studies 
described above may be rare events and difficult to account for in the design of a clinical trial. 
Studying PrEP efficacy against drug-resistant HIV-1 is hindered by not knowing the genotype or 
the amount of virus in which clinical trial participants are exposed. The design of the Partners-
PrEP trial, with matched serodiscordant couples, is the only ethical way to test resistance 
transmission in humans; however, it was not discussed if any of the HIV-1+ partners in the trial 
had a drug-resistant genotype (19). Because transmitted resistance is infrequent and not ethical to 
purposefully test in humans, animal models have been developed to test the efficacy of PrEP 
against drug-resistant virus transmission.   
1.2.4 Animal models for HIV-1 infection 
Cell culture-based studies cannot accurately reflect the complexities of pathogen infection in a 
host. For example, a novel therapeutic compound that targets a pathogen may be highly effective 
in vitro but host factors such as bioavailability, metabolism, and tissue penetration may affect 
clinical efficacy. Thus, robust in vivo models should be utilized to study such intricate 
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interactions. To truly understand host and pathogen interactions, it is ideal to study routes of 
infection, disease pathogenesis, and therapeutic strategies in the host species. However, HIV-1 is 
a human-specific pathogen with no cure, thus it would be unethical to intentionally infect people 
to study the virus and its associated disease and treatment. The use of animal models in the HIV-
1 field links in vitro discoveries to in vivo studies and mitigates the high costs associated with 
long-term human trials that require hundreds to thousands of participants. Animal studies permit 
manipulation of experimental variables such as genetic backgrounds of the animals, virus 
challenge stocks, time and route of infection, duration and adherence of treatment, invasive 
sampling, and other factors that cannot be controlled or sanctioned in human trials. Animals 
allow researchers to logically and ethically model specific scenarios for hypothesis-driven 
investigation and provide in vivo proof-of-concept data that can guide clinical trial designs or 
predict study outcomes. Currently, the two most common animals used for HIV-1 modeling are 
macaques and humanized mice.  
Phylogenetic evidence strongly suggests that HIV-1 evolved from multiple simian 
immunodeficiency virus (SIV) cross-species transmissions from African non-human primates 
(NHP) (358-360), and has been circulating in the human population since the early 1900s (361). 
However, the SIV crossover responsible for the majority of the HIV-1 pandemic originates from 
chimpanzees (360), the family of animals most genetically related to humans (362). However, 
HIV-1 does not readily infect NHPs nor recapitulate AIDS disease progression (363). SIV does 
not progress to AIDS in its natural African primate hosts, and pathogenesis is abrogated by 
sustained regulation of immune functions and control of chronic immune activation, which are 
deregulated hallmarks of infection in non-natural primate species or HIV-1 in humans (364, 
365). However, a serendipitous discovery in the mid-1980s revealed that Asian rhesus macaques 
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could be infected with SIV to recreate a disease pattern that resembles AIDS in humans (366, 
367). Historically, the rhesus macaque (Macaca mulatta), an Old World monkey endogenous to 
central Asia, is the most widely used animal for HIV-1 model research, but other species of 
Asian macaques, including pigtailed (Macaca nemestrina) and cynomolgus (Macaca 
fascicularis), are also utilized (368).  
SIV or simian-human immunodeficiency virus (SHIV) in macaques offers the advantage 
of mirroring HIV-1 infection in humans through similar target cells, immune response, and 
pathogenesis. SHIVs are chimera viruses that contain coding regions from HIV-1 in the SIV 
genome to model the effects of HIV-1-specific treatments or prevention strategies in NHPs (369-
372). Infection of macaques with SIV recapitulates the pathogenesis hallmarks of HIV-1 
infection including CD4+ T cell depletion (373), microbial translocation (182), and AIDS (366, 
367). In addition, macaques are outbred, which allows for modeling of infection within hosts of 
varying genetic backgrounds. There are many well-characterized SIV and SHIV strains that can 
be used for NHP infection (374); however, consideration is warranted when choosing a NHP 
species and challenge virus because of differences in viremia levels, disease progression and 
pathogenesis, characterization and diversity of protective MHC alleles and innate immune 
factors, efficacy of therapy, and physiologic cycles (368, 374, 375). For example, female rhesus 
and pigtailed macaques both experience menstrual cycles, but the former has seasonal cycles 
while the latter has monthly cycles more comparable to human women (376, 377). Greater 
thinning of the vaginal epithelium in pigtailed macaques during the luteal phase makes them 
more susceptible to vaginal infections than rhesus macaques (378).  
Despite the knowledge gained from modeling SIV and SHIV infections in NHPs, neither 
virus is HIV-1, and results from macaque models using either virus should be validated in the 
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context of HIV-1 infection in humans. HIV-1 cannot be used to recapitulate AIDS in macaques 
because of NHP restriction factors. Macaque variations of tripartite-motif-containing protein 5α, 
APOBEC3, tetherin, and SAM domain- and HD-domain-containing protein 1 inhibit HIV-1 
replication in macaques due to the lack of the necessary HIV-1 factors evolved by SIV to counter 
these immune mechanisms (379-383). Also, while most anti-HIV-1 drugs will work against SIV 
(384-386), differences between SIV and HIV-1 RT (387, 388) prevent NNRTIs from working 
against SIV. For in vivo studies of NNRTIs, a chimeric RT-SHIV virus is used for infection of 
NHPs (369, 370, 389). Aside from physiological limitations, macaques studies can be limited by 
availability, facility space, and high costs associated with purchase and maintenance. Hence, an 
ideal macaque model would be much less expensive and permit the use of HIV-1. 
A second animal model for studying HIV-1 infection is the humanized mouse. 
Humanized mice are generated by transplant and engraftment of human cells and/or tissue into 
an immunodeficient mouse strain for recapitulation of a human immune system in a small animal 
(390). Procedures for creating humanized mice can be as simple as an intravenous (IV) injection 
of human peripheral blood lymphocytes or as complicated as invasive surgery for the 
transplantation of human tissues (391). Humanized mice provide the key advantage of an in vivo 
system in which actual HIV-1 and human cell response can be studied. Mice are also readily 
available to order from vendors or can be bred quickly, are significantly less expensive than 
NHPs, are easier to handle, and require less space and maintenance, thus allowing for larger 
cohorts. 
There are several different methods and genetic backgrounds that can be utilized to 
generate humanized mice (390). Severe combined immunodeficiency (scid) mice transplanted 
with fetal thymus and LN tissue and liver cells (392) were first shown to be susceptible to HIV-1 
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infection in the late 1980s (393). However, less technically challenging humanized mouse 
models include Scid mice only injected with human peripheral blood leukocytes (394, 395) or 
cluster of differentiation 34 (CD34) positive hematopoietic stem cells (396). Scid mice have a 
mutation in the protein kinase, DNA activated, catalytic polypeptide (Prkdcscid) gene that causes 
defects in DNA repair and inhibits the generation of B and T cells (397, 398), which allows 
engraftment of human cells with limited host immune response to the non-mouse cells. However, 
these scid models display leaky B and T cell development (399) and NK cell activity that rejects 
human cell engraftment (400). Recombination-activating gene (Rag1/2) deficient mice are 
deficient in adaptive immune cell development and eliminate B and T cell leakiness, but still 
have active NK cells (401, 402). The crossbreeding of scid or Rag1/2 with non-obese diabetic 
(NOD) mice generated an immunodeficient mouse line that lacks both adaptive immune and NK 
cell activity (403-405). However, the addition of mutations in the interleukin-2 receptor gamma 
chain (IL2rg) to the scid/NOD or Rag1/2/NOD lines further impairs B, T, and NK cell 
development and function (406-408) and provides the highest level of human cell engraftment 
compared to the aforementioned strains (409-412). These different genetic lines (and others) can 
be used to for HIV-1 infection and treatment studies; however, the model principally used for 
HIV-1 PrEP research is the bone marrow, liver, and thymus (BLT) mouse. To generate BLT 
mice, immunodeficient animals are irradiated and transplanted with human fetal liver and 
thymus tissue (413-416). Post-tissue transplantation, the mice are injected IV with autologous 
human CD34+ hematopoietic stem cells isolated from the fetal liver and allowed to rest for 8-12 
weeks until human immune cells reconstitute the recipient. The genetic backgrounds 
recommended for BLT surgery are NOD-PrkdcscidIL2rgTm1Wjl (NSG), NOD.Cg-
PrkdcscidIl2rgtm1Sug, or C.129(Cg)-Rag2tm1Fwa9Il2rgtm1Cgn (391). The presence of the human 
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thymus provides stem cells with an environment for education and HLA-restriction of human 
origin. These mice also develop human immune cell reconstitution at mucosal tissues (315, 417-
419), a feature not seen in the aforementioned humanized mouse models (368). However, BLT 
mice do have limitations such as a shortened life span due to graft versus host disease (420), poor 
lymphoid structure development (421, 422), limited B cell maturation (423), and the necessity 
for human cytokines for improved human myeloid and NK cell function (424). Unlike NHPs, 
large volumes of blood and survival tissue biopsies are not practical in mice for longitudinal 
survival studies. Assays that require plasma (e.g. measurement of plasma viremia) have reduced 
sensitivity in mouse samples due to the trade-off between sampling frequency and safe blood 
draw volumes. In addition, tissue samples require euthanizing animals. Finally, the 
immunodeficient genetic background of these animals requires stringent aseptic handling and 
housing to prevent secondary infections that could cause confounding morbidity or mortality. 
Although not perfect because of physiological and anatomical differences, animal models 
serve as pre-clinical systems to evaluate ART and PrEP regimens before more expensive human 
testing. Therefore, there will always be a need to use animals to safely transition from drug 
discovery to clinical trials and provide proof-of-concept for antiretroviral agents and 
prophylactic regimens. 
1.2.4.1 Macaque models for PrEP  
Macaques have been utilized to test PrEP strategies for over 20 years. Studies with macaques 
have mirrored the success of human PrEP trials with daily oral Truvada (17), intermittent oral 
Truvada (22), and microbicide gels (18). In animal models, there are two virus challenge 
paradigms applied: a single high-dose or repeated low-dose model. The reasoning for the former 
model is that if an agent can protect from a single high-dose virus challenge, usually beyond 
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physiologic norms, then success should logically extend to lower more realistic inoculums. This 
paradigm allows for quicker, less complicated studies. The latter model is employed to mimic 
physiological HIV-1 inoculums to which humans would be repeatedly exposed (425, 426). There 
have been dozens of studies published using both challenge paradigms to study PrEP efficacy 
with experimental and approved compounds in macaques. As previously discussed, approved 
antiretroviral drugs are more likely to also be accepted for prophylaxis, and Table 2 summarizes 
the design and outcome of studies that employed macaque models to assess approved 
antiretroviral drugs as PrEP. 
PrEP intervention with approved NRTIs was shown to be viable as early as 1992. In a 
small study, two infant macaques were protected from SIV infection when administered oral 
AZT before and after IV challenge (427); however, this success was not repeated in a follow-up 
study with newborn macaques given a different PrEP dose and virus challenge (428). Because of 
frequent dosing and side effects, AZT is not an ideal candidate for PrEP, but these studies 
provided proof-of-concept for pre-exposure intervention with small molecules to inhibit HIV-1 
infection. TFV, considered a more tolerable and potent drug than AZT, proved to be a more 
suitable PrEP candidate as daily subcutaneous (SC) injections protected 100% of juvenile 
macaques from a high-dose SIV challenge (453). Subsequent studies with low and high doses of 
oral TFV administered prior to and after oral SIV challenge prevented infection in nearly 100% 
of newborn macaques in an effort to mimic mother-to-child transmission during breast-feeding 
(429, 431). Conversely, regular oral TFV dosing exhibited little to partial protection from 
multiple oral SIV challenges in infant macaques (432, 434); however, it was concluded that 
protection was dose-dependent implying that a fixed dose was not adequate to provide protective 
drug concentrations as the animals matured (434). Discrepancies between these studies can be
  43 
Table 2. Macaque studies using FDA-approved antiretroviral drugs as PrEP to prevent mucosal transmission of SIV or SHIV 
NHP species PrEP (dose) Dosing Strategy Virus Challenge (route) Outcome Ref. 
Rhesus  
(infant) 
oral AZT  
(50 mg/kg) 
2 h pre-challenge and 
every 8 hours for 6-10 
weeks 
SIVmac single,  
low dose (IV) 
2/2 protected (427) 
       
Rhesus 
(newborn) 
oral AZT 
(25 mg/kg) 
2 h pre-challenge and 
every 8 hours for 15 
months 
SIVmac single,  
high dose (IV) 
0/3 protected, 
significantly better 
clinical outcomes 
(428) 
       
Rhesus 
(newborn) 
SC TFV  
(30 mg/kg) 
4 h pre- and 20 h post- 
challenge 
SIVmac251 single, 
high dose (oral) 
4/4 protected (429) 
       
Rhesus 
(newborn) 
SC TFV 
(30 mg/kg) 
1 d pre-challenge and 
continued daily for 4 
weeks 
K65R 
SIVmac055 
 
2 high doses 24 h 
apart (oral) 
2/5 protected, 
delayed disease 
course 
(430) 
       
Rhesus 
(newborn) 
SC TFV  
(4 mg/kg) 
 
4 h pre- and 20 h post-
challenge 
SIVmac251 single,  
high dose (oral) 
3/4 protected (431) 
       
Rhesus 
(infant) 
oral TFV 
(~0.01-0.02 mg/kg) 
Full dose once daily 
1.5 h pre-challenge or 
2 half doses daily 1.5 h 
pre-challenge and 2.5 h 
post-challenge 
SIVmac251 repeated,  
low dose (oral) 
1/4 protected (1 full 
dose) 
2/4 protected (2 half 
doses) 
(432) 
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Table 2 continued 
Rhesus  
 
oral TFV  
(22 mg/kg)  
1) 2 h pre-challenge 
then daily for 36 weeks 
2) 2 h pre-challenge 
then weekly for 36 
weeks 
SHIV162p3 repeated,  
low dose (rectal) 
1/4 protected (daily) 
0/4 protected 
(weekly) 
median infection 
time: 1.5 weeks 
(untreated), 6.0 
weeks (weekly), 7.0 
weeks (daily) 
(433) 
       
Rhesus 
(infant) 
 
 
 
 
 
 
oral TFV  
(10 mg/kg)  
1) 6 d pre- and 1 d 
post-challenge 
2) 2 d pre- and 2 weeks 
post-challenge 
SIVmac251 1) 5x daily, low dose 
(oral) 
2) 5x daily, low dose 
(oral) 
1) 5/6 protected 
2) 5/6 protected 
follow-up challenges 
resulted in 60% 
infection of those 
initially protected 
(434) 
       
Rhesus TFV gel (1%) 1) 15 min pre-
challenge  
2) 120 min pre-
challenge 
SIVmac251/32H single, high dose 
(rectal) 
1) 4/6 protected  
2) 2/3 protected 
(435) 
       
Rhesus  
 
1) SC FTC  
(20 mg/kg) 
2) oral FTC/TFV 
(20 & 22 mg/kg) 
3) SC FTC/TFV 
(20 & 22 mg/kg) 
4) SC FTC/TFV 
(20 & 22 mg/kg) 
1-3) daily7-9 d pre-
challenge then daily for 
18 weeks 
4) 2 h pre-challenge 
and 24 h post-challenge 
SHIV162p3 repeated,  
low dose (rectal) 
1) 2/6 protected 
2) 4/6 protected 
3) 6/6 protected 
4) 6/6 protected 
significant delay in 
infection in PrEP vs. 
untreated groups 
 
(316) 
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Table 2 continued 
Rhesus  
 
1-3) oral FTC/TFV 
(20 & 22 mg/kg) 
 
 
1) 22 h pre-challenge 
and 2 h post-challenge 
2) 3 d pre- and 2 h 
post-challenge 
3) 7 d pre- and 2 h 
post-challenge 
4) 2 h pre- and 26 h 
post-challenge 
SHIV162p3 repeated,  
low dose (rectal) 
1) 5/6 protected 
2) 5/6 protected 
3) 4/6 protected 
4) 3/6 protected 
significant delay in 
infection in PrEP 
groups vs. untreated 
 
(436) 
       
Rhesus 1) MVC gel 
(0.25 mM) 
2) MVC gel 
(0.5 mM) 
3) MVC gel 
(2 mM) 
4-5) MVC gel 
(6 mM) 
1-4) 30 min pre-
challenge 
5) 0.5-12 h pre-
challenge 
 
SHIV162p3  single,  
high dose (vaginal) 
1) 2/4 protected 
2) 3/4 protected 
3) 3/4 protected 
4) 6/7 protected 
5) 50% efficacy 
reduction at 4 h pre-
challenge 
(437) 
       
Rhesus  oral FTC/TFV 
(20 & 22 mg/kg) 
3 d pre-challenge and 2 
h post-challenge 
M184V 
SHIV162p3 
repeated, low dose 
(rectal) 
5/5 protected (438) 
       
Rhesus 
 
 
MVC gel  
(3.3%) 
30 min pre-challenge SHIV162p3 single,  
high dose (vaginal) 
4/4 protected (439) 
       
Rhesus  oral FTC/TFV 
(20 & 22 mg/kg) 
 
3 d pre-challenge and 2 
h post-challenge 
K65R 
SHIV162p3 
repeated, low dose 
(rectal) 
5/6 protection,  
10x the K65R 
inoculum needed to 
be as infective as 
WT virus 
(440) 
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Table 2 continued 
Rhesus oral MVC  
(44 mg/kg) 
1 d pre-challenge and 2 
h post-challenge 
SHIV162p3 repeated, low dose 
(rectal) 
1/6 protected (441) 
       
Rhesus 1) TFV gel (1%) 
2) MVC gel (1%) 
3) TFV/MVC gel 
30 min pre-challenge SHIV162p3 repeated low-dose 
(rectal) 
1) 4/6 protected  
2) 4/6 protected 
3) 4/6 protected 
(442) 
       
Pig-tailed 1) TFV gel (1%) 
2) TFV/FTC gel  
(1 and 5%) 
 
1-2) 30 min pre-
challenge 
SHIV162p3 repeated, low dose 
(vaginal) 
1) 6/6 protected 
2) 6/6 protected 
(443) 
       
Pig-tailed TFV gel (1%) 3 days pre-challenge SHIV162p3 repeated, low dose 
(vaginal) 
4/6 protected (444) 
       
Pig-tailed oral FTC/TFV 
(20 & 22 mg/kg) 
 
24 h pre-challenge and 
2 h post-challenge 
SHIV162p3 repeated,  
low dose (vaginal) 
6/6 protected (445) 
       
Pig-tailed 
 
IVR TFV  
(10% by weight) 
1 week pre-challenge, 
replaced every 4 weeks 
SHIV162p3 repeated,  
low dose (vaginal) 
6/6 protected (446) 
       
Pig-tailed 
(DMPA-
treated) 
oral FTC/TFV 
(20/22 mg/kg) 
24 h pre-challenge and 
2 h post-challenge 
SHIV162p3 repeated,  
low dose (vaginal) 
6/6 protected (447) 
       
Pig-tailed TFV gel (1%) 30 min before 
challenge 
K65R 
SHIV162p3 
repeated, low dose 
(vaginal) 
5/6 protected  (448) 
       
Pig-tailed 
 
IVR TFV  
(10% by weight) 
1 week pre-challenge, 
replaced every 4 weeks 
in presence of DMPA 
SHIV162p3 repeated,  
low dose (vaginal) 
5/6 protected  
1 infected after 8 
challenges 
(449) 
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Table 2 continued 
Pig-tailed 1) oral FTC/TFV 
(20/22 mg/kg) 
2) TFV IVR  
(60 mg) 
3) TFV gel (1%) 
1) 24 h pre-challenge 
and 2 h post-challenge 
2) 1 week pre-
challenge 
3) 30 min pre-
challenge 
1) SHIV162p3 
2) SHIV162p3 
3) K65R 
SHIV162p3 
 
1-2) repeated, low 
dose (vaginal) 
3) repeated, high 
dose (vaginal) 
1) 6/6 protected 
2) 3/6 protected 
3) 5/6 protected 
(450) 
       
Pig-tailed 
(STI+) 
oral FTC/TFV 
(20/22 mg/kg) 
24 h pre-challenge and 
2 h post-challenge 
SHIV162p3 repeated,  
low dose (vaginal) 
4/6 protected (451) 
       
Pig-tailed IVR FTC/TFV 
(68 & 65 mg) 
1 week pre-challenge 
 
SHIV162p3 repeated, low dose 
(vaginal) 
6/6 protected 
(bi-weekly IVR 
changes) 
(452) 
       
Cynomolgus 
(juvenile) 
1) SC TFV  
(20 mg/kg) 
2) SC TFV  
(30 mg/kg) 
2 d pre-challenge and 
continued daily for 4 
weeks 
SIVmne single,  
high dose (IV) 
1) 5/5 protected  
2) 10/10 protected  
(453) 
AZT, zidovudine; DMPA, depot medroxyprogesterone; FTC, emtricitabine; IV, intravenous; MVC, maraviroc; SC, subcutaneous; 
STI, sexually transmitted infection; TFV, tenofovir 
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attributed to design dissimilarities such as drug dose, route, and animal age. Yet, the conclusions 
emulate lessons from the Partners PrEP and TDF2 trials where infection in participants with 
detectable TFV was associated with lower plasma drug concentrations (19, 20), suggesting a 
specific drug concentration that needs to be achieved and maintained for protection. Of note, it 
was shown that active TFV concentrations greater than the in vitro effective concentration to 
prevent 95% of infection in vaginal lymphocytes is correlated with protection in macaques from 
vaginal transmission (444), providing a reference for mucosal protection in females for future 
studies.  
Although newborn and infant macaque studies provided pre-clinical data on the benefits 
of PrEP, the majority of HIV-1 incidences in humans are a result of sexual transmission among 
adults (454). Two studies directly modeled the ability of TFV-based PrEP to prevent rectal 
infection in adult macaques to support the results of Truvada clinical trials. Once-daily or weekly 
oral TFV administered two hours prior to repeated rectal challenges with low-dose SHIV 
delayed infection by 5-6 challenges in treated animals; however, the overall infection rate was 
similar between the groups (433). Daily oral Truvada also reduced infection 7.8-fold in another 
study and was shown to be superior to FTC alone (316). These two studies provided proof-of-
concept that daily oral PrEP could provide protection or delay infection in groups that are at risk 
of HIV-1 transmission via rectal exposure, which was the concern addressed in the iPrEx trial 
(17). A similar pre- and post-exposure dosing design successfully modeled intermittent Truvada 
PrEP to inhibit SHIV infection, too. When given 22 hours, 3 days, or 7 days prior to challenge 
followed by a dose two hours post-challenge, intermittent Truvada was as protective as daily oral 
dosing (436). These results mirror the outcome of the iPERGAY trial, which showed an 82% 
reduction in rectal HIV-1 infections in MSM that used intercourse-dependent oral Truvada (22). 
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Although not explored in humans yet, intermittent oral Truvada was also shown to provide full 
protection against repeated vaginal challenges in macaques (445). 
Alternative NRTI delivery strategies, such as IVRs containing TFV have been tested as 
PrEP in macaques as well. The TFV IVR provided consistently high drug concentrations in 
vaginal fluid and local tissues in macaques (446, 449) and were significantly higher than those 
reported to be protective in human women using a 1% TFV gel (18). The TFV IVR provided 
significant protection or delay in infection from repeated low-dose vaginal SHIV challenges in 
cycling and hormone-treated pigtailed macaques (446, 449). Interestingly, one of the studies 
showed infection inhibition in an IVR preparation also containing a contraceptive hormone 
(449), which provides in vivo proof-of-concept for a multipurpose IVR. Such a multifunctional 
product could empower women in areas such as Africa where the HIV-1 prevalence is higher in 
young females than males (455). To expand the utility of IVRs, work has begun on a product that 
provides contraception and the ability to block HIV-1 and sexually transmitted viruses (456).  
Like NRTIs, NNRTIs have also been modeled in macaques as PrEP. However, NNRTIs 
are not effective against SIV unlike other antiretroviral drug classes (384-386). NNRTI 
resistance in SIV is due to a 60% homology difference between the RT coding regions of SIV 
and HIV-1 (387) and NNRTI-resistance mutations that occur naturally in SIV RT (388). To 
address this issue, a chimeric virus that replaces the SIV RT sequence with the RT coding region 
of HIV-1HXB2 (457) in the SIV genome was created and named RT-SHIV (Figure 6). Two 
versions of RT-SHIV were developed using either SIVmac239 (369) or SIVmne (370) as backbones 
for use in rhesus or pigtailed macaques, respectively. In vitro drug susceptibility of RT-SHIV is 
similar to that of HIV-1 (370, 386, 458-460). Infection of macaques with RT-SHIV leads to 
viremia and disease progression equivalent to SIV (369, 461, 462) and responds to NNRTI 
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therapy with viral suppression and evolution of resistance mutations documented in human 
treatment failures (369, 389, 463-468). Despite the availability of RT-SHIV, only a few 
experimental NNRTIs have been investigated as PrEP in macaques.   
Two phenylethylthioureathiazole compounds, MIV-150 and MIV-160 (469), were each 
explored as microbicide gels and IVRs using the RT-SHIV challenge model. MIV-150 was 
originally co-formulated with Carraguard as a topical gel and shown to be highly effective at 
preventing vaginal and rectal infection when applied 30 minutes before challenge in animals 
with or without a herpes simplex virus type 2 (HSV-2) co-infection (470-472). Zinc acetate was 
then added to the gel because of its potential to block HSV-2, and the new formula prevented 
100% of vaginal RT-SHIV infections when applied within 4-24 hours of repeated challenges 
(473, 474). However, the gel was only 50% effective in preventing rectal infection within 8 
hours of use (474), indicating a limited window of efficacy. Unfortunately, the gel formulation 
was not successful at preventing HSV-2 infection (475). MIV-150 was also tested in an IVR 
delivery system and provided significant protection when placed two weeks or 24 hours before 
challenge and left in place for two weeks post-challenge (476). Removal of the ring soon after 
challenge abrogated the inhibitory effect demonstrating that prolonged use of the product is 
necessary to prevent infection. The related compound MIV-160 was 100% effective when 
delivered by an IVR but showed no protection combined in a Carraguard/zinc acetate gel and has 
not moved into clinical testing (477). Although only the gel formulation of MIV-150 is currently 
in safety trials (https://clinicaltrials.gov; NCT02033109), macaque models demonstrate the 
potential of MIV-150 to be administered in two separate delivery systems to increase user 
options for PrEP while eliminating less effective candidates (MIV-160).  
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Figure 6. Comparison of the HIV-1, SIV, and RT-SHIV genomes. 
The RT coding region of SIV is replaced with the RT coding region of HIV-1 to create a virus 
that is infectious in macaques and susceptible to NNRTIs. Figure reproduced and adapted with 
permission from Ambrose et al. 2007 (478), © Elvesier. 
 
MC1220, a member of the 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines family of 
NNRTIs (479), was tested as a topical vaginal microbicide and IVR. A 0.5% or 1.5% gel 
formulation provided 50% protection in rhesus macaques when challenged with a high dose of 
RT-SHIV 30 minutes after gel application (480). This result was replicated in a follow-up study, 
but efficacy was nonexistent in a 0.1% gel formulation (481), suggesting a protective threshold 
beginning at a 0.5% preparation. Similar partial protection was reported for a MC1220 IVR in 
macaques challenged repeatedly with low-doses of RT-SHIV; however, the animals displayed a 
significant delay in infection between the IVR and placebo groups (482). Unlike MIV-150, 
MC1220 is not currently in clinical trials.  
Like IVRs, long-acting injectable PrEP formulations are designed to provide 
antiretroviral drug depots for sustained release to eliminate issues with missed pills. Unlike 
IVRs, injectable PrEP provides a drug depot that cannot be removed, thus guaranteeing 
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adherence. Currently there are two drugs being explored for long-acting injectable PrEP, the 
approved NNRTI RPV and the experimental integrase inhibitor CAB (311, 483). Long-acting 
CAB (CAB LA) has been shown to protect 75% and 100% of macaques from intravaginal and 
intrarectal challenges, respectively, if plasma drug concentrations were above a defined 
protective threshold (484, 485). To elucidate the protective threshold of CAB LA, the drug was 
administered to macaques that were then repeatedly challenged intrarectally with low doses of 
SHIV (484). As drug concentrations waned, the authors analyzed plasma concentrations at time 
of infection and determined that 4-fold the PAEC90 of infections provided complete protection 
with decreasing efficiency as plasma drug concentrations declined below 3-fold the PAEC90 
(484). The authors also showed that the plasma concentrations needed to reach the protective 
threshold were obtainable in humans (484), thus providing a realistic drug concentration target 
for clinical trials. This diligence may provide improved outcomes in clinical trials because 
dependence on in vitro effective values does not necessarily translate to efficacy in vivo due to 
the complex interaction of drug and host factors.  
Despite the benefits of testing PrEP agents and modalities in animals prior to clinical 
trials, not all animal models translate to human success. Because of the favorable safety profile 
of TFV and success as PrEP in macaques, it was formulated into a well-tolerated 1% vaginal gel 
to be marketed as a female-controlled prophylactic agent (486). Before movement into efficacy 
trials, the gel was tested in pigtailed macaques due to similarities between the animal and human 
menstrual cycles (443). Application of the gel 30 minutes prior to virus challenge protected 
every animal from 20 separate low-dose vaginal challenges, and the same result was seen with a 
1% TFV/5% FTC gel. However, reduced protection in the same model was reported when the 
gel was applied 3 days before challenge, indicating that the gel has a multi-day effective window 
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but would be most efficient prior to intercourse (444). Of note, 1% TFV gel was shown to 
considerably reduce rectal vaginal infections from challenge with SHIV (435, 442, 448, 450). 
Unfortunately, the CAPRISA 004 clinical trial was unable to repeat the success reported in the 
macaque models not because the gel was ineffective but rather because of participant adherence 
(18). A similar discrepancy was seen with carrageenan, a small molecule that blocks viral entry 
and the active ingredient of Carraguard. Despite success predicted by macaque modeling for a 
vaginal gel containing Carraguard (470), significant protection was not reported in a clinical trial 
despite lower infection rates in the Carraguard group (326). This was attributed to low adherence 
and unreliable monitoring (326). Dissimilarities in success between macaque and human studies 
emphasize the caution that must be exercised when interpreting results from animal models 
because of factors such as adherence, which cannot be controlled in human trials.  
An example of the utility of macaque models and their necessity in PrEP research is 
highlighted by the failed microbicide nonoxynol-9, a widely available spermicide. Clinical trials 
of nonoxynol-9 formulated as a vaginal gel revealed that greater use of the product led to a 
significant increase in HIV-1 infection attributed to lesions caused by the product (330). 
Irritation and disruption of macaque vaginal epithelium and microflora by nonoxynol-9 had been 
previously reported (487) but was not referenced in the clinical trial publication. Later, 
nonoxynol-9 gel showed a similar disruptive effect from repeated exposure in macaque rectal 
tissue, which confirmed side effects reported in humans (488). Had the available animal safety 
data been heeded and the gel tested in a repeated dose-challenge model in macaques, it is likely 
the product would have been shelved before moving into clinical trials, thus saving resources and 
avoiding an undesirable outcome.  
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Aside from testing dosing strategies and efficacy of PrEP, NHPs can be used to model the 
consequences of drug resistance. Because the current PrEP candidates are also prescribed for 
ART, there is potential that PrEP rollout could increase prevalence of circulating drug-resistant 
HIV-1 by selecting mutations post-infection or failing to inhibit drug-resistant transmissions. 
Within two studies 12 macaques became infected while receiving oral Truvada PrEP, but only 
two animals developed FTC-associated resistance mutations (M184I/V) despite continued 
treatment for over 9 weeks post-infection for all animals (316, 436). Resistance was not detected 
in infected macaques receiving oral TFV for >20 weeks post-infection (433), nor was drug 
resistance selected during TFV vaginal gel, rectal gel, or IVR PrEP studies with continued 
application of the products post-infection (442, 444, 449). Despite a small sample size, few 
instances of resistance selection in macaques were reflected in human trials where resistance 
development was rare in individuals infected after starting PrEP (320).  
A similar issue is the selection of resistance mutations in HIV-1+ individuals given PrEP, 
an event that has been realized in clinical trials albeit in a small number of participants (318-
320). This scenario is modeled by simply providing monotherapy to infected animals (389, 465, 
489, 490), but the PrEP delivery method needs to be considered. An excellent example is a study 
that compared resistance selection by systemic versus local PrEP (491). Daily IM injections of 
MIV-150 provided systemic concentrations of the compound and selected for known NNRTI 
resistance mutations (e.g., K101E, K103N, Y181C) in 100% of RT-SHIV infected macaques; 
however, localized drug release from an IVR did not select for mutations in plasma or LNs in the 
majority of animals (491). The mutations found in the IVR-treated animals were detected at low 
prevalence and were transient as opposed to the systemic animals that showed steady 
maintenance of the mutant populations (491). These results demonstrate that the mode of PrEP 
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delivery can affect resistance selection, and the consequences of infection during PrEP should be 
properly explored in animal models prior to clinical trials.  
The transmission of drug-resistant HIV-1 is another concern with PrEP. It is possible that 
drug concentrations able to inhibit wild-type (WT) virus may not be effective at blocking drug-
resistant virus infection. The only way to ethically explore drug-resistant virus transmission is to 
treat animals with PrEP and then challenge with drug-resistant isolates. This scenario was first 
modeled in newborn macaques given SC TFV PrEP (430). The macaques were challenged orally 
with SIV possessing the K65R TFV-resistant mutation. Infection was prevented in 40% of 
animals; although, PrEP-treated animals displayed better growth and significantly delayed 
disease course compared to untreated controls (430). High-level of protection from K65R SHIV 
infection in a vaginal microbicide model was also reported (450). Two studies using an 
intermittent oral Truvada strategy showed that PrEP still provides protection against repeated 
rectal challenges of SHIV with Truvada-resistant mutations; although, the lack of infection is 
believed to be a result of reduced fitness of the drug-resistant mutants (438, 440, 492). These 
models provide evidence that PrEP may not increase the prevalence of select transmitted drug-
resistant mutations; however, drug-resistant virus challenges should be investigated for each 
PrEP agent and modality.  
NHPs occupy a critical role in the pipeline of PrEP development because they are 
excellent models for predicting the efficacy and consequences of PrEP. With rigorous animal 
modeling, ineffective compounds such as nonoxynol-9 can be shelved, or successes like Truvada 
can be moved into human trials. For example, a variety of experimental entry inhibiting 
molecules and antibodies has been modeled in macaques to demonstrate in vivo effectiveness as 
microbicides that could be used in future PrEP trials (493-499). Although there is no recognized 
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standard macaque model for PrEP research, macaques are invaluable for testing dosing 
strategies, efficacy, and resistance selection and should not be overlooked in future PrEP work. 
1.2.4.2 BLT mouse models for PrEP  
A less expensive alternative to NHPs for in vivo PrEP research is the humanized mouse model. 
Although a variety of immunodeficient genetic lines of mice and humanization methods are 
available for HIV-1 research (390, 421), the BLT model is favored for PrEP studies because 
animals display excellent human immune cell reconstitution in vaginal and rectal tissues (315, 
417-419), the main sites of HIV-1 transmission (454). As described above, these mice are 
generated by transplantation of human fetal liver and thymus tissues under the kidney capsule of 
immunodeficient mice followed by an injection of autologous human CD34+ stem cells (413-
415). BLT mice have been successfully employed in PrEP studies with FDA-approved NRTIs, 
NNRTIs, and integrase inhibitors (Table 3).  
Like macaques, the BLT mouse model has been used to demonstrate the protective 
efficacy TFV-based PrEP strategies. Daily FTC and TFV displayed protection from vaginal and 
rectal HIV-1 transmission in BLT mice (315, 500, 506). Although the drugs were not 
administered orally, the inhibition of HIV-1 infection in mice provided a second pre-clinical in 
vivo model for the utility of systemic FTC and TFV as PrEP. To further validate the BLT model, 
a study was performed to emulate the PrEP methods tested in a microbicide trial (18). Over 88% 
of mice treated vaginally with 1% TFV gel in a similar timeframe recommended for women in 
the CAPRISA 004 trial were protected from HIV-1 infection (500). The same formulation also 
showed near complete protection from rectal HIV-1 infection when applied 30 minutes prior to 
challenge (507). The high rate of protection in mice (500, 507) and macaques (443, 444) is likely
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Table 3. BLT humanized mouse studies using approved ART as PrEP to prevent mucosal infection by HIV-1 
PrEP agent (dose) Dosing Challenge 
virus 
Challenge 
route 
Outcome Ref. 
FTC (3.5 mg) &  
TFV (5.2 mg)  
daily IP dose 2 d pre- and 5 d 
post-challenge 
HIV-1JR-CSF vaginal 5/5 protected (315) 
      
TFV (1% gel) dosing 4 h pre- and 4 h post-
challenge 
HIV-1JR-CSF vaginal 7/8 protected (500) 
      
FTC (28 μM) &  
TFV (16.5 μM) gel 
single dose 30 min pre-
challenge 
HIV-1JR-CSF vaginal 8/9 protected (500) 
      
RPV nanoparticle gel 
(17.5 μg gel) 
single dose 1.5 or 25 h pre-
challenge 
HIV-1RHPA vaginal 4/4 protected at 1.5 h challenge 
4/8 protected from 24 h challenge 
(501) 
      
RPV LA (15 mg) single IM dose 1 week pre-
challenge 
HIV-1CH040 vaginal 6/6 protected (501) 
      
RPV LA (15 mg) single IM dose 1 or 4 weeks 
pre-challenge 
HIV-1CH040 
HIV-1RHPA 
HIV-1JR-CSF 
HIV-1THRO 
vaginal 7/10 protected from 1st challenge 
3/7 protected from 2nd challenge 
(501) 
      
RAL LA  
(300 mg/kg) 
single SC dose 1 or 4 weeks 
pre-challenge 
HIV-1CH040 
HIV-1THRO 
vaginal 6/6 protected from 1st challenge 
3/5 protected from 2nd challenge 
(502) 
      
TFV nanoparticle gel 
(0.1%, 0.5%, & 
1.0%) 
single dose  
4 h pre-challenge (0.1%) 
1 d pre-challenge (0.5%) 
7 d pre-challenge (1.0%) 
HIV-1WITO 
HIV-1SUMA 
vaginal 4/4 protected with 0.1% 
6/6 protected with 0.5% 
0/5 protected with 1.0% 
(503) 
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Table 3 continued      
TFV & EVG 
nanoparticles  
(200 mg/kg each) 
single SC dose 4 or 14 days 
pre-challenge 
HIV-1WITO 
HIV-1SUMA 
vaginal 5/5 protected at day 4 
3/5 protected at day 14 
 
(504) 
      
TFV (20, 50, 140, or 
300 mg/kg) 
daily IP dose 3 d pre- and 4 d 
post-challenge 
HIV-1JR-CSF 
 
vaginal 7/14 protected at 20 mg/kg 
8/12 protected at 50 mg/kg  
11/13 protected at 140 mg/kg 
11/11 protected at 300 mg/kg 
(505) 
      
FTC (3.5 mg) &  
TFV (5.2 mg)  
daily IP dose 3 d pre- and 4 d 
post-challenge 
HIV-1JR-CSF rectal 9/9 protected (506) 
 
TFV (1% gel) single dose 30 min pre-
challenge 
HIV-1JR-CSF 
HIV-1THRO 
rectal 11/12 protected from HIV-1JR-CSF 
6/6 protected from HIV-1THRO 
(507) 
      
FTC (3.5 mg) &  
TFV (5.2 mg) 
daily IP dose 3 d pre- and 4 d 
post-challenge 
HIV-1JR-CSF oral 5/5 protected  (508) 
FTC, emtricitabine; TFV, tenofovir; RPV, rilpivirine; RAL, raltegravir; EVG, elvitegravir; IM, intramuscular; IP, intraperitoneal; 
SC, subcutaneous 
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attributable to the guaranteed adherence of the animals, which is impossible to enforce in 
humans; however, these distinct animals models suggest that 1% TFV gel should be an effective 
PrEP strategy if used properly, a concept demonstrated by increased protection rates in 
participants considered to be adherent in the CAPRISA 004 study (444).  
Long-acting injectable formulations of RPV and the integrase inhibitor raltegravir (RAL) 
have also been tested in BLT mice. IM and SC injections of RPV and RAL, respectively, were 
given to mice one week prior to intravaginal challenge with transmitted/founder strains of HIV-1 
(501, 502). Three separate experiments showed 70-100% protection from HIV-1 transmission 
with either drug; however, efficacy decreased for both drugs by 4 weeks post-dosing as nearly 
half the mice became infected after a follow-up challenge despite the presence of drug above 
defined protective concentrations (501, 502). Lack of protection from the second challenges is 
likely a result of waning drug concentrations, which reinforces the need for regular dosing to 
maintain protective concentrations of HIV-1 inhibitors. For both studies, the drug doses 
administered to mice provided drug concentrations near or above biologically relevant 
concentrations measured in humans. While concentrations of RAL in mice were similar to those 
reported in humans (502), the sustained protective plasma concentrations of RPV reported in 
mice (501) may not be attainable in a clinical setting (338, 340, 348). The disparity between 
protective concentrations of RPV in mice and in humans highlights the need to use well-
characterized, biologically relevant animal models for pre-clinical studies.  
The concern over PrEP selection of drug resistance has not been directly explored in 
humanized mouse; however, resistance mutations were not detected by population-based 
sequencing in the few breakthrough infections reported to occur in mice treated with FTC and 
TFV (506), TFV gel (507), RPV LA (501), or RAL LA (502). Inhibition of drug-resistant HIV-1 
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transmission has not been addressed in BLT mouse models either; although, one study did report 
inefficient vaginal infection with TFV-resistant virus in BLT mice (509) similar to what was 
shown in macaques (440, 510) 
Overall, results of BLT mouse studies with approved ART drugs show near complete 
protection when the animals are treated and challenged to reflect recommended use of PrEP in 
humans (Table 3). These outcomes are similar to the results of macaque studies and demonstrate 
the utility of the humanized mouse as an in vivo model for HIV-1 PrEP research. As in 
macaques, novel PrEP strategies such as experimental NRTIs (511), peptide and small molecule 
entry inhibitors (500), CCR5 and viral protein small interfering RNA (siRNA) (512), transgenic 
immunoglobulin A expression vectors (513), lymphocyte function-associated antigen 1-targeting 
liposomal CCR5 siRNA nanoparticles (514), and an adeno-associated virus vector for broadly 
neutralizing antibody production (515) have been tested in BLT mice to show successful 
inhibition of HIV-1 infection and potential as future PrEP strategies. Despite ongoing research to 
improve human immune cell function in mice to expand their utility for HIV-1 research (424, 
516), humanized mice are a cost-effective alternative to NHPs for PrEP studies.
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2.0  SPECIFIC AIMS 
Without an effective vaccine to prevent HIV-1 infection, PrEP is currently an effective option to 
reduce global HIV-1 transmission. Clinical trials have shown that daily oral Truvada is effective 
at preventing HIV-1 transmission in high-risk populations and has been approved for clinical 
use. However, PrEP is most efficacious if individuals are adherent to the prescribed regimen. In 
an effort to improve PrEP adherence, a long-acting injectable formulation of the antiretroviral 
drug RPV was developed to provide sustained drug concentrations via monthly dosing. Because 
RPV has a similar resistance profile to other clinically-approved NNRTIs, there is potential that 
rollout of RPV LA PrEP could increase the prevalence of circulating drug-resistant HIV-1, thus 
excluding the use of NNRTI-containing ART in newly infected persons. To address resistance 
concerns with RPV LA PrEP, the first two Aims focus on the selection and transmission of HIV-
1 drug resistance in animal models. The third Aim focuses on the in vitro resistance profiles of 
novel RPV analogs that could be further investigated as ART or PrEP. 
AIM 1: Study the selection of RPV resistance by RPV LA monotherapy in a RT-
SHIV macaque model. The standard of HIV-1 care is to provide ART that contains multiple 
antiretroviral drugs with distinct resistance profiles to preserve viral suppression in the event of 
DRM development. Individuals who become infected with HIV-1 prior to or after receiving RPV 
LA may be more likely to select for DRMs due to RPV monotherapy. Because it is unethical to 
test resistance selection by RPV LA in HIV-1+ individuals, we investigated whether RPV LA 
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could select for drug resistance in RT-SHIV-infected pigtailed macaques. We hypothesized that 
RT-SHIV plasma viremia would rebound after RPV LA dosing, and the virus population would 
contain RPV-associated resistance mutations in the HIV-1 RT coding region. 
AIM 2: Investigate the efficacy of RPV LA to prevent mucosal transmission of HIV-
1 with NNRTI-resistant mutations in humanized mice. Because of the increase in global 
ART, prevalence of NNRTI-associated resistance mutations is increasing. It is possible that an 
individual receiving RPV LA PrEP could be exposed to HIV-1 with a RPV-associated DRM. In 
this event, the likelihood of RPV LA to prevent transmission of the drug-resistant virus is 
unknown. To test the efficacy of RPV LA to inhibit vaginal transmission of NNRTI-resistant 
HIV-1, we challenged humanized mice with two drug-resistant HIV-1 clones that had either low- 
or high-levels of RPV resistance and compared them to mice challenges with WT HIV-1. We 
hypothesized that biologically relevant concentrations of RPV LA would inhibit infection by WT 
HIV-1 but not drug-resistant isolates. 
AIM 3: Determine the in vitro resistance profile of mutations in HIV-1 selected by 
novel RPV analogs. HIV-1 has a high mutation rate and can develop resistance in the presence 
of antiretroviral drugs. However, cross-resistance between NNRTIs can limit ART options in 
individuals failing therapy. New antiretroviral compounds that are effective against HIV-1 with 
known DRMs must be discovered. Given the favorable potency and safety profile of RPV, 
analogs with changes to its structure were developed to inhibit HIV-1 with known NNRTI-
associated DRMs. To understand the mechanism of actions of three RPV analogs, HIV-1 was 
selected in the presence of the compounds to identify novel DRMs. We hypothesized that the 
analogs would select for novel resistance mutations that would not display cross-resistance to 
other NNRTIs.  
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3.0  AIM 1: LOW FREQUENCY OF DRUG-RESISTANT VARIANTS SELECTED BY 
LONG-ACTING RILPIVIRINE IN MACAQUES INFECTED WITH SIMIAN 
IMMUNODEFICIENCY VIRUS CONTAINING HIV-1 REVERSE TRANSCRIPTASE 
Kevin Melody1, Sarah McBeth2, Christopher Kline2, Angela D.M. Kashuba3, John W. Mellors2, 
Zandrea Ambrose1, 2 
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3.1 PREFACE 
Results of this work were partially presented as a poster titled “Selection of drug resistance in a 
reverse transcriptase simian-human immunodeficiency virus macaque model using long-acting 
rilpivirine” at the 2014 International Workshop on Antiviral Drug Resistance in Berlin Germany.  
This work, essentially as presented here, was originally published in the Journal of 
Antimicrobial Agents and Chemotherapy (copyright © American Society for Microbiology) as: 
Melody K, McBeth S, Kline C, Kashuba AD, Mellors JW, Ambrose Z. 2015. Low Frequency of 
Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian 
Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase. Antimicrob Agents 
Chemother 59:7762-7770. Permission to reprint this work was granted by the American Society 
of Microbiology (http://journals.asm.org).  
The work presented in this chapter is for completion of Aim 1 in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy. Kevin Melody processed blood samples, 
sequenced HIV-1 clones from plasma vRNA, and performed drug susceptibility assays. Chris 
Kline isolated vRNA from plasma samples and performed quantitative reverse transcriptase PCR 
(qRT-PCR) on plasma and tissue samples. Sarah McBeth sequenced vRNA variants isolated 
from tissue samples. Angela Kashuba completed the PK analysis of RPV in macaques to 
determine RPV LA dosing. 
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3.2 ABSTRACT 
PrEP using antiretroviral drugs is effective in reducing the risk of HIV-1 infection, but adherence 
to the PrEP regimen is needed. To improve adherence, a long-acting injectable formulation of the 
NNRTI RPV has been developed. However, there are concerns that PrEP may select for drug-
resistant mutations during preexisting or breakthrough infections, which could promote the 
spread of drug resistance and limit options for antiretroviral therapy. To address this concern, we 
administered RPV LA to macaques infected with RT-SHIV. Peak plasma RPV levels were 
equivalent to those reported in human trials and waned over time after dosing. RPV LA resulted 
in a 2-log decrease in plasma viremia, and the therapeutic effect was maintained for 15 weeks, 
until plasma drug concentrations dropped below 25 ng/ml. RT mutations E138G and E138Q 
were detected in single clones from plasma virus in separate animals but not consistently, and no 
resistance mutations were detected in vRNA isolated from tissues. WT and E138Q RT-SHIV 
displayed similar RPV susceptibilities in vitro, whereas E138G conferred 2-fold resistance to 
RPV. Overall, selection of RPV-resistant variants was rare in an RT-SHIV macaque model 
despite prolonged exposure to slowly decreasing RPV concentrations following two injections of 
RPV LA. 
3.3 INTRODUCTION 
Despite increasing use of ART, which suppresses viral replication and reduces the risk of HIV-1 
transmission, an estimated two million new HIV-1 infections still occur annually worldwide (1). 
While research continues to deﬁne effective, vaccine-elicited protective immune responses, PrEP 
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has proven effective in reducing HIV-1 transmission. Thus far, clinical trials have exhibited a 44 
to 75% reduction in HIV-1 infections in individuals treated with TFV with or without FTC (17, 
19-21). These successes led to FDA approval of daily oral TFV-FTC PrEP for high-risk 
populations. 
One prominent issue with PrEP is that efﬁcacy is dependent on adherence. Data from 
clinical trials has shown that participants with detectable plasma drug concentrations indicative 
of adherence have reduced risk of HIV-1 infection, while poor PrEP adherence confers little 
protection (14, 17-19, 517). Although recent work suggests that sexual event-driven TFV-FTC 
administration can be effective in men (316, 436, 445), sporadic PrEP adherence may lower 
PrEP efﬁcacy and promote selection of drug-resistant variants. To reduce pill burden, long-acting 
injectable nanoparticle formulations of the NNRTI RPV and an experimental integrase inhibitor, 
CAB, have been developed (338, 518). Injectable PrEP formulations create a depot at the 
injection site and provide drug release for weeks to months, thus eliminating the need for daily 
drug administration. Long-acting injectable medications have been used successfully to 
administer antipsychotics, contraceptives, hormone replacements, and cancer treatments (341, 
519-521). 
RPV is the most recently approved NNRTI for ART in combination with other 
antiretrovirals in patients with plasma viremia of less than 100,000 copies of HIV-1 RNA/ml 
(213, 292, 522). Clinical trials have shown RPV-TFV-FTC to be non-inferior to and more 
tolerable than EFV-based ART (292). During these trials, patients failing RPV-based ART also 
tended to select unique NNRTI-associated resistance mutations in RT compared with those on an 
EFV-based regimen (306). RPV LA is an injectable nanoparticle formulation that has been 
shown to be safe and tolerable, with detectable drug concentrations maintained in plasma and 
67 
tissues weeks after a single injection (340, 347, 483, 523). Multiple clinical trials are under way 
to test safety and acceptability of RPV LA as PrEP in HIV-1-uninfected men and women (523). 
Of concern with RPV LA PrEP is the development of drug resistance if an individual 
with an undetected HIV-1 infection receives PrEP or someone on PrEP becomes infected, 
resulting in treatment with RPV monotherapy. Additionally, while patients on a pill-based 
regimen can cease PrEP and rapidly clear the drug, injectable medications will require weeks to 
reach undetectable concentrations. These situations may increase the selection of DRMs, 
promoting spread of drug resistance and limiting future ART options through cross-resistance 
(16). Resistance analyses of breakthrough infections in TFV-FTC clinical trials revealed that 
selection of DRMs was rare in patients who became infected after receiving PrEP, but DRMs did 
develop in the few individuals that were HIV-1+ before initiating PrEP (318-320). 
Although the development of DRMs during TFV-FTC PrEP clinical trials was rare (318-
320), there is currently no published data on the resistance outcome of long-acting PrEP as 
monotherapy. We report here on a pilot study to explore the selection of drug resistance by RPV 
LA in RT-SHIV-infected macaques. RT-SHIVmne is a chimeric SIV that contains the HIV-1 
reverse transcriptase coding region (370, 389). SIV is not susceptible to NNRTIs due to sequence 
differences within the RT coding region, but NNRTI sensitivity is established by swapping the 
SIV and HIV-1 RT coding regions (369, 458). RT-SHIV macaque models have been used to 
study HIV-1 ART, drug resistance, PrEP, and persistence (369, 389, 464, 466, 467, 470, 472, 
473, 476, 477, 480, 491, 524-529). In this study, we treated RT-SHIV-infected macaques with 
RPV LA and measured plasma viremia, drug concentrations, and drug-resistant isolates over 35 
weeks. Our data show that viremia was suppressed by RPV LA monotherapy, which rebounded 
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to pretherapy levels as plasma drug concentrations waned. However, resistance to RPV in RT-
SHIV was difﬁcult to select both in vitro and in vivo. 
3.4 MATERIALS AND METHODS 
3.4.1 Cell culture and antiretroviral inhibitors 
293T (530) and TZM-bl (531, 532) cell lines were cultured in Dulbecco’s modiﬁed Eagle’s 
medium (DMEM; Life Technologies) supplemented with 10% fetal bovine serum (FBS; Atlanta 
Biologicals) and 100 U/ml of penicillin, 100 μg/ml of streptomycin, and 0.292 mg/ml of L-
glutamine (P-S-G; Life Technologies). This mix of DMEM, FBS, and P-S-G will henceforth be 
referred to as complete DMEM (cDMEM). GHOST-R3/X4/R5 cells (533) were maintained in 
the same medium as described above with the addition of 100 μg/ml of G418 (Life 
Technologies), 100 μg/ml of hygromycin (Life Technologies), and 0.5 μg/ml of puromycin 
(EMD Millipore). CEMx174 cells were cultured in RPMI 1640 medium supplemented with 10% 
FBS and 1% P-S-G. All cell lines were incubated at 37°C with 5% CO2. 
RPV was acquired from the National Institute of Health (NIH) AIDS Reagent Program. 
RPV LA was donated by Janssen Sciences UC Ireland. 
3.4.2 Virus production and titer determination 
Plasmids encoding HIV-1LAI with silent restriction sites within RT (534) and RT-SHIVmne (389) 
were used for virus production by transfection into 293T cells with Lipofectamine 2000 (Life 
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Technologies) and stored at -80°C. Mutations were introduced into the plasmids by site-directed 
mutagenesis using either the QuikChange II XL kit (Agilent Technologies) or the Q5 site-
directed mutagenesis kit (New England BioLabs). Virus was harvested 48 hours after 
transfection and titered on GHOST cells as previously described with modifications (533). 
GHOST cells were seeded in a 24-well plate at 2x104 cells/0.5 ml in cDMEM. The following 
morning, media was removed and cells were exposed to cDMEM with dilutions of virus stock. 
Cells and virus were incubated for 2 hours, after which virus and media were replaced with fresh 
cDMEM and allowed to incubate for 48 hours. After 48 hours, cells were trypsinized using 
0.25% trypsin-EDTA (Gibco), fixed in paraformaldehyde at a final concentration of 2%, and 
analyzed for green fluorescent protein expression by flow cytometry on a LSRII flow cytometer 
(BD Biosciences). Titers of RT-SHIV stocks were determined using TZM-bl indicator cells and 
β-galactosidase staining as previously described (370, 535). 
3.4.3 Animals 
Two juvenile pigtailed macaques were housed at the University of Pittsburgh in accordance with 
American Association of Accreditation of Laboratory Animal Care (AAALAC) standards. All 
procedures were performed according to protocols approved by the Institutional Animal Care 
and Use Committee (IACUC). The animals were negative for serum antibodies to HIV type 2, 
SIV, type D retrovirus, and simian T-lymphotropic virus type 1 at study initiation. Animals were 
infected IV with 1x105 infectious units (IU) of RT-SHIVmne. At 6 and 8 weeks post-infection, 
animals were treated with 200 mg/kg of RPV LA by IM injection near the scapula. This dosing 
regimen was determined by prior PK analysis that showed that a single 50 mg/kg dose of RPV 
LA did not result in plasma drug concentrations above 16 ng/ml within 24 hours of 
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administration, consistent with our previous observations of rapid metabolism of NNRTIs in 
pigtailed macaques (data not shown). Blood was drawn under anesthesia weekly or bimonthly. 
Animals were euthanized at 35 weeks post-infection, and multiple tissues, including axillary LNs 
and ileum, were immediately ﬂash frozen and stored in liquid nitrogen. 
3.4.4 T cell counts and vRNA isolation 
Plasma was separated from EDTA-treated whole blood by centrifugation at 400 x g for 10 min 
and stored at -80°C until processed. vRNA was isolated from plasma as previously described 
(536). Brieﬂy, plasma was mixed with Tris-buffered saline (Sigma) and pelleted by 
centrifugation at 21,000 x g for 1 hour. Virus was then suspended in 3 M guanidinium chloride, 
50 mM Tric-HCl (pH 7.6), 1 mM CaCl2, and 1 mg/ml of proteinase K and incubated at 42°C for 
1 hour, followed by addition of 5.7 M guanidine thiocyanate, 50 mM Tris-HCl (pH 7.6), 1 mM 
EDTA, and 600 μg/ml of glycogen and a 5 min incubation at room temperature. RNA was 
washed with isopropanol and ethanol and samples were suspended in 10 mM Tris-HCl (pH 8). 
Tissue vRNA isolation was performed as previously described (537). 
Peripheral blood mononuclear cells (PBMCs) were isolated from samples using 
lymphocyte separation medium (Corning) and treated with ACK Lysing Buffer (Life 
Technologies) and washed with phosphate buffered saline, pH 7.4 (PBS; Life Technologies) to 
remove red blood cells. PBMCs were stained with NHP T lymphocyte cocktail (BD Biosciences) 
with antibodies against cluster of differentiation 3 (CD3), CD4, and CD8. CD3+CD4+, and 
CD3+CD8+ cell populations were measured by ﬂow cytometry. Isotype cocktail C (BD 
Biosciences) was used for isotype controls. 
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3.4.5 RPV plasma and tissue concentrations 
RPV was extracted from monkey plasma using protein precipitation followed by liquid 
chromatograph-tandem mass spectrometry (LC-MS/MS) analysis. Calibration standards and 
quality control (QC) samples were prepared in monkey plasma (EDTA) on the day of analysis. 
Fifty microliters of each plasma sample was mixed with 50 μl of a 50:50 methanol-water mixture 
containing amprenavir-d4 as the internal standard. Then, 300 μl of methanol was added to each 
sample. Following vortex and centrifugation steps, the resulting supernatant was transferred to a 
96-well plate for LC-MS/MS analysis. Tissues were homogenized in 1 ml of 70:30 acetonitrile–1 
mM ammonium phosphate (pH 7.4) with a Precellys hard tissue grinding kit tube (Cayman 
Chemical), followed by a similar plasma preparation procedure. Tissue weights ranged from 84.2 
to 95.4 mg. Analyte concentrations from tissue homogenates were normalized to tissue weight. A 
tissue density of 1 g/ml was used to convert concentrations into ng/ml. A Shimadzu high-
performance liquid chromatography system was used for separation, and an AB SCIEX API 
5000 mass spectrometer (AB SCIEX) equipped with a turbo spray interface was used as the 
detector. The samples were analyzed with a set of calibration standards and QC samples, with a 
dynamic range of 0.5 to 2,000 ng/ml. The precision and accuracy of the calibration standards and 
QC samples were within the acceptable range of 15%. 
3.4.6 vRNA quantitation 
Copies of vRNA were measured by generation of cDNA from vRNA isolated from plasma or 
tissues by the SuperScript III ﬁrst-strand synthesis kit (Life Technologies) with the SIVgag-R 
primer (5’-CACTAGGTGTCTCTGCACTATCTGTTTTG-3’). qPCR was performed on cDNA 
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using SsoFast probes SuperMix (Bio-Rad), SIVgag-F (5’-GTCTGCGTCATCTGGTGCATTC-3’) 
and SIVgag-R primers, and the SIVgag-probe (5’-FAM-
CTTCCTCAGTGTGTTTCACTTTCTCTTCTGCG-3’ 6-carboxytetramethylrhodamine dye). 
CCR5 primers and probe were previously described (537). Reaction conditions were 1 cycle of 
95°C for 2 min followed by 45 cycles of 95°C for 15 s and 60°C for 1 min. 
3.4.7 vRNA sequencing 
The RT coding region was ampliﬁed from cDNA generated from vRNA isolated from plasma or 
tissues using nested PCR. The ﬁrst round of PCR was performed with the Platinum Taq DNA 
polymerase high-ﬁdelity kit (Life Technologies), using primers ZA01 (5’-
CTAGATCTGAATTTGCCTGCCC-3’) and ZA02 (5’-
TGTAACAGGAATAGAGTTAGGTCC-3’) with the following reaction conditions: 94°C for 2 
min; 40 cycles of 94°C for 15 s, 49°C for 30 s, and 68°C for 2 min; and 1 cycle of 68°C for 5 
min. DNA was puriﬁed using the ExoSAP-IT PCR cleanup kit (Affymetrix) per the 
manufacturer’s instructions. The second round of PCR ampliﬁcation was performed with the 
Platinum PCR Supermix kit (Life Technologies), using primers RT19 (5’-
GCAAAAGGATTAAAGGGACAA-3’) and RT22 (5’-
GGGTAATCCAAATTTGAATACCAATCCT-3’) with the following reaction conditions: 94°C 
for 2 min; 26 cycles of 94°C for 15 s, 63°C for 30 s with -0.5°C increments per cycle, and 72°C 
for 2 min; 15 cycles of 94°C for 15 s, 50°C for 30 s, and 72°C for 2 min; and 1 cycle of 72°C for 
5 min. The PCR product was then cleaned using the Wizard SV gel and PCR cleanup system 
(Promega) and cloned into TOPO vectors using the pCR 2.1-TOPO TA cloning kit (Life 
Technologies) per the manufacturer’s instructions. Bacterial colonies were screened for full-
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length RT sequence by PCR. RT-containing TOPO vectors were isolated from overnight 
bacterial cultures using the QiaPrep Spin Miniprep kit (Qiagen). Sequences were analyzed using 
Lasergene (DNASTAR). 
3.4.8 RT-SHIV in vitro resistance selection 
CEMx174 cells (538) were infected with WT RT-SHIV at a multiplicity of infection (MOI) of 
0.05 in medium and incubated at 37°C for 2 hours. Cells and virus were then resuspended in 
medium containing 0.1 nM RPV. Cultures were passaged every 2 to 3 days in new medium. If 
cytopathic effects (CPE) were apparent, vRNA was isolated from culture supernatant using the 
RNeasy minikit (Qiagen) and sequenced as described above. If the RT sequence from vRNA 
isolated from the supernatant was WT, then 50 μl of culture supernatant was used to infect fresh 
CEMx174 cells and the RPV concentration was doubled to begin a new round of selection. 
3.4.9 Drug susceptibility assay 
Drug susceptibility assays were performed as previously described, with minor modiﬁcations 
(370). TZM-bl cells were seeded at 5x103 cells in 96-well cell culture-treated white plates 
(PerkinElmer). The following day, virus and serial drug dilutions were prepared in phenol red-
free DMEM (Life Technologies) supplemented with 1% P-S-G and 10% FBS or different 
amounts of human or macaque serum. Medium containing virus (MOI of 0.05) and drug 
dilutions in a total volume of 0.2 ml was added to each well in triplicate. Wells with virus and no 
drug were used as 100% infection controls. Plates were incubated at 37°C for 48 hours. 
Luciferase activity was measured using Britelite Plus reagent (PerkinElmer) on a Luminoskan 
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Ascent microplate luminometer (Thermo Scientiﬁc). Relative light units (RLU) were converted 
to percent infection by dividing the RLU of each drug dilution by the RLU of the 100% infection 
control. Wells containing cells with no virus and no drug were used to normalize for background 
luciferase output. The EC50 was calculated using PRISM 6 (GraphPad). Speciﬁcally, EC50 was 
calculated by log transforming drug concentrations and using a four-parameter variable slope 
nonlinear regression for curve ﬁtting analysis. 
3.5 RESULTS 
3.5.1 RPV LA treatment of RT-SHIV-infected macaques 
To assess the potential for selection of drug-resistant virus in vivo during RPV LA treatment, two 
pigtailed macaques were infected with RT-SHIV at week 0. Both animals showed peak viremia 
between 1x106 and 1x107 copies of vRNA/ml, which declined to a set point of 5x105 to 9x105 
vRNA copies/ml (Figure 7). Based on PK results (data not shown), animals were treated with 
two 200 mg/kg IM doses of RPV LA at weeks 6 and 8 post-infection. Post-treatment, there was 
an immediate ~2-log decline in plasma viremia, which was maintained at approximately 
1.35x104 vRNA copies/ml until 21 weeks post-infection. Viral loads slowly rebounded thereafter 
to pretherapy set point values (Figure 7). There was a transient decrease in the percentage of 
CD4+ T cells in both animals after infection, followed by a steady post-treatment increase for the 
remainder of the study (data not shown). The only adverse events attributed to RPV LA 
treatment were redness and swelling at the injection sites. 
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Figure 7. Plasma RT-SHIV levels in two macaques treated with RPV LA monotherapy. 
Animals were infected at week 0 and received two IM does of RPV LA at 6 and 8 weeks post-
infection (designated by arrows under the x axis). Plasma viremia (blue lines) and RPV 
concentrations (red lines) were measured. The dashed lines indicate the limit of detection of the 
qRT-PCR assay (50 RNA copies/ml). 
 
 
Although a standard protective concentration of RPV has not been deﬁned, the in vitro 
EC50 of RPV is 0.1 to 0.7 nM (265, 286), and our dosing strategy was designed to achieve 
plasma RPV concentrations equivalent to that reported for humans: 50 ng/ml (136 nM) (286, 
338). Maximum plasma RPV concentrations of 86.5 ng/ml and 40 ng/ml (214.7 nM and 99.3 
nM) were detected at week 10 post-infection in animals M170 and M171, respectively (Figure 
7). Plasma RPV concentrations were greater than 15 ng/ml (40.9 nM) in both animals up to 29 
weeks after the ﬁrst RPV LA injection. Virus rebound appeared to be associated with declining 
drug concentrations, although there was not a signiﬁcant correlation between plasma RPV 
concentrations and viral loads by linear regression (R2 = 0.15). RPV concentrations in the 
axillary LN and ileum were 4- to 421-fold higher than in plasma at the time of necropsy (week 
35 post-infection) (Table 4). As tissue homogenate concentrations are averaged across a 
heterogeneous matrix, these data do not differentiate between extracellular or intracellular drug 
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exposure and intracellular drug exposure between cell types. Therefore, the averaged 
concentration could signiﬁcantly over represent the concentration of drug in mononuclear cells. 
Since it is difﬁcult to isolate mononuclear cells from tissue without extracellular leaching of drug 
during the isolation process, intracellular drug concentrations in tissues, and the resulting 
pharmacodynamic effect, are an area of continued study. 
 
Table 4. RPV concentrations (ng/ml) in plasma and tissues of both animals at 35 weeks 
post-infection 
 RPV concentrations (ng/ml) 
Site Animal M170 Animal M171 
Plasma 18 18 
Axillary LN 155 7,590 
Ileum 136 80 
 
3.5.2 Plasma RT-SHIV drug resistance detection 
To identify selection of RPV-resistant variants, we sequenced the RT coding region of plasma 
virus at week 6 prior to therapy and at weeks 9, 13, 21, and 25 post-infection. At all time points, 
the full-length consensus RT sequence matched the starting RT sequence, indicating a lack of 
detectable mutations that constituted more than 20% of the virus population (data not shown). 
However, partial and full clonal RT regions were sequenced and revealed many minor viral 
variants in the plasma (Table 5). Based on Poisson distribution, the probability of detecting 
variants present at 5% frequency in a virus population with 90% certainty requires analysis of at 
least 45 clones. Hence, approximately 45 clones were sequenced at 6, 9, 13, and 25 weeks post-
infection. The majority of clonal sequences was either WT or had mutations in RT amino acids 1 
to 250 that are not associated with known drug resistance. E138G was identiﬁed in a single clone 
at both weeks 9 and 13 in animal M170 but was not detectable later. E138Q was identiﬁed in a 
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single clone at week 25 in animal M171. T69A and K65R are NRTI-associated resistance 
mutations that were also identiﬁed, but they were also detected at frequencies as low as 
E138G/Q. 
To determine if E138G or E138Q conferred RPV resistance in RT-SHIV, the mutations 
were made in both HIV-1 and RT-SHIV and were tested for susceptibility to RPV compared to 
that of WT viruses in vitro. WT HIV-1 and RT-SHIV displayed similar RPV susceptibilities, 
with EC50s of 0.67 ± 0.08 and 0.35 ± 0.06 nM (Table 6). E138G conferred a slight increase in 
EC50 compared to WT virus in both HIV-1 and RT-SHIV backbones: EC50s of 0.94 ± 0.03 and 
0.76 ± 0.12 nM (1.4- and 2.2-fold changes), respectively. Conversely, E138Q conferred a 4.3-
fold EC50 increase above WT HIV-1 (2.85 ± 0.08 nM) and no difference from WT RT-SHIV 
(0.30 ± 0.05 nM). These EC50s for WT, E138G, and E138Q HIV-1 were similar to values 
previously reported (265, 284). 
3.5.3 Tissue RT-SHIV drug resistance detection 
Because no consistent RT mutations were identiﬁed in plasma virus from either animal, vRNA 
isolated from axillary LN and ileum obtained at 35 weeks post-infection was clonally sequenced. 
Axillary LNs were chosen because they were the lymphoid tissues closest to the injection site. 
Tissues of the gastrointestinal tract were also sampled because they are known to harbor large 
numbers of infected cells, particularly in the terminal ileum (150). High levels of RT-SHIV RNA 
copies were measured by qRT-PCR in both the axillary LN and ileum taken at necropsy from 
both animals (Table 7). While measurements were not taken prior to drug exposure or during 
peak plasma drug concentrations, the results suggest that signiﬁcant viral transcription occurs in 
the LN and ileum despite high RPV levels at those sites (Table 4). 
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Table 5. Mutations identified in RT of plasma RT-SHIV RNA 
 Mutations in RT-SHIV RTa (No. of clones) 
Animal Week 6
b Week 9 Week 13 Week 21 Week 25 
M170 WT (14) 
Non-DRM (31) 
WT (25) 
Non-DRM (19) 
R125G, E138G (1) 
WT (19) 
Non-DRM (25) 
S68G, E138G (1) 
WT (4) 
Non-DRM (6) 
WT (24) 
Non-DRM (19) 
K65R (1) 
      
M171 WT (22) 
Non-DRM (23) 
WT (26) 
Non-DRM (19) 
WT (24) 
Non-DRM (20) 
T69A (1) 
WT (5) 
Non-DRM (5) 
WT (21) 
Non-DRM (19) 
E138Q, P157-, L213F, V244C (1) 
a Results represent a mix of full-length and partial (amino acids 1-250) RT sequences. 
b Prior to RPV-LA administration (6 and 8 weeks post-infection). 
WT, wild-type; non-DRM, mutations not associated with drug resistance; -, codon deletion; underline, known RPV-associated 
resistance mutations. 
 
Table 6. RPV susceptibility of HIV-1 and RT-SHIV with select mutations identified in plasma and tissue vRNA 
Virus Mutation(s) in RT sequence EC50 (nM)
a Fold-change from WT virusb 
HIV-1 WT 0.67 ± 0.08 1 
E138G 0.94 ± 0.03 1 
E138Q 2.85 ± 0.08 4 
A33V 0.42 ± 0.07 0.6 
Y181H 0.17 ± 0.02 0.3 
A33V, Y181H 0.13 ± 0.01 0.2 
    
RT-SHIV WT 0.35 ± 0.06 1 
E138G 0.76 ± 0.12 2 
E138Q 0.30 ± 0.05 0.8 
a Values represent mean and standard deviation of 3 independent experiments, each performed in triplicate. 
b Fold-change is calculated as the ratio of the mean EC50 of mutant to WT virus.  
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Table 7. RNA copies of RT-SHIV gag and macaque CD4 measured from tissue RNA 
  Number of copies (x 106)b  
Animal Tissue
a gag copies CD4 copies gag/CD4 Ratio 
M170 Axillary LN 28 ± 0.5 327 ± 10 0.09 
Ileum 334 ± 36 126,237 ± 58,548 0.003 
     
M171 Axillary LN 10 ± 0.8 29 ± 2 0.3 
Ileum 7,863 ± 367 54,343 ± 493 0.1 
a Tissues taken at 35 weeks post-infection. 
b Mean ± standard deviation, measured by qRT-PCR in duplicate. 
 
Table 8. Mutations identified in RT of RT-SHIV RNA isolated from tissues  
Animal Tissue
a Mutations in RT-SHIV RTb (No. of clones) 
M170 Axillary LN WT (1) 
A33V (10) 
M16I, A33V (2) 
A33V, I135T (2)  
A33V, V179A (1) 
A33V, I195V, R206G (1) 
Q85R, H96R (1) 
P217S (1) 
K220E (1) 
Ileum WT (8) 
A33V (10) 
A33V, D218G (1) 
A33V, V245A (1) 
   
M171 Axillary LN WT (12) 
N54S (1) 
D76G (1) 
E79G (1) 
G112D (1) 
G155R (1) 
S163G, G196E (1) 
H208R, D250G (1) 
G242. (1) 
Ileum WT (14) 
A33V, Q145R (2) 
A33V, K173R (1) 
A33V, Y181H (2) 
A33V, T200A (1) 
a Tissues taken at 35 weeks post-infection. 
b Sequences represent amino acids 1-250 of RT; WT, wild-type; ., stop codon 
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No known DRMs were detected in 20 clones from either tissue from both animals (Table 
8). However, the A33V mutation was identiﬁed in 45% of ileum clones from both animals and 
80% of axillary LN clones from animal M170. This mutation also was identiﬁed in a single clone 
in the plasma for M170 at week 9 (Table 5). Y181H was present and linked to A33V in two 
clones from the ileum of animal M171. While Y181H has not previously been reported in 
association with NNRTI resistance, Y181C, Y181I, and Y181V mutations display RPV 
resistance (265). Interestingly, we detected G112D in a single clone obtained from one axillary 
LN from animal M171. This mutation confers 2-fold resistance to RPV and was selected by an 
RPV analog in vitro (see Chapter 5). 
Due to the high frequency of the A33V mutation in the viruses isolated from tissues and 
the association of RPV resistance with mutations at position 181, the amino acid substitutions 
A33V and Y181H were made separately and together in HIV-1 and tested for RPV sensitivity. 
A33V did not confer RPV resistance, while Y181H alone or with A33V conferred 
hypersusceptibility to RPV compared to WT HIV-1: 0.3- and 0.2-fold, respectively (Table 6). 
3.5.4 Effects of human and macaque plasma on RPV inhibition of HIV-1 and RT-SHIV 
As RPV inhibition of HIV-1 was greatly decreased by the presence of high human serum 
proteins in vitro (265), the effect of macaque serum on RT-SHIV inhibition by RPV was 
investigated in cell culture. Similar to previously published results in which 50% human serum 
increased the EC50 of RPV against HIV-1 18.5-fold (265), 25% human serum reduced RPV 
inhibition of HIV-1 in vitro in our study 12-fold (Table 9). Similarly, addition of macaque serum 
increased the EC50 of RPV against RT-SHIV compared to the values with medium with FBS 
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(Table 9). The results suggest that macaque serum proteins do not impact RPV activity against 
RT-SHIV more than human serum proteins. 
Selection of RPV resistance in RT-SHIV was also difﬁcult to achieve in CEMx174 cells 
using the same virus stock as used to infect the macaques. RT-SHIV-infected cells were exposed 
to increasing concentrations of RPV for 350 days (0.1 to 409.6 nM), and vRNA isolated from 
supernatants from all time points had WT sequence in the RT coding region (data not shown). 
This is in contrast to selection of Y181C or K103N in RT-SHIV in CEMx174 cells by NVP or 
EFV, respectively (370). 
 
Table 9. Effect of human and macaque serum on RPV EC50 
Virus Serum EC50 (nM)
a Fold-Changeb 
HIV-1 10% FBS 0.54 ± 0.05 1 
5% Human 1.34 ± 0.10 3 
10% Human 2.45 ± 0.44 5 
25% Human 6.72 ± 0.39 12 
    
RT-SHIV 10% FBS 0.42 ± 0.08 1 
5% Macaque 0.45 ± 0.21 1 
10% Macaque 1.16 ± 0.15 3 
a Mean ± standard deviation of triplicates from one experiment. 
b Compared to assay performed with 10% FBS. 
 
3.6 DISCUSSION 
Although global HIV-1 incidence is decreasing in large part due to rollout of ART, an effective 
vaccine or cure is not yet available. In lieu of a vaccine, FDA-approved PrEP comprised of two 
NRTIs can reduce infections in high-risk populations (17-21). However, the most signiﬁcant 
barrier to PrEP efﬁcacy is patient adherence, as >90% protection is observed in patients with 
consistently detectable plasma drug concentrations, whereas no protection is seen in participants 
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showing undetectable drug concentrations (14, 15, 17, 21, 517, 539). To improve adherence, a 
long-acting injectable nanoparticle formulation of RPV has been developed and is currently 
being evaluated in clinical trials (523). However, inappropriate use of PrEP by suboptimal 
dosing or in individuals who are HIV-1+ may lead to development of drug resistance. The 
development of DRMs during PrEP could limit future therapy options, as was the case in single-
dose NVP trials to prevent mother-to-child transmission of HIV-1 (540). 
As there are no currently published data on the effect of RPV LA on HIV-1 resistance 
selection, we designed a pilot study to explore whether RPV LA monotherapy could select for 
drug resistance in a preexisting RT-SHIV infection in macaques. Although untreated macaques 
were not included as a comparison control, the peaks and set points of plasma viremia in the two 
animals in this study were similar to those in our previous study (389). While RPV LA dosing 
and metabolism in macaques were different than in humans, its administration in this study led to 
plasma RPV concentrations detected in the animals that were comparable to concentrations 
reported for humans who received 600 mg RPV LA doses (338, 340). RPV LA treatment 
displayed a therapeutic effect with approximate 2-log decreases in plasma viremia one week 
after treatment that was sustained for roughly 15 weeks after the ﬁrst injection, and viremia 
increased as plasma RPV concentrations dropped below 25 ng/ml (68 nM). Axillary LN and 
ileum RPV concentrations were at least 4.5-fold greater than plasma concentrations 29 weeks 
after the ﬁrst injection, which is consistent with a previous report showing that RPV LA achieves 
higher concentrations in LNs than in plasma (347). While tissues were not assessed at earlier 
time points for vRNA and drug concentrations, it is likely that tissue RPV concentrations were 
higher at earlier time points, and it is clear that drug concentrations were not sufﬁcient to fully 
suppress virus replication in tissues or blood, as evidenced by high RT-SHIV RNA levels.  
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Despite waning RPV plasma concentrations and lack of complete virus suppression, 
which may be seen in noncompliant individuals and suggesting suboptimal in vivo drug 
inhibition, persistent DRMs were not selected in the plasma or tissues of either animal after RPV 
LA administration. This is in contrast to our previous studies, in which EFV monotherapy was 
administered over four days in RT-SHIV-infected macaques and rapidly selected the NNRTI 
resistance mutation K103N in the plasma virus that affected the efﬁcacy of subsequent 
combination therapy containing EFV, particularly in two animals with high plasma viremia 
levels similar to the animals in this study (389, 527, 541). Another study using a different strain 
of RT-SHIV in rhesus macaques also showed that K103N and other DRMs arise during EFV 
monotherapy (466). The RT mutation K103N confers approximately 20- to 35-fold resistance to 
HIV-1 in vitro and arises in HIV-1-infected individuals on EFV-based ART (265, 542). 
In contrast, K103N and other single DRMs selected by NNRTIs approved earlier than 
RPV, such as Y181C, confer no or low-level (i.e., 1- to 3-fold) resistance to RPV (265). K103N 
was not detected in patients failing RPV-containing ART in two clinical trials (306). In fact, with 
the exception of K101P, Y181I, and Y181V, which confer signiﬁcant resistance to RPV in vitro 
(52-, 15-, and 12-fold changes above WT HIV-1, respectively), HIV-1 with any other single 
NNRTI-associated resistance mutation has no or low-level resistance to RPV (265). Unlike 
K103N and Y181C, the mutations K101P and Y181I/V require at least two base changes to be 
made and therefore are likely more difﬁcult to develop. In addition, the accumulation of multiple 
NNRTI resistance mutations, as occurs in treatment-experienced HIV-1+ individuals, can 
enhance RPV resistance (265, 283, 306, 543), which is less likely to occur prior to therapy or to 
be transmitted to newly infected individuals (285). Thus, it appears that isolates that are highly 
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resistant to RPV are difﬁcult to develop compared to mutants that arise during use of other 
NNRTIs, such as EFV and NVP. 
Similarly, in a macaque study investigating sustained release of the novel NNRTI MIV-
150 from IVRs in RT-SHIV-infected rhesus macaques, DRMs were not detected by clonal 
sequencing of plasma virus after 42 days in 5/6 animals using the IVR; however, DRM selection 
did occur when animals were treated systemically with MIV-150 (491). One IVR-treated animal 
had a single plasma clone containing Y181I, while all other clones were WT. Similar results 
were found in LNs at day 57, and no DRMs were detected in vRNA isolated from the cervix or 
vagina, the site of drug release. 
Recently, one individual unexpectedly became infected with HIV-1 in the lowest RPV 
LA dose arm (300 mg) of the SSAT 040 trial (1/66 in the overall study and 1/20 in the 300-mg 
dose arm), which evaluated the PK of the drug in HIV-1- individuals (351). K101E was selected 
in the RT of plasma HIV-1 after seroconversion (i.e., K101E HIV-1 was not transmitted to this 
individual), and K101E HIV-1 clones had 4-fold resistance to RPV in vitro compared to that of 
WT virus. K101E or E138K/Q was the most common RT mutation detected in patients failing 
RPV-containing therapy in the ECHO, THRIVE, and STaR studies, with E138K constituting the 
majority of detected NNRTI-associated resistance mutations (306, 544). Molecular modeling 
studies of RPV bound to the crystal structure of HIV-1 RT show the formation of a salt bridge 
between E138 and K101 in the WT p66 subunit (545). This interaction was lost with the 
substitution of the low-level RPV-resistant mutations E138A/G/K/R/Q or K101E, suggesting 
that disruption of the K101-E138 salt bridge causes low-level RPV resistance (301). A higher 
prevalence of E138 mutations, particularly E138K/G, in HIV-1 from individuals failing RPV-
containing therapy is unknown but may be due to mutational bias (546) or G-to-A hypermutation 
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(547). The E138Q/G mutations that were selected by RPV LA in the macaques in our study and 
the K101E mutation that was selected in the individual who failed RPV LA were likely 
stochastic events. 
While this is a small pilot study, the data are encouraging that drug resistance may be 
difﬁcult to develop in HIV-1 RT during RPV LA monotherapy compared to NNRTIs approved 
prior to RPV. The single DRMs that we did detect remained a minor species despite persistent 
drug concentrations. Future studies looking at a larger group of animals with different viremia 
levels and comparing daily oral RPV dosing to dosing with RPV LA with different lengths of 
sustained released are warranted to understand how they inﬂuence the development of drug 
resistance. In addition, the effect of development of minority, low-level RPV-resistant viruses on 
subsequent combination therapy should be addressed. 
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4.1 PREFACE 
Results from this research were presented in part as an oral presentation titled “Vaginal 
transmission of WT or resistant HIV-1 was not inhibited by long-acting rilpivirine at high plasma 
and genital concentrations in BLT mice” at the 2016 HIV Research for Prevention conference in 
Chicago, Illinois.  
The work presented in this chapter is for completion of Aim 2 in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy. Kevin Melody performed the in vitro virus 
assays, all in vivo work, and population sequencing of breakthrough infection vRNA. Mackenzie 
Cottrell and Angela Kashuba completed PK analysis of RPV in plasma and tissue samples 
collected by Zandrea Ambrose and Kevin Melody. Moses Bility and Kevin Melody conducted 
the surgeries to generate a cohort of BLT humanized mice. Chris Kline performed the plasma 
vRNA extractions and qPCR assays. Single-genome sequencing was performed by Brandon 
Keele. Statistical analysis was performed with assistance from Kathleen Shutt. 
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4.2 ABSTRACT 
RPV LA is an injectable long-acting formula of the antiretroviral RPV, which was developed to 
improve PrEP adherence. To determine whether RPV LA could prevent transmission of RPV-
resistant HIV-1, BLT humanized mice were challenged vaginally with WT, low-resistant 
(Y181C), or high-resistant (Y181V) HIV-1 at days 1 or 7 after RPV LA administration. At day 7 
post-RPV LA dosing, drug concentrations in mouse plasma and mucosal tissues were similar to 
human women given a 1,200 mg dose of RPV LA; whereas, RPV concentrations were >7-fold 
higher at day 1 post-dosing. Sixty-six percent of mice challenged with WT HIV-1 became 
infected in both dosing groups versus 86% of untreated mice; however, 0 or 50% of mice 
became infected with Y181C HIV-1 at days 1 or 7 post-RPV LA dosing, respectively, compared 
to 63% of untreated mice. In contrast, 88% of untreated and 100% of day 1 post-RPV LA dosing 
Y181V-challenged mice became infected. A group of mice were challenged with WT HIV-1 at 
day 7 post-RPV LA dosing to compare efficacy of HIV-1 inhibition via rectal or vaginal 
challenge. Forty percent of rectally challenged compared to 66% of vaginally challenged mice 
that received PrEP were infected with WT HIV-1. Population sequencing of plasma vRNA 
isolated from a subset of mice infected with WT or Y181C HIV-1 did not detect DRMs in RT. 
We conclude that RPV LA is effective at preventing vaginal transmission of low-level RPV-
resistant HIV-1 at plasma and mucosal RPV concentrations that are not achieved in humans. In 
addition, breakthrough infection in the presence of RPV LA does not readily select for resistance 
mutations.  
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4.3 INTRODUCTION 
An estimated 2.1 million new HIV-1 infections occurred in 2015 (1). In the absence of a vaccine, 
daily oral PrEP with Truvada, a combination of FDA-approved NRTIs, is shown to be effective 
at preventing HIV-1 transmission in animal models (315, 316) and human clinical trials (17, 19, 
20, 23). Truvada is currently available as PrEP for high-risk individuals in nearly a dozen 
nations. Microbicide gels and IVRs containing RT inhibitors have also been shown to be 
effective at inhibiting HIV-1 transmission (18, 336), but are not yet approved by the FDA. 
Despite significant rates of HIV-1 inhibition in most PrEP trials, lack of adherence is the biggest 
barrier to PrEP efficacy (14, 15, 18).  
To increase adherence to PrEP, the FDA-approved antiretroviral drug RPV was 
developed into an injectable long-acting nanoparticle formulation, RPV LA (311, 347). RPV is 
the most potent approved NNRTI and has a favorable safety and tolerability profile that makes it 
ideal for nanoparticle formulation (311, 312). The long-acting formulation creates a depot of 
drug at the site of injection and provides sustained systemic release and maintenance of proposed 
protective RPV concentrations. RPV LA dosing would eliminate the need for daily Truvada 
pills, reduce lapse in systemic drug concentrations from missed doses, and allow adherence 
monitoring by healthcare providers. Phase I clinical trials with RPV LA showed that it is safe 
and tolerable with only mild reported adverse events (338, 340, 348). PK data reveals that a 
1,200 mg dose of RPV LA administered monthly should achieve plasma and tissue RPV 
concentrations estimated to be effective at inhibiting HIV-1 infection for at least one month post-
dosing (338, 340, 348). A Phase II clinical trial to determine long-term safety and tolerability of 
RPV LA is currently underway (https://clinicaltrials.gov; NCT02165202). 
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A concern of using drugs approved for both ART and PrEP (i.e. Truvada or potentially 
RPV) is the potential inability of the PrEP agent to prevent transmission of drug-resistant HIV-1. 
Subsequently, transmitted drug-resistant virus could reduce ART options in newly infected 
individuals. For example, RPV is a diarylpyrimidine similar to ETR (286). Because of their 
similar structures, they select for similar DRMs that confer resistance to both drugs (265, 548). 
Additionally, all currently approved NNRTIs target the same binding pocket in RT (49, 218, 288, 
549); hence, some mutations can confer cross-resistance to all NNRTIs (16, 265). With increases 
in global availability of ART, there is also a significant increase in drug-resistant HIV-1 
transmission, particularly NNRTI resistance (285). It is estimated that prevalence of RPV 
resistance is as high as 3.6% depending on geographic location, but the frequency of DRMs at 
amino acid 138 of RT can be as high as 6.1% depending on HIV-1 subtype (310). Increasing 
DRM prevalence could lead to individuals on PrEP being at higher risk of exposure to drug-
resistant HIV-1.  
To determine if RPV LA can inhibit transmission of drug-resistant HIV-1, we treated 
BLT mice with RPV LA and then mucosally challenged them with WT or drug-resistant HIV-1. 
To determine if there is a threshold for which RPV is still protective against RPV-resistant HIV-
1, mice were challenged with HIV-1 containing a low-resistant (Y181C) or high-resistant 
(Y181V) DRM. We chose Y181C because it is the second most prevalent NNRTI-associated 
DRM (285), while Y181V is one of the few single DRMs that confer greater than 10-fold 
resistance to RPV (265). Both mutations are also considered surveillance transmitted DRMs 
(309). Rectal challenges with WT HIV-1 were also performed to compare the ability of RPV LA 
to inhibit transmission via different mucosal routes. In addition, the RT region of plasma HIV-1 
from mice that became infected was sequenced to determine if DRMs were selected by systemic 
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RPV after breakthrough infection. Our data indicate that RPV LA inhibits vaginal infection with 
low-level resistant virus but only at high plasma and tissue RPV concentrations not achieved in 
humans. Our data also suggest that selection of DRMs is unlikely in the event of breakthrough 
infection during RPV LA PrEP. 
4.4 MATERIALS AND METHODS 
4.4.1 Cell lines and RPV 
293T, TZM-bl, and GHOST-R3/X4/R5 cells were cultured as described in section 3.4.1. Human 
PBMCs were isolated from whole blood by density gradient centrifugation using lymphocyte 
separation media followed by ACK Lysing Buffer incubations and PBS washes to remove red 
blood cells. PBMCs were stimulated for 48 hours in RPMI 1640 with 10% FBS, 1% P-S-G, 50 
U/ml interleukin-2 (IL-2; Roche), and 5 μg/ml phytohaemagglutinin (Thermo Fisher). After 
stimulation, PBMCs were washed and cultured in RPMI 1640 with 10% FBS, 1% P-S-G, and 20 
U/ml IL-2. All cell lines and cell culture experiments were maintained at 37º C with an 
atmosphere of 5% CO2. 
RPV was acquired from the NIH AIDS Reagent Program. RPV LA was obtained from 
Janssen Sciences UC Ireland. 
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4.4.2 HIV-1 production 
HIV-1NL4-BAL is a chimeric CXCR4-tropic virus with a CCR5-tropic envelope gene (550) and 
will be referred to as HIV-1. The Y181C and Y181V mutations were generated in a full length 
HIV-1 proviral plasmid using a Q5 site-directed mutagenesis kit. HIV-1 production and virus 
titer on GHOST-R3/X4/R5 cells were performed as described in section 3.4.2. 
4.4.3 RPV susceptibility of WT and drug-resistant HIV-1 
Susceptibility of HIV-1 to RPV or RPV LA was tested as described in section 3.4.9 with minor 
changes. 1x104 TZM-bl cells/well were seeded in 96-well cell culture-treated white plates. The 
day following seeding, the cells were incubated with virus at a MOI of 0.02 in media with 10% 
FBS. 
4.4.4 HIV-1 replication assay 
PBMCs were infected with WT, Y181C, or Y181V HIV-1 at a MOI of 0.01 and incubated for 2 
hours at 37ºC. After the incubation, cells were washed with PBS, resuspended in medium, and 
incubated at 37ºC. Half the media was replaced every 2 days. During media replacement, the 
removed supernatants were filtered using a 0.45 μm MCE membrane syringe filter (Argos 
Technologies) and stored at -80oC. HIV-1 capsid protein (p24) in the supernatant samples was 
measured using the HIV-1 p24 ELISA kit (Xpress Bio). 
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4.4.5 Animals 
Female BLT humanized or NSG mice were obtained from Jackson Laboratory and were housed 
at the University of Pittsburgh Division of Laboratory Animal Resources. All procedures were 
performed in accordance with AAALAC and were approved by the University of Pittsburgh 
IACUC. Humanization of NSG mice was performed as previously described (413). Briefly, NSG 
mice were irradiated with 200 cGy of 137Cs, and fur on the left lateral side was removed the night 
before surgery. On the day of surgery, mice were anesthetized with 2% isoflurane and injected 
SC with 5 mg/kg carprofen (Thermo Fischer) and IP with 5 mg/kg ceftiofur (Thermo Fischer). 
Approximate 1 mm3 pieces of thawed human fetal liver and thymus tissue were implanted under 
the left kidney capsule of each mouse. Following suturing, the mice were injected IV with 
approximately 1.5x105 autologous human CD34+ cells. At 12 weeks post-surgery, the mice were 
assessed for human immune reconstitution. To measure the frequency of human immune cells, 
blood was collected by submandibular bleeding (551) and PBMCs were isolated and stained for 
live/dead-APC-Cy7 populations (BD Biosciences) anti-human cluster of differentiation 45 
(CD45)-PE (Miltenyi), CD3-V450, CD4-PerCP-Cy 5.5, and CD8-FITC (BD Biosciences). Cell 
populations were analyzed by flow cytometry using the following gating strategies: lymphocytes 
(side scatter area by forward scatter area) -> single cells (forward scatter height by forward 
scatter area) -> live/dead (forward scatter area by APC-Cy7) -> human CD45+ (forward scatter 
height by PE) -> human CD45+CD3+ (PE by V450) -> human CD45+CD3+CD4+ and 
CD45+CD3+CD8+ (FITC by PerCP-Cy 5.5). Non-transplanted NSG mice were used as controls 
and demonstrated no staining for human cell markers. The average human CD45+ cell 
reconstitution of mice used in this study was 46.2 ± 12.3%.  
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To determine the PK of RPV LA in female BLT mice, the drug was administered IM into 
the left gastrocnemius muscle at 150 mg/kg to 14 mice. Blood samples were collected at 1, 2, 6, 
12, 24, 48 hours, and 7 days post-injection. At each time-point, two animals were sacrificed and 
blood, female genital tract, and rectal tissue were harvested.  
To determine RPV LA efficacy to prevent HIV-1 transmission, mice were treated with 
RPV LA as described above. At days 1 or 7 post-RPV LA dosing, mice were challenged 
vaginally with 1x105 IU of WT, Y181C, or Y181V HIV-1 in <15 μl of PBS. Another cohort was 
challenged rectally with 1x105 IU of WT HIV-1 at day 7 post-RPV LA dosing. Untreated mice 
were challenged in the same manner and used as controls. Blood was collected in EDTA-treated 
tubes (Ram Scientific) by submandibular bleeding, and plasma was separated by centrifugation 
at 400 x g for 10 min and stored at -80oC until RNA extraction. Mice were considered infected if 
they had detectable plasma viremia at two time points. PBMCs were isolated from whole blood 
by two ACK Lysing Buffer incubations and one PBS wash and stored at -80oC. Blood samples 
were collected weekly for the first 3 weeks post-challenge and then bi-weekly until 10 weeks 
post-challenge. Due to the frequency of blood collection, mice were injected IP with pre-warmed 
PBS after each blood sample for fluid replacement, and DietGel 76A (ClearH2O) was provided 
to each cage to improve recovery. After 10 weeks, mice were euthanized and brain, lung, liver, 
spleen, left kidney with thymus organoid, mesenteric LNs, small intestine, female genital tract, 
and colon tissue were harvested. If possible, tissue samples were collected in triplicate and flash 
frozen whole, flash frozen in RNAlater (Ambion), or suspended in 10% buffered formalin 
(Sigma). 
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4.4.6 PK analysis of RPV LA 
RPV concentrations in plasma and tissue were measured as described in section 3.4.5. 
4.4.7 Quantitation of plasma HIV-1 RNA 
Plasma HIV-1 RNA was isolated as previously described (552) and quantified by the single copy 
assay (553). Briefly, avian sarcoma-leukosis virus, kindly provided by Stephen Hughes, was 
spiked into each plasma sample as an internal RNA isolation control and total viral RNA was 
isolated with guanidinium isothiocyanate and glycogen. cDNA synthesis was performed with 
random hexamers. Quantitative PCR was performed in duplicate for all samples and standards. 
4.4.8 Sequencing of vRNA 
Population sequencing of vRNA recovered from plasma of the mice was performed using nested 
PCR.  cDNA was generated from vRNA using the SuperScript III ﬁrst-strand synthesis kit with 
random hexamer primers. The cDNA was first amplified using the primers BAL3F (5’-
TGTGGAAAGGAAGGACACC-3’) and BAL5R (5’-
TCACTATTATCTTGTATTACTACTGC-3’) with the following reaction conditions: 94°C for 2 
min; 40 cycles of 94°C for 15 s, 49°C for 30 s, and 68°C for 3 min; and 1 cycle of 68°C for 5 
min. The second round of PCR ampliﬁcation was performed using primers LAI-RT-F (5’-
TTTGCCAGGAAGATGGAAAC-3’) and LAI-RT-R (5’-TCACTAGCCATTGCTCTCCA-3’) 
with the following reaction conditions: 94°C for 2 min; 26 cycles of 94°C for 15 s, 63°C for 30 s 
with -0.5°C increments per cycle, and 72°C for 2 min; 15 cycles of 94°C for 15 s, 52°C for 30 s, 
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and 72°C for 2 min; and 1 cycle of 72°C for 5 min. The Platinum Taq DNA polymerase high-
ﬁdelity kit was used for both rounds of PCR. PCR products were purified with the Wizard SV 
gel and PCR cleanup system. The full RT coding region was sequenced using primers LAI-RT-
F, 200F (5’-GTAGGATCTGACTTAGAAA-3’), 350F (5’-CAGGAAAATATGCAAGAATG-
3’), and LAI-RT-R. Sequences were assembled and analyzed using Sequencher (Gene Codes 
Corporation) and Lasergene (DNASTAR). 
 Single-genome sequencing was performed as previously described (554). 
4.4.9 Statistical analyses 
Fischer’s exact test was used to test for efficacy to prevent HIV-1 infection between untreated 
and RPV LA-treated groups challenged with the same virus. Two-sided log-rank test was 
conducted to determine differences in time to vRNA detection in plasma samples. Mann-
Whitney test was used to analyze differences in plasma viremia. A p value of ≤0.05 was 
considered statistically significant for all tests. 
4.5 RESULTS 
4.5.1 In vitro RPV susceptibility and replication of WT and mutant HIV-1 
Mutations at amino acid position 181 in RT have been shown to confer resistance to RPV (265). 
Site-directed mutagenesis was used to introduce the Y181C (TAT -> TGT) or Y181V (TAT -> 
GTT) mutations into the HIV-1 proviral plasmid. To confirm resistance of Y181C/V HIV-1, 
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susceptibility of the WT and mutant viruses to RPV was determined in a single-cycle replication 
assay. The EC50 values of RPV to WT, Y181C, and Y181V HIV-1 were 0.6, 1.2, and 16.4 nM, 
respectively (Figure 8A). This translated to 2- and 27-fold resistance conferred by Y181C and 
Y181V mutations, respectively. The fold-change in EC50 for Y181C HIV-1 was consistent with 
previous reports (265, 543), but the EC50 for Y181V HIV-1 was twice as high (265). 
Nonetheless, Y181C and Y181V displayed the desired low- and high-level resistance to RPV.  
 
 
Figure 8. In vitro susceptibility of HIV-1 to RPV. 
TZM-bl cells were cultured in the presence of HIV-1 and serial dilutions of powder RPV or RPV 
LA. Luciferase production was used as a measure of the efficacy of drugs to prevent infection. 
Results are normalized to luciferase production in cells infected with HIV-1, but not treated with 
RPV. Susceptibility of WT, Y181C, and Y181V HIV-1 to powder RPV was determined and the 
results are representative of 3 independent experiments each performed in triplicate (A). The 
potency of RPV LA to inhibit WT HIV-1 infection was compared to powder RPV (B). Error bars 
represent standard deviation of experimental triplicates.  
 
To confirm potency of our RPV LA stock, WT HIV-1 susceptibility to reconstituted 
powder RPV (used above) and RPV LA was directly compared (Figure 8B). Both powder RPV 
and RPV LA showed similar levels of potency to inhibit WT HIV-1 at 0.6 and 0.4 nM, 
respectively. Thus, our stock of RPV LA should be potent enough to inhibit HIV-1 transmission. 
98 
 Replication of WT, Y181C, and Y181V HIV-1 was determined in activated human 
PBMCs in vitro. Both mutants had 5-fold or less p24 production at all time points and similar 
replication kinetics compare to WT HIV-1 (Figure 9). Our results for Y181C virus replication 
capacity are similar to a slight replication deficiency relative to WT HIV-1 reported in a 
transformed T lymphocyte cell line (555). Reports directly comparing WT and Y181V HIV-1 
replication have not been published. Our in vitro data show that our challenge viruses are 
susceptible to RPV, infectious, and replication competent in primary human cells.  
 
                                           
Figure 9. In vitro replication kinetics of WT, Y181C, and Y181V HIV-1 in primary human 
cells. 
Human PBMCs were infected with WT, Y181C, or Y181I HIV-1 at a MOI of 0.02. Culture 
supernatant was measured for virus p24 as a marker for virus production. 
 
4.5.2 Plasma and mucosal tissue PK of RPV LA after a single dose 
To assess the PK of RPV, drug concentrations were measured in plasma, female genital tract, 
and rectal tissues of female BLT mice administered a 150 mg/kg dose of RPV LA (Figure 10). 
The only side effect noticed was limping directly after the injection. Plasma RPV peaked in the 
plasma at a mean concentration of 2,277 ng/ml three hours post-injection and declined to a mean 
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concentration of 130 ng/ml by seven days. The RPV concentrations in female BLT mice at day 7 
post-dosing are consistent with peak concentrations reported in human women given a single 
1,200 mg dose of RPV LA (338, 340). Mean drug concentrations in female genital tract tissue 
peaked at 653 ng/ml at 12 hours and declined to a mean of 93 ng/ml at day 7, which is 50% 
higher than RPV concentrations in women 28 days after a single 1,200 mg dose of RPV LA 
(338). Concentrations of RPV in rectal tissue varied, likely from the presence of fecal matter in 
the samples. The mean RPV concentration in rectal tissue at day 7 post-dosing was 37 ng/ml, 
which is half of the concentration reported in men 14 days after being given a 600 mg dose of 
RPV LA (338). Mean RPV concentrations measured in the mice were 3- to 11-fold higher than 
the PAEC90 of 12.1 ng/ml reported by Jackson et al. (338). Thus, biologically relevant plasma 
and mucosal tissue concentrations of RPV were achieved in BLT mice at day 7 post-dosing. 
 
                              
Figure 10. PK profile of RPV LA in BLT mice. 
Female BLT mice were administered a single 150 mg/kg IM dose of RPV LA. RPV 
concentrations were measured in plasma, female genital tract, and rectal tissues at 1, 3, 6, 12, 24, 
and 48 hours and 7 days post-dosing. The dashed line represents the PAEC90 of 12.1 ng/ml, 
which is the theoretical protection limit of RPV. 
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4.5.3 Inhibition of HIV-1 vaginal transmission after RPV LA PrEP 
To determine the efficacy of RPV LA to inhibit vaginal transmission of HIV-1, control and 
treated BLT mice were challenged with WT virus one week after receiving RPV LA. Six of 7 
(85.7%) and 4/6 (66.7%) mice became infected in the untreated and RPV LA-treated groups, 
respectively (Table 10). Due to the lack of protection at day 7 post-RPV LA dosing, we 
hypothesized that the drug concentrations may have been too low to be effective. Thus, we chose 
to challenge animals when RPV was at higher concentrations. An additional group of animals 
was challenged with WT HIV-1 at day 1 post-RPV LA dosing when plasma and vaginal drug 
concentrations were 7- and 9-fold higher, respectively. Again, 4/6 (66.7%) treated mice became 
infected with WT HIV-1 (Table 10). There was no significant difference in number of infected 
animals between treated and untreated groups despite RPV concentrations (p = 0.559). 
We also hypothesized that the different concentrations of RPV would affect HIV-1 
detection and plasma viremia. Regardless of RPV concentrations at time of challenge, there was 
no significant delay in time to detect infection between untreated and mice challenged at days 1 
(p = 0.188) or 7 after RPV LA dosing  (p = 0.144) (Figure 11A). One animal challenged with 
WT HIV-1 had a blip in plasma viremia that approached 1x103 vRNA copies/ml at week 7 post-
challenge but was below the limit of detection at subsequent time points and was considered 
uninfected. Furthermore, plasma viremia was undetectable for two mice infected with WT HIV-1 
at day 1 post-RPV LA dosing until week 7 post-challenge (Figure 11A). At week 5 post-
challenge, the delay in detectable plasma viremia between untreated and day 1 post-RPV LA-
treated groups approached significance (p = 0.076). Infected animals in both groups of RPV LA-
treated mice had lower mean plasma viremia than untreated mice until week 5 post-challenge 
(Figure 12A), suggesting a transient suppressive effect on HIV-1 replication by RPV. Overall 
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plasma viremia levels were similar between the treated groups, indicating no advantage in virus 
suppression at higher concentrations of RPV. Plasma viremia levels in both RPV LA groups 
were not statistically different from untreated mice.  
 
Table 10. Outcome of BLT mice treated with RPV LA and challenged with WT or drug-
resistant HIV-1 
Virus Treatmenta Challenge route Infected p valueb 
WT No Drug vaginal 6/7 - 
 RPV LA D1 vaginal 4/6c 0.559 
 RPV LA D7 vaginal 4/6 0.559 
     
Y181C No Drug vaginal 5/8 - 
 RPV LA D1 vaginal 0/6 0.031 
 RPV LA D7 vaginal 3/6d 0.999 
     
Y181V No Drug vaginal 7/8 - 
 RPV LA D1 vaginal 6/6 0.999 
     
WT No Drug rectal 4/6 - 
 RPV LA D7 rectal 2/5 0.567 
a D1 and D7 represent days after RPV injection that mice were challenged with HIV-1. 
b Results of Fischer’s Exact Test for difference between No Drug and treatment groups of same 
virus and challenge route. 
c A mouse in this group had detectable plasma viremia at one week and is considered uninfected. 
d A mouse in this group had detectable plasma viremia but died before confirmation with a 
second sample and is considered uninfected. 
  
Similar to mice challenged with WT HIV-1, there was no significant difference between 
the numbers of infected mice in the untreated and day 7 post-RPV LA-treated groups (p = 0.999) 
challenged with Y181C HIV-1 (Table 10). Five of 8 (62.5%) and 3/6 (50%) animals were 
infected in the untreated and treated groups, respectively. One mouse in the treated group had 
detectable plasma viremia at week 7 post-challenge, but died before infection could be confirmed 
with a follow-up sample and was considered uninfected. Time to detection of HIV-1 was not 
significantly different between these groups (p = 0.509) (Figure 11B), nor was the difference in 
mean plasma viremia levels (p = 0.073) (Figure 12B). The treated group had similar but lower 
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mean plasma viremia kinetics than untreated mice for the entirety of the study. However, all 
mice challenged at day 1 post-RPV LA-dosing were protected from Y181C HIV-1 transmission 
(p = 0.031) (Figure 11B), demonstrating that RPV LA can inhibit vaginal transmission of a low-
level RPV-resistant virus.  
 
 
Figure 11. Time to detection of HIV-1 infection in BLT mice. 
Kaplan-Meier plots display the number of BLT mice considered uninfected by HIV-1 at each 
week post-challenge as measured by qPCR (limit of detection of 400 vRNA copies/ml). Mice in 
each group were vaginally challenged (A-C)  with 1 x 105 IU of WT (A, black), Y181C (B, red), 
or Y181V (C, purple) HIV-1 at 1 or 7 days post-RPV LA dosing. Another group of mice was 
rectally challenged (D) with 1 x 105 IU of WT (D, green) HIV-1. The number of mice per group 
is shown in parentheses. 
 
 
As higher resistance is conferred by Y181V, only mice treated with RPV LA one day 
before virus inoculation were challenged with Y181V HIV-1. Infection rates were nearly 
identical in untreated and treated groups with 7/8 (87.5%) and 6/6 (100%) mice infected with 
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Y181V HIV-1, respectively. The difference in numbers of infected animals was not significant 
(p = 0.999) (Table 10). Similar to the other HIV-1 clones, there was not a significant difference 
in time to detect infection (p = 0.361) (Figure 11C). Unlike the mice infected by WT and Y181C 
viruses, mice infected with Y181V HIV-1 had nearly identical mean plasma viremia levels at all 
time points (Figure 12C), suggesting that RPV LA had no effect on Y181V HIV-1 transmission 
or replication post-infection. 
 
 
Figure 12. Plasma viremia in BLT mice infected with HIV-1. 
Average and standard error mean of plasma viremia in untreated and RPV LA-treated BLT mice 
infected vaginally with WT (A, black), Y181C (B, red), or Y181V (C, purple) HIV-1 or infected 
rectally with WT (D, green) HIV-1. The black long-dash line represents the assay limit of 
detection (400 RNA copies/ml). 
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4.5.4 Rectal WT HIV-1 challenge of RPV LA-treated mice  
A recent study reported that less RPV is required to inhibit HIV-1 infection of human colonic 
tissues compared to ectocervical explant tissues (349). Additional explant studies concluded that 
rectal tissues sampled from RPV LA-treated humans (600 or 1,200 mg doses) are protected from 
ex vivo HIV-1 infection if tissue RPV concentrations were ≥91 ng/ml, but protective values for 
cervical and vaginal tissues could not be calculated (348). To determine if less RPV LA is 
required to inhibit rectal HIV-1 transmission, BLT mice were rectally challenged with WT HIV-
1 at day 7 post-RPV LA dosing. Two of 5 (40%) mice receiving RPV LA became infected with 
WT HIV-1, while 4/6 (66%) of the untreated animals became infected (Table 10). This 
difference was not statistically significant (p = 0.567), nor was there significant difference in 
time to detect HIV-1 between untreated and treated groups (p = 0.201) (Figure 11D). Similar to 
vaginal infections, the plasma viral load was initially transiently lower in the animals infected by 
rectal challenge; however, the mean plasma viremia was higher for untreated mice infected 
rectally compared to untreated mice infected vaginally (Figure 12A, D). Mean plasma viremia in 
the day 7 post-RPV LA rectal and day 1 post-RPV LA vaginal groups were nearly identical 
through week 9 post-challenge (Figure 12A, D). This result suggests that less RPV is required in 
rectal tissue to achieve the same effect in vaginal tissue, similar to results in Dezzutti et al. (349).  
4.5.5 Sequencing for detection of RPV resistance mutations in treated mice 
HIV-1 infection in people treated with a single antiretroviral drug can rapidly select DRMs (268-
270), which was also observed in one participant in a RPV LA clinical trial (351). To determine 
if HIV-1 in PrEP-treated mice developed RPV-associated DRMs, virus isolated from the final 
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plasma sample from a subset of mice infected with WT or Y181C HIV-1 was sequenced. In the 
absence of RPV, no mutations were selected in WT virus, and Y181C was preserved (Table 11). 
In the presence of RPV, no DRMs were detected in RPV LA-treated mice infected with WT (n = 
2), and Y181C (n = 3) was preserved with no additional DRMs. One silent base change and one 
codon change (G550K) in the RNaseH domain was detected in all sequences regardless of 
treatment or challenge virus (data not shown). G550K is not associated with resistance and is the 
consensus amino acid at this position according to the HIV Drug Resistance Database (266), thus 
G550K likely improves replication of our HIV-1 clone in vivo. 
 
Table 11. Sequences of the RT coding region in untreated and RPV LA-treated mice 
infected with WT or Y181C HIV-1 as performed by population sequencing 
Challenge  
virus 
Animal Treatmenta Challenge  
route 
Weeks post- 
challenge 
Sequenceb 
WT 448-004 No Drug vaginal 10 WT 
 943-005 No Drug vaginal 10 WT 
 943-004 RPV LA D7 vaginal 7 WT 
 912-014 RPV LA D7 vaginal 10 A304V 
     
Y181C 448-024 No Drug vaginal 10 Y181C 
 912-007 No Drug vaginal 10 Y181C 
 943-003 RPV LA D7 vaginal 10 E6K, Y181C 
 912-009 RPV LA D7 vaginal 10 Y181C 
 912-017 RPV LA D7 vaginal 10 Y181C 
a Mice were either untreated or received RPV LA 7 days pre-challenge. 
b Results represent the full RT coding region from the HIV-1 plasma population. 
 
 Because population-based sequencing detects mutations at a prevalence >20% of the 
population, we also performed single-genome sequencing on mice infected after treatment to 
detect mutations at a frequency of 2%. Of the 23 plasma samples subjected to single-genome 
sequencing, DRMs were detected in 11 of the animals within the first 277 bases of RT (Table 
12). DRMs were detected in 2/5 (40%) of animals that did not receive RPV LA and 9/18 (50%) 
of animals that were treated. DRMs were not prevalent in more than 10% of the genomes 
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isolated per animal, thus population sequencing would have missed these mutations. We detected 
the NNRTI-associated resistance mutations K101E (linked to E138K in one animal), E138K/Q, 
Y188H, H221Y, P225H, and the NRTI-associated mutations L74V (linked to E138K in one 
animal) and M184I/V. The most prevalent DRM was the RPV-associated mutation E138K, 
which was detected in 2-9.5% of samples in 6 animals. H221Y was the only other mutation 
identified in more than one animal. Of note, the Y181C/V mutations remained constant as seen 
for Y181C with population sequencing. Only a single genome in two animals infected with 
Y181C HIV-1 displayed a reversion to Y181. 
Samples from 8 animals were subjected to both sequencing methods. The A304V and 
E6K mutations identified by population sequencing (Table 11) in animals 912-014 and 943-003 
were not found in any of the single genomes. This discrepancy may be attributed to differences 
in PCR or sequencing reaction conditions. Conversely, animals 943-004, 448-024, and 912-017 
had one DRM in at least one sequence (Table 12), which were not detected by population 
sequencing.  
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Table 12. Detection of DRMs by single-genome sequencing in HIV-1 isolated from plasma 
of BLT mice  
Challenge  
virus 
Animal Treatmenta Challenge  
route 
Weeks post- 
challenge 
DRMs 
(% of sequences)b 
WT 448-004 No Drug vaginal 14 n/a 
 255-002 RPV LA D1 vaginal 10 n/a 
 255-007 RPV LA D1 vaginal 10 n/a 
 255-022 RPV LA D1 vaginal 10 H221Y (2.1) 
 255-044 RPV LA D1 vaginal 8 E138K (6.4) 
K101E/E138K (2.1) 
 912-008 RPV LA D7 vaginal 10 n/a 
 912-014 RPV LA D7 vaginal 10 n/a 
 943-004 RPV LA D7 vaginal 7 E138Q (2.2) 
 255-012 RPV LA D7 rectal 10 n/a 
 255-017 RPV LA D7 rectal 10 E138K (2.3) 
M184V (2.3) 
      
Y181C 448-024 No Drug vaginal 14 H221Y (2.2) 
 912-007 No Drug vaginal 10 n/a 
 912-009 RPV LA D7 vaginal 10 n/a 
 912-017 RPV LA D7 vaginal 10 M184I (4.3) 
 943-003 RPV LA D7 vaginal 10 n/a 
      
Y181V 255-031 No Drug vaginal 10 E138K (2.4) 
L74V/E138K (4.5) 
L114V/E138K/G196R (2.4) 
 943-021 No Drug vaginal 10 n/a 
 255-006 RPV LA D1 vaginal 5 Y188H (2.2) 
 255-013 RPV LA D1 vaginal 10 n/a 
 255-025 RPV LA D1 vaginal 10 E138K/G155E (2.2) 
 255-038 RPV LA D1 vaginal 10 E138K (2.3) 
P225H (2.3) 
 255-045 RPV LA D1 vaginal 10 E28K/E138K (2.3) 
E138K/D237N/D250N (2.3) 
 255-056 RPV LA D1 vaginal 10 n/a 
a Mice were either untreated or received RPV LA at 1 or 7 days pre-challenge. 
b Results represent amino acid positions 1-277 of RT 
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4.6 DISCUSSION 
Because of its safety, potency, and sustained drug release, RPV LA is under consideration as 
potential PrEP to inhibit HIV-1 infection; however, the global presence of NNRTI-resistant HIV-
1 calls into question the utility of RPV LA PrEP to prevent transmission of virus with DRMs. 
High plasma concentrations of RPV LA were previously shown to inhibit vaginal transmission 
of WT HIV-1 clones in a BLT mouse model (501), but inhibition of WT and drug-resistant HIV-
1 infection at biologically relevant concentrations of RPV has not been tested. Thus, BLT mice 
were treated with RPV LA and challenged with WT HIV-1 or clones with a single DRM that 
conferred low- (Y181C) or high-levels (Y181V) of RPV resistance. The primary goal of this 
work was to determine if RPV LA could inhibit mucosal transmission of WT and drug-resistant 
HIV-1. Secondarily, if RPV LA failed to prevent HIV-1 transmission, we also wanted to 
determine if breakthrough infection selects for drug resistance.  
We found that RPV LA at plasma and mucosal tissue concentrations comparable to 
values reported in humans did not significantly inhibit vaginal transmission of either WT or 
Y181C HIV-1. As we had determined our stock of RPV LA to be effective, the lack of 
protection was attributed to inadequate RPV concentrations in vivo. Therefore, we performed a 
second round of vaginal challenges when RPV concentrations were approximately 8-fold higher 
in plasma and vaginal tissues and similar to plasma concentrations reported in a study that 
reported protection in RPV LA-treated mice challenged with transmitted/founder infectious 
molecular clones of HIV-1 (501). We found that the higher RPV concentrations did not 
significantly protect mice from a WT HIV-1 clone with robust replication, thus future 
experiments with clinical transmission/founder HIV-1 are planned. While our clone may be too 
robust for this model and clinical isolates are representative of actual circulating HIV-1, 
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sequence variability would introduce a confounding factor and would not allow a direct 
comparison of infection and prophylaxis between WT HIV-1 and clones with a single DRM.  
Despite a lack of significant inhibition of WT HIV-1 transmission, mice challenged with 
Y181C HIV-1 were fully protected from infection at high RPV concentrations. This result shows 
that RPV LA can be protective in the event of drug-resistant HIV-1 exposure; however, our 
results also indicate that biologically relevant concentrations of RPV reported in humans (338) 
and recapitulated in our mice do not appear to be sufficiently protective. Like all NNRTIs, RPV 
binds highly to serum proteins (265, 556), and there is not a method of easily differentiating 
between protein-bound and free active RPV. Thus, the higher RPV concentrations for the mice 
challenged at day 1 post-RPV LA dosing may have provided enough free drug to inhibit Y181C 
HIV-1 and compensate for resistance provided by the mutation. While the 12.1 ng/ml PAEC90 
may be the protective threshold, current methods of RPV detection likely underestimate the 
concentration of active drug. Thus, higher RPV LA doses may be necessary to provide inhibitive 
concentrations; however, the feasibility and toxicity of such doses should be studied. 
However, it could be argued the inhibition of Y181C HIV-1 at higher RPV 
concentrations could be attributed to viral fitness. Macaque studies have shown that infection 
rates by TFV- (K65R) or FTC-resistant (M1814V) SHIV clones are lower than WT SHIV in the 
presence of Truvada PrEP due to reduced fitness and not necessarily the presence of drug (440, 
492). A reduction in mucosal transmission of K65R HIV-1 was also reported in humanized mice 
(509). However, results from our in vitro replication kinetics assay and a previous study (555) 
show that Y181C does not confer a substantial replication defect to HIV-1 when compared to 
WT virus. Also, similar numbers of untreated and sub-optimally treated animals were infected 
with our stock of virus; therefore, we credit the lack of Y181C HIV-1 infection to RPV activity.  
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While Y181C HIV-1 transmission was fully inhibited by RPV LA, the opposite was 
noted for Y181V HIV-1, which was expected given the level of resistance provided by the 
mutation (~30-fold). The lack of substantial difference in viral replication between WT and 
Y181V HIV-1, and its ability to break through RPV LA PrEP suggests that Y181V could be of 
greater clinical concern because its prevalence could increase if RPV LA is approved for PrEP. 
Y181V is already detected in treatment-experienced populations (557, 558) and is considered a 
surveillance transmitted DRM (309); thus, RPV LA users could be exposed to HIV-1 with the 
mutation and potentially become infected due to lack of prophylactic efficacy. Theoretically 
there is a concentration of RPV that should inhibit Y181V HIV-1 transmission, but the 
concentration of such a dose may not be tolerable or achievable in vivo. 
Although we did not observe significant inhibition of WT HIV-1 transmission in RPV 
LA-treated animals, the time to HIV-1 detection results are interesting in regard to virus 
replication and resistance selection. While the same numbers of mice were infected in both RPV 
LA-treated groups challenged with WT HIV-1 (days 1 or 7 post-RPV LA), detection of HIV-1 
was delayed until week 7 post-challenge in two mice challenged at day 1 after RPV LA dosing. 
This was also observed in one Y181C animal challenged at day 7 post-RPV LA injection. 
Therefore, RPV LA likely provided a therapeutic advantage by suppressing systemic viremia 
below the limit of detection for a sustained amount of time. We postulate that RPV waned after 
week 5 post-challenge to a concentration below which virus replication was no longer inhibited 
in the vaginal tissue. It is possible that a more sensitive vRNA detection method could have 
uncovered infection sooner, but the limitation in blood draw volumes in mice does not allow for 
high sensitivity of vRNA detection and greater sampling frequency. Nonetheless, our results 
raise the following questions: would WT HIV-1-infected animals maintain undetectable levels of 
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plasma viremia over the course of monthly RPV LA doses, or would low-level undetectable 
replication eventually select for drug-resistant variants? While we did not detect any DRMs by 
population sequencing in a subset of animals infected with WT or Y181C virus at 7 days post-
RPV LA dosing, single-genome sequencing of a broader subset of infected mice revealed the 
selection of DRMs in nearly half the animals, albeit at <10% of the individual virus populations. 
Interestingly, DRMs not associated with RPV were selected, thus displaying how stochastic the 
HIV-1 mutation process can be. These results recapitulate the sequencing results seen in our 
macaques given RPV LA monotherapy (Chapter 3); however, sequencing of other time points 
could be performed to determine the stability of the DRMs and if RPV truly selects for resistance 
or if the detected DRMs were transient random events from mutational bias or hypermutations 
(546, 547). The idea of a “smoldering” HIV-1 infection presents the opportunity to use reporter 
viruses and visual techniques, such as in vivo bioluminescence or immunofluorescence assays, to 
identify sanctuary sites where virus replication occurs despite systemic drug concentrations. We 
could then study drug penetration at sanctuary sites through PK analysis and track HIV-1 
evolution under near-suppressive drug pressure using sensitive sequencing techniques. Such 
studies could reveal areas of improvement for RPV LA dosing and better identify the 
circumstances of DRM evolution.  
While the majority of new HIV-1 infections occur through vaginal exposure, rectal tissue 
is also a significant route of transmission (10). RPV LA is shown to penetrate both tissue 
compartments and concentrate to levels that should be protective (338, 348). However, human 
explant models indicate that there is a difference in RPV protection between the two mucosal 
tissue compartments, which is likely due to differences in RPV penetration (348, 349). Our 
results were unclear due to statistical power, but they suggest that RPV LA may be more 
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effective at inhibiting HIV-1 transmission in rectal rather than vaginal tissue. Through week 5 
post-challenge, the numbers of infected animals were similar between vaginally and rectally 
challenged groups at days 1 and 7 post-RPV LA injection, respectively. Had the number of 
infected animals remained the same through the end of the study, our data would have mirrored 
those of Dezzutti et al. where higher RPV concentrations would be required to be equally 
protective in ectocervical tissue as colonic tissue (349). Elucidating the difference in the ability 
of RPV LA to inhibit HIV-1 transmission by mucosal compartment will be important as RPV 
LA trials are currently focused on women at risk of vaginal infection; whereas, our results and 
published explant data indicate that RPV LA may be more suitable for populations at risk of 
rectal infection. 
In conclusion, our data suggest that RPV LA at biologically relevant concentrations 
reported in humans is ineffective at significantly inhibiting vaginal transmission of WT or drug-
resistant HIV-1. However, we do show that RPV LA can inhibit vaginal transmission of HIV-1 
with a low-level RPV resistance mutation at plasma and tissue concentrations nearly 1-log higher 
than those reported in humans. We also showed that virus with high RPV resistance can be 
transmitted in the presence of high concentrations of RPV, which may not be achievable or 
sustained in vivo. Thus, we conclude that the level of resistance conferred by a mutation can 
affect PrEP efficacy. Our data also support that selection of DRMs after breakthrough infection 
during RPV LA PrEP may be difficult as RPV-associated DRMs were selected but only in a 
small number of animals and at low prevalence. Overall, our study raises more questions with 
RPV LA that should be addressed to better understand the effect of HIV-1 resistance on the PrEP 
strategy. Also, careful consideration, specifically in regard to dosing, should be made before 
moving RPV LA into Phase III clinical trials to test the efficacy of this PrEP modality.  
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5.1 PREFACE 
Results from this research were presented as a poster titled “In vitro HIV-1 infection in the 
presence of a rilpivirine analog selects for a novel combination resistance mutation” at the 2015 
Palm Springs Symposium on HIV/AIDS in Palm Springs, California.  
Results from this work were included in two publications: 
Our results were included in two publications: 
1) Smith SJ, Pauly GT, Akram A, Melody K, Ambrose Z, Schneider JP, Hughes SH. 
2016. Rilpivirine and doravirine have complementary efficacies against NNRTI-resistant HIV-1 
mutants. J Acquir Immune Defic Syndr 72: 485-491. 
2) Smith SJ, Pauly GT, Akram A, Melody K, Rai G, Maloney DJ, Ambrose Z, Thomas 
CJ, Schneider JT, Hughes SH. 2016. Rilpivirine analogs potently inhibit drug-resistant HIV-1 
mutants. Retrovirology 13: 11. 
 The work presented in this chapter is for completion of Aim 3 in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy. Kevin Melody performed all work reported 
in this chapter.  
  
115 
5.2 ABSTRACT 
Analogs of the FDA-approved NNRTI RPV were designed to preserve the potency and 
tolerability of RPV and broaden efficacy against drug-resistant HIV-1. Three analogs, 7, 11, and 
13, showed similar in vitro efficacy against a panel of NNRTI-resistant HIV-1 isolates and were 
chosen for resistance selection to understand the mechanisms of HIV-1 antiretroviral activity. 
Resistance selection was conducted by passaging HIV-1-infected cells in increasing 
concentrations of the compounds. The RT coding region of virus isolated from culture 
supernatants was sequenced and analyzed for mutations that could confer drug resistance. 
Compounds 7 and 11 selected for known RPV-associated resistance mutations K101E, E138K, 
Y181C, or M230I in single clones, which showed similar resistance phenotypes to the analogs as 
to RPV. However, compound 13 consistently selected a combination of two mutations in RT: 
G112D and M230I. Virus with either G112D or M230I alone conferred resistance to the NRTI 
FTC or all NNRTIs, respectively. Together, G112D and M230I conferred a >2-fold decrease in 
NNRTI susceptibility beyond that conferred by M230I alone, but the presence of M230I 
abrogated FTC resistance of G112D and caused hypersusceptibility to three NRTIs and a 
pyrophosphate analog. Replication assays revealed that G112D/M230I virus has better 
replication kinetics than virus with either single mutation, yet all three mutants displayed 
decreased replication capacity compared to WT HIV-1. Our data suggests that RPV analog 13 
selects a combination of mutations through a novel mechanism of action. RT polymerization 
assays and modeling of drug binding is underway to confirm the results of our drug susceptibility 
assays and to better understand the resistance conferred by G112D, M230I, and G112D/M230I. 
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5.3 INTRODUCTION 
Due to lack of fidelity by RT during reverse transcription (239, 240) and a high replication rate 
(263), HIV-1 evolves frequent mutations. These mutations can lead to the selection of isolates 
with DRMs that are not fully suppressed by therapeutic agents (264). Thus, the evolution of 
drug-resistant HIV-1 necessitates adjusting ART regimens to maintain viremia suppression in 
HIV-1+ individuals. Some DRMs can confer cross-resistance to all drugs of the same class (16). 
Consequently, evolution of cross-resistant DRMs could eliminate the use of an entire 
antiretroviral drug class, thus limiting alternative ART regimens in HIV-1+ individuals.  
Due to increasing prevalence of HIV-1 drug resistance (285), new antiretroviral drugs 
effective against viruses with known DRMs are needed. RPV is a diarylpyrimidine NNRTI that 
possesses flexible arms, which allows it to better conform to changes in RT structure and 
maintain efficacy against common DRMs associated with more rigid NNRTIs (265, 286, 288). In 
in vitro studies, RPV was shown to have a higher genetic barrier to resistance than the NNRTIs 
EFV and NVP (265). While the use of EFV and NVP is often abrogated by a single non-
synonymous base change that leads to high levels of resistance, RPV-associated mutations with 
single base changes confer low-level reductions in susceptibility (<4-fold change). High-level 
resistance (>10-fold change) is conferred by 2 base changes in a single codon (e.g., Y181I/V) or 
multiple amino acid mutations (e.g., K103N/Y181I) (265, 303). Compared to EFV, RPV was 
shown in two phase III clinical trials to have similar efficacy, better tolerability, and selection of 
different DRMs (292). Participants who failed treatment predominantly selected for the DRMs 
K103N or E138K in the EFV or RPV arms, respectively (306). Efficacy against common 
NNRTI-resistant mutations, a higher genetic barrier to resistance, and a favorable safety profile 
makes RPV an attractive NNRTI; however, the mechanism of action of RPV to prevent HIV-1 
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replication is similar to all approved NNRTIs, and cross-resistant DRMs exist that would negate 
the use of this drug class (49, 218, 265, 288) 
To address cross-resistance in NNRTIs, analogs of RPV with changes to the pyrimidine 
and 4-amino-benzonitrile moieties were developed to maintain the potency and safety of RPV 
while potentially altering the mechanism of action (543). The acrylonitrile ring moiety was left 
unchanged because it is essential for RPV function as it binds a hydrophobic pocket in RT (286, 
288, 289). Of 22 analogs tested, three compounds displayed similar therapeutic indices and 
antiretroviral efficacies as RPV in a panel of HIV-1 with mutations in RT including L100I, 
K103N, V106A, E138K, Y181C, Y188L, H221Y, and K103N/Y181C (543). It is possible that 
the modifications made in these analogs result in new mechanisms of action that would select for 
novel resistance mutations. If this is the case, these analogs could reveal new virus-drug 
interactions that could enhance our understanding of HIV-1 biology and lead to development of 
new RT inhibitors for use in ART or PrEP. The goal of this work was to investigate the 
genotypic and phenotypic resistance profiles of a subset of these RPV analogs: 7, 11, and 13 
(Figure 13). By determining the resistance profile of these compounds, we can infer their 
mechanisms of HIV-1 inhibition. We hypothesized that the analogs would select for DRMs that 
would not display cross-resistance to other NNRTIs. 
        
Figure 13. Chemical structures of RPV and analogs 7, 11, and 13. 
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5.4 MATERIALS AND METHODS 
5.4.1 Cell lines and compounds  
293T, TZM-bl, and GHOST-R3/X4/R5 were maintained as described in section 3.41. HuT-R5 
(559) cells were grown in RPMI 1640 media (Invitrogen) supplemented with 10% FBS, 100 
U/ml penicillin, 100 μg/ml streptomycin, 0.292 mg/ml L-glutamine, 500 μg/ml G418, and 0.5 
μg/ml puromycin. All cell lines and cell culture experiments were maintained at 37º C with an 
atmosphere of 5% CO2. 
RPV and RPV analogs 7, 11, and 13 were kindly provided by Steve Hughes (543). NVP, 
EFV, ETR, ddI, FTC, TFV, and AZT were obtained from the AIDS Reagent Program, Division 
of AIDS, National Institute of Allergy and Infectious Diseases, NIH. Foscarnet (PFA) was a kind 
gift provided by Dr. John Mellors. 
5.4.2 HIV-1 production 
HIV-1xxLAI, a HIV-1LAI clone with silent restriction sites within RT (534), was used in all cell 
culture assays and will hereafter be referred to as HIV-1. RT mutations were made in the proviral 
plasmid using the QuikChange II XL site-directed mutagenesis kit (Agilent Technologies). 
Viruses were generated by transfection of 293T cells and titered on GHOST-R3/X4/R5 cells as 
described in section 3.4.2. 
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5.4.3 Selection of HIV-1 resistance mutations with RT inhibitors 
HuT-R5 cells were infected with HIV-1 at a MOI of 0.05 for 2 hours at 37º C. After virus 
exposure, cells were cultured in media containing inhibitors at a concentration 4-fold above the 
reported EC50 (543). Cell cultures were split every 2-3 days until CPE was noted. After 
observation of CPE, aliquots of cell-free supernatant were harvested and stored at -80º C and 
drug concentrations in the cultures were increased 2-fold. 
vRNA was isolated from cell-free supernatants with the RNeasy Mini Kit (Qiagen). 
cDNA was generated from recovered vRNA using the SuperScript III First-Strand Synthesis kit 
using random hexamer primers (Invitrogen). vDNA was isolated from supernatant-free infected 
cells by the QiAmp DNA Mini Kit (Qiagen). The RT coding region was amplified using 
Platinum PCR Supermix (Invitrogen) with primers LAI-RTF (5’-
TTTGCCAGGAAGATGGAAAC-3’) and LAI-R (5’-TCACTAGCCATTGCTCTCCA-3’). PCR 
reaction conditions were 94º C for 2 min; 35 cycles of 94º C for 30 s, 52º C for 30 s, 72º C for 2 
m; and one cycle at 72º C for 5 min. Amplified PCR products were cloned into TOPO vectors 
using a pCR 2.1-TOPO TA Cloning kit (Invitrogen). Bacteria colonies were screened for full-
length RT insertion by PCR with the aforementioned primers and reaction conditions. Colonies 
positive for RT were cultured overnight at 37ºC in Luria-Bertani broth (Mo Bio Laboratories, 
Inc.) supplemented with 50 μg/ml carbenicillin (Thermo Fischer Scientific). Plasmid was 
recovered using the QIAprep Spin Miniprep Kit (Qiagen) and sequenced using primers LAI-RT-
F, 200F, and 350F. Sequences were analyzed using Lasergene (DNASTAR). 
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5.4.4 Drug susceptibility assays 
Susceptibility to RPV analogs, NNRTIs, NRTIs, and a pyrophosphate analog were performed as 
described in section 4.4.3. 
5.4.5 HIV-1 replication assay 
Virus replication was measured as described in 4.4.4 with the use of HuT-R5 cells and not 
PBMCs. A Retrotek HIV-1 p24 antigen ELISA kit (ZeptoMetrix) was used for the data 
displayed in Figure 15. 
5.5 RESULTS 
5.5.1 Selection of DRMs in HIV-1 by RPV and compounds 7 and 11 
To select mutations in HIV-1 that confer resistance to the RPV analogs, HuT-R5 cells were 
infected with WT HIV-1 and passaged in increasing concentrations of RPV or analogs until viral 
replication was similar in the absence of drug. The RT coding region of vRNA isolated from 
culture supernatants was amplified by PCR, cloned, and sequenced. After each concentration 
change, RPV and compounds 7 and 11 displayed similar CPE patterns of large syncytia and 
substantial cell death and were increased gradually to concentrations 128-fold above their 
respective EC50 values until virus replication was robust within 60 days post-infection (Figure 
14A). Sequencing of RT clones from RPV, compound 7, and compound 11 cultures revealed the 
121 
selection of RPV-associated mutations at ≥64-fold the starting EC50 values (Table 12). K101E 
was detected in 43% of clones isolated from the RPV culture, and this mutation is a known RPV-
associated DRM (16, 265, 306). Like RPV, compound 7 selected K101E, albeit in 100% of 
clones (Table 12). 
 
 
Figure 14. Increase in RT inhibitor concentrations during HIV-1 resistance selection. 
HuT-R5 cells infected with HIV-1 and cultured in the presence of RPV or RPV analogs were 
monitored for CPE, at which time RT inhibitor concentrations were increased. Resistance 
selection in WT HIV-1-infected cells cultured in RPV, compound 7, or compound 11 were 
started at  4-fold above their respective EC50 (A). Alternatively, two resistance selection cultures 
of WT HIV-1 in compound 13 were started at 2- or 4-fold above the EC50, while M230I HIV-1 
selection in compound 13 was started at 4-fold above the EC50 (B). 
 
Compound 11 selected a more complex resistance profile than compound 7. RPV-
associated resistance mutations E138K, Y181C, and M230I were detected separately in 10%, 
50%, and 20% of clones, respectively (Table 12). However, two mutations not previously 
associated with RPV resistance were discovered with consistency. E40K was detected in 50% of 
clones, both alone and with Y181C, indicating a possible linkage between the mutations. D67E 
was detected in 20% of clones along with Y181C or M230I. The lack of consistent DRMs 
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indicates that selection in compound 11 may not have been complete at termination of the 
cultures. Because both compounds 7 and 11 selected known RPV-associated DRMs, selection 
experiments were not repeated.   
 
Table 13. RT sequences of HIV-1 clones isolated from supernatant of cell cultures in RPV, 
compound 7, and compound 11 
Compound Total days 
in selection 
Fold-change 
from EC50 
Clone Mutations in RTa 
RPV 56 128 1-3 WT 
4-5 K101E 
6 S489P 
7 K101E, S489P 
     
Analog 7 49 128 1-7 K101E 
8 K101E, S105IFS 
9 K101E, I375* 
10 K101E, G456R 
     
Analog 13 57 64 1 E40K 
2 L246P 
3 E138K 
4-5 E40K, V111A, Y181C 
6 D67E, Y181C, T400A 
7 E40K, Y181C, L301P 
8 D67E, S105IFS, K154EFS, M230I 
9 M16V, M230I, Q330*, K465E, G556R 
10 E40K, T69A, Y181C, L228P, I375N 
a Bold, RPV-associated mutations. 
FS, frameshift; *, stop codon. 
 
5.5.2 Selection of a novel combination of RT mutations in HIV-1 by compound 13 
Unlike selection with RPV and compounds 7 and 11, cells cultivated in the presence of 
compound 13 displayed few small syncytia and maintained large cell clusters similar to an 
uninfected culture. Because of the lack of robust CPE, concentrations of compound 13 were not 
increased as frequently or as high compared to RPV and compounds 7 and 11 (Figure 14B). CPE 
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suppression by compound 13 was maintained at a concentration 8-fold above the EC50 for >130 
days in two separate cultures started at 2- or 4-fold above the EC50. 
vDNA from cells and vRNA from supernatant were isolated at day 156 post-infection 
from the culture begun at 2-fold the EC50. The mutations G112D and M230I were identified in 
near full-length RT sequences from both vDNA and vRNA populations (Table 13). This 
mutation combination was also observed in 2/3 of vRNA clones we could obtain, but only 
M230I alongside K101E was detected in the single vDNA clone. Sequencing of population and 
clonal vDNA and vRNA from the culture started at 4-fold above the EC50 also revealed G112D 
and M230I linkage, which was observed in 100% of the sequences.  
To determine if M230I would allow quicker selection of G112D in the presence of 
compound 13, HuT-R5 cells were infected with M230I HIV-1 and cultured in media containing 
compound 13. Seven days after switching the compound concentration to 16-fold above the EC50 
(Figure 14B), G112D and K196R were detected by population sequencing of vRNA (Table 13). 
Interestingly, sequencing of additional archived supernatant samples from the culture started at 
2-fold above the EC50 revealed that G112D evolved prior to M230I and was observed as early as 
63 days post-infection (Table 13). This was similar to the time needed for G112D to evolve in 
M230I HIV-1 in the presence of compound 13. Our data suggest that G112D is not a 
spontaneous mutation and arises with M230I to provide an advantage to HIV-1 in the presence 
of RPV analog 13 in vitro.  
5.5.3 Resistance phenotypes of RT mutants selected by RPV and RPV analogs 
Viruses with known RPV-associated mutations were resistant to RPV and the respective 
compounds in which they were selected (Table 14). The mutations K101E, E138K, and Y181C 
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in HIV-1 conferred low-level resistance to RPV, which is comparable with previous reports 
(265, 543). Although only consistently detected in RPV and compound 7 cultures, K101E HIV-1 
was tested for resistance against all three RPV analogs because it is a known DRM selected in 
vitro and in vivo by RPV (265, 283, 306) and was not included in the original analog experiment 
(543). K101E conferred low-level resistance to RPV and compounds 11 and 13 compared to WT 
HIV-1 (2.8- to 3.5-fold), but resistance was slightly higher against compound 7 (6.0-fold). This 
difference between K101E resistance to RPV and compound 7 was similar in another study 
(560). E138K and Y181C also conferred low-level resistance to both RPV and compound 11 
(2.0- to 3.5-fold). However, virus with Y181C and E40K or D67E had similar resistance to RPV 
and compound 11 as Y181C alone (3.0- to 3.5-fold).  
 Of the known mutations tested, M230I HIV-1 showed the highest resistance to RPV and 
analogs (Table 14). The EC50 values of RPV and compounds 11 and 13 were 7.3- to 9.8-fold 
higher for M230I HIV-1 than WT HIV-1; however, EC50 values were similar for D67E/M230I 
HIV-1 and M230I HIV-1, suggesting that D67E does not have a direct role in resistance. The 
EC50 values for compound 11 to M230I HIV-1 and the culture supernatant were similar, 
implying that M230I is the mutation mainly responsible for HIV-1 resistance to compound 11 in 
the culture (Table 12). Of note, the addition of G112D to M230I tripled the resistance of M230I 
HIV-1 to both RPV (30.3-fold) and compound 13 (20.4-fold), whereas G112D alone was as 
susceptible as WT virus to both compounds (1.1- to 1.8-fold). The EC50 values of compound 13 
to G112D/M230I HIV-1 and the compound 13 supernatant were similar, suggesting that the dual 
mutant is likely responsible for resistance in our compound 13 culture.  
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Table 14. RT sequences of HIV-1 populations and clones isolated from supernatant of cell cultures compound 13 
Virus Days of selection Nucleic acid source Positions sequenced Mutations in RTa 
WT 
(2x EC50 start) 
63 RNA (population) 1-250 K64*, S69C, G112D 
91 RNA (population) 1-250 G112D, M230I 
156 RNA (population) 1-140, 228-450 G112D, M230I, V381L 
 DNA (population) 1-120, 210-560 G112D, M230I 
 RNA (clone) 1-560 G112D, M230I 
 RNA (clone) 1-560 V10I, G112D, K126E, M230I 
 RNA (clone) 1-560 K43R, E53G, K281*, E297G, A360V, P433L 
 DNA (clone) 1-560 K101E, M230I, L391P 
     
WT 
(4x EC50 start) 
199 RNA (population) 1-560 G112D, M230I 
 DNA (population) 1-560 G112D, M230I 
 RNA (clone) 1-560 G112D, M230I 
 RNA (clone) 1-560 G112D, M230I 
 RNA (clone) 1-560 G112D, M230I, L517FFS 
 RNA (clone) 1-560 G112D, M230I, D250V, T403I 
 DNA (clone) 1-560 G112D, M230I 
 DNA (clone) 1-560 G112D, M230I, K331E 
 DNA (clone) 1-560 P55L, G112D, M230I, R448G 
     
M230I 59 RNA (population) 1-470 G112D, K196R, M230I 
a Bold, RPV-associated mutations.  
FS, frameshift; *, stop codon. 
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Table 15. In vitro antiviral activity of RPV and compounds 7, 11, and 13 against WT or mutant HIV-1 
 EC50 (nM) (Fold-change above WT)
a 
Virus RPV Compound 7 Compound 11 Compound 13 
Supernatantb - 23.6 (12.4) 5.5 (9.2) 24.8 (20.7) 
WT 0.4 ± 0.1 (1.0) 1.9 ± 0.4 (1.0) 0.6 ± 0.1 (1.0) 1.2 ± 0.2 (1.0) 
K101E 1.4 ± 0.4 (3.5) 11.4 (6.0) 1.7 ± 0.4 (2.8) 3.6 ± 0.9 (3.0) 
G112D 0.7 ± 0.04 (1.8) - - 1.3 ± 0.3 (1.1) 
E138K 1.0 ± 0.2 (2.5) - 1.2 ± 0.3 (2.0) - 
Y181C 1.4 ± 0.3 (3.5) - 1.7 ± 0.3 (2.8) - 
E40K/Y181C 1.4 ± 0.4 (3.5) - 1.8 ± 0.3 (3.0) - 
D67E/Y181C 1.2 ± 0.2 (3.0) - 1.7 ± 0.2 (2.8) - 
M230I 3.9 ± 0.6 (9.8) - 5.9 ± 1.3 (9.8) 8.8 ± 1.3 (7.3) 
D67E/M230I 3.4 ± 0.6 (8.5) - 6.2 ± 1.8 (10.3) - 
G112D/M230I 12.1 ± 1.1 (30.3) - - 24.5 ±  1.9 (20.4) 
a Average and standard deviation values based on 3-6 independent experiments each performed in triplicate. Bulk virus results based 
on 1 independent experiment performed in triplicate. 
b Virus population in supernatant at time of DRM detection. 
-, not done. 
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5.5.4 Effect of select RT mutations on HIV-1 replication 
Since the D67E mutation did not enhance resistance, we hypothesized that it may act as a 
compensatory mutation to increase replication capacity of HIV-1 with the DRMs Y181C or 
M230I. To measure virus replication in vitro, HuT-R5 cells were infected with WT, M230I, or 
D67E/M230I HIV-1 and passaged for 12 days. Virus production was measured by HIV-1 capsid 
protein (p24) in the culture supernatants (Figure 15A). Cells infected with WT HIV-1 
demonstrated high levels of CPE and cell death early, which explains the initial exponential 
increase in p24 production followed by a plateau after day 4 post-infection. In contrast, HIV-1 
with M230I or D67E/M230I mutations produced approximately 1-log less p24 through day 4 and 
surpassed the WT culture after day 6 post-infection. Overall, the replication curves for M230I 
and D67E/M230I were similar suggesting that D67E is not a compensatory mutation. 
Replication assays were not performed for E40K viruses. 
The consistent detection of G112D and M230I mutations by sequencing HIV-1 selected 
in compound 13 cultures suggests an advantage for virus with both mutations; although, G112D 
alone did not confer resistance to RPV or compound 13. Replication kinetics of WT, G112D, 
M230I, and G112D/M230I HIV-1 indicate that the single mutations cause reduced replication 
capacity (Figure 15B). G112D HIV-1 and M230I HIV-1 displayed a 1- to 2-log difference in p24 
concentrations through day 6 of the assay and had similar growth curves. Similar to the 
D67E/M230I experiment, WT virus p24 production plateaued after day 6, whereas the single 
mutant viruses continued to produce p24 after 6 days post-infection. However, G112D appears to 
be compensatory to M230I as replication capacity was 0.5- to 1.0-log higher for the double 
versus single mutant viruses through day 6 post-infection. While not as efficient at p24 
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production as WT HIV-1 early in the experiment, the replication curve of G112D/M230I HIV-1 
mirrored that of WT HIV-1 with a plateau in virus production after day 6 post-infection. Based 
on two separate replication assays using these viruses, replication fitness is ranked as WT > 
G112D/M230I > G112D > M230I. Combined with the resistance data, it appears that the G112D 
mutation is responsible for improved replication and increased resistance in M230I HIV-1.  
 
 
Figure 15. Replication kinetics of WT and mutant HIV-1. 
HuT-R5 cells were infected with WT or mutant HIV-1, and p24 concentrations in culture 
supernatants were measured by ELISA. Concentrations of p24 in cultures infected with WT, 
M230I, or D67E/M230I HIV-1 (A) or WT, G112D, M230I, or G112D/M230I HIV-1 (B) are 
shown. Results of (B) are representative of two independent experiments. 
 
5.5.5 G112D/M230I HIV-1 susceptibility to NNRTIs and NRTIs 
Although G112D/M230I HIV-1 had enhanced resistance to RPV and compound 13 and 
improved replication capacity over virus with either mutation alone, we investigated the 
inhibition of this double mutant by a broader panel of RT inhibitors. Testing the mutant virus for 
susceptibility to other RT inhibitors will determine if there is a cross-resistance profile and 
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subsequently how the mutant may avoid inhibition by compound 13. WT, G112D, M230I, and 
G112D/M230I HIV-1 were tested for susceptibility against a panel of FDA-approved NNRTIs 
(EFV, ETR, and NVP), NRTIs (AZT, ddI, FTC, TFV), and a pyrophosphate inhibitor (PFA) 
(Table 15). Similar to RPV and compound 13, G112D HIV-1 had no resistance to other NNRTIs 
and the NRTI TFV (0.7- to 1.2-fold). However, this mutant did have intermediate resistance 
(16.1-fold) to FTC, while displaying hypersusceptibility to AZT and PFA (0.2-fold). Conversely, 
M230I conferred resistance to all three NNRTIs (6.5- to 10.6-fold) and hypersusceptibility to all 
NRTIs (0.1- to 0.3-fold). Virus with both G112D and M230I had increased resistance to NNRTIs 
compared to M230I alone (16.5- to 17.9-fold) as was seen with RPV and compound 13. 
Interestingly, the addition of M230I to G112D virus abrogated the resistance to FTC (3.9-fold) 
observed with G112D alone. The dual mutant also displayed hypersusceptibility to AZT (0.1-
fold) and PFA (0.1-fold), and a mild increase in susceptibility to TFV (0.6-fold). Our results 
indicate that HIV-1 with G112D and M230I is cross-resistant to all clinically relevant NNRTIs 
and FTC, susceptible to ddI and TFV, but hypersusceptible to AZT and PFA. 
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Table 16. Change in in vitro susceptibility of RT inhibitors against G112D, M230I, or G112D/M230I HIV-1 
 EC50 Fold-Change above WT
a 
Virus ETR EFV NVP AZT ddI FTC TFV PFA 
G112D 1.2 1.2 0.7 0.2 2.0 16.1 0.7 0.2 
M230I 6.5 8.2 10.6 0.2 0.1 0.1 0.3 0.3 
G112D/M230I 16.5 17.9 17.0 0.1 0.7 3.9 0.6 0.1 
a Values represent fold-change based on mean mutant EC50/ mean WT EC50. All data are representative of 3 individual experiments, 
each performed in triplicate. 
ETR, etravirine; EFV, efavirenz; NVP, nevirapine; AZT, zidovidine; ddI, didanosine; FTC, emtricitabine; TFV, tenofovir; PFA, 
foscarnet. 
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5.6 DISCUSSION 
Despite the efficacy of available antiretroviral drugs to suppress HIV-1 replication, DRMs 
evolve in the virus and limit alternative therapy options, especially if the mutations impart cross-
resistance to multiple drugs. To counter drug resistance, new compounds must be developed that 
are potent, safe, and effective against isolates with known resistance mutations. The goal of this 
work was to determine the resistance profile of three RPV analogs that met these criteria (543), 
which would shed light on their mechanisms of action as HIV-1 inhibitors. Because of the 
structural changes to RPV that would affect drug-virus interactions, we hypothesized that these 
analogs could select novel resistance mutations in HIV-1 RT.  
Results from our in vitro assays demonstrate that compounds 7 and 11 select for known 
RPV-resistant RT mutations K101E, E138K, Y181C, and M230I. These mutations were 
previously selected under RPV pressure in vitro and in clinical trials (265, 283, 295, 306). 
Detection of K101E HIV-1 after selection with compound 7 is not surprising because modeling 
shows this compound forms a H-bond between its pyrimidine moiety and the K101 residue of 
RT (543), similar to RPV (288). Loss of this interaction through K101E likely reduces the 
binding capacity of compound 7; however, the decrease in susceptibility conferred by K101E did 
not account for the total resistance seen in our culture supernatant. Genotypic evidence indicates 
that K101E is a key mutation in HIV-1 resistance to compound 7, but other undetected mutations 
may account for the greater resistance seen in the virus supernatant. Additional selection cultures 
could be performed to address this disparity.  
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In contrast to selection of a single HIV-1 DRM by compound 7, resistance to compound 
11 was more complex. Three distinct RPV-associated DRMs, E138K, Y181C, and M230I, were 
detected in vRNA isolated from the compound 11 culture. The selection of these DRMs by 
compound 11 is likely attributable to its proposed binding to RT, which is similar to RPV (560). 
The change from a pyrimidine (RPV) to a purine (compound 11) moiety allows the central ring 
to sit deeper in the NNRTI-binding pocket while maintaining hydrogen bonds with K101 and the 
shared water molecule between the drug and E138 (560), indicating that K101E also causes 
resistance to compound 11. The cyanovinyl and benzonitrile moieties of compound 11 occupy a 
similar confirmation as RPV in RT (560), which could explain the similar resistance Y181C and 
M230I to both RPV and compound 11. Additional mutations not associated with NNRTI 
resistance, E40K and D67E were also detected in combination with Y181C or Y181C and 
M230I, respectively. The selection of E40K with Y181C and/or M230I was previously reported 
in RPV and ETR selection cultures (265, 548). Similarly, D67E has been observed in ART-
treated patients with NRTI-associated resistance mutations (561, 562), but it was not associated 
with phenotypic resistance (561). However, these mutations did not meaningfully alter the 
resistance phenotype of Y181C or M230I to RPV or compound 11, and D67E did not appear to 
provide a compensatory benefit to M230I HIV-1 replication capacity. A study by our 
collaborators revealed that D67E, but not E40K, confers low-level resistance to RPV and 
compounds 7 and 13, while neither mutation conferred resistance to compound 11 (560). 
Nonetheless, compounds 7 and 11 did not select for novel DRMs and both displayed genotypic 
and phenotypic resistance profiles similar to RPV. 
Contrary to RPV and compounds 7 and 11, compound 13 selected HIV-1 clones with two 
mutations in RT: G112D and M230I. Our data indicate that G112D enhances both resistance to 
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NNRTIs and replication capacity of virus also containing the M230I mutation. The resistance 
phenotype of G112D/M230I is unique as these mutations together conferred >10-fold resistance 
to all NNRTIs and increased susceptibility to some NRTIs and a pyrophosphate analog. This 
phenomenon was also seen with the I132M RT mutation, which was resistant to NVP but 
hypersusceptible to the NRTIs TFV and lamivudine (563). RT polymerization assays performed 
by our collaborators confirm the resistance of M230I and G112D/M230I to compound 13 and 
susceptibility to PFA (data no shown). The selection of these mutations and their resistance 
phenotype suggests that compound 13 has a different mechanism of action than RPV and the 
other analogs.  
While compound 13 likely binds the NNRTI-binding pocket, the change from a 
pyrimidine moiety in RPV to a purine moiety (reversed in compound 11) may also exert an 
effect on dNTP binding and incorporation, which is not see in other NNRTIs. G112D is located 
near the conserved D110 and YMDD motif necessary for catalysis during reverse transcription 
(564, 565). Pressure in this region from compound 13 binding to RT may explain the 
development of G112D. Interestingly, this mutation showed high resistance to FTC but not other 
NRTIs. FTC resistance is associated with the M184 position, which is part of the YMDD motif 
(313, 564). M184I/V mutations increase selectivity for the natural dNTP over FTC because 
branching of isoleucine and valine side chains hinders incorporation of the drug (566, 567). 
Therefore, it is possible that G112D provides some level of steric hindrance that reduces FTC 
efficacy or confers a selective advantage of natural dNTPs over FTC. G112D and G112D/M230I 
HIV-1 were also hypersusceptible to AZT and PFA, which is unique because DRMs associated 
with these drugs tend to be antagonistic (568-570). However, HIV-1 with mutations Q151I/V has 
been shown to be hypersusceptible to both AZT and PFA (570). The Q151 residue resides in the 
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RT motif responsible for binding the viral template strand and dNTPs during reverse 
transcription, and specifically contacts the viral genomic template (565, 570). Therefore, the 
similar hypersusceptible phenotypes of Q151I/V HIV-1 and G112D/M230I HIV-1 further 
suggest that compound 13 affects dNTP processing in a manner unique from other NNRTIs. 
To elucidate the function of these mutations in RT and their resistance mechanism, 
biochemical assays and modeling should be performed. DNA- and RNA-dependent DNA 
polymerase assays performed by our collaborators indicate a defect in polymerization of RTs 
with the M230I mutation, whereas polymerization of G112D RT is comparable to WT RT (data 
not shown). To determine the effects of RT inhibitors on RT with G112D, M230I, or 
G112D/M230I mutations, polymerization assays should be repeated in the presence of drugs to 
confirm the resistance or hypersusceptibility phenotypes we report in viral assays. Single step 
incorporation assays could also be implemented to determine if the RT mutations confer 
preference for the NRTIs or natural dNTPs, potentially pointing to the mechanisms of NRTI 
hypersusceptibility or resistance. However, modeling of compound 13 in RT, as has been 
completed for compounds 7 and 11 (543, 560), should be performed to predict the mechanism of 
resistance. Modeling could show how the difference in structures between compound 13 and 
RPV could affect drug-RT contacts. For example, the presence of the purine moiety in 
compound 13 most likely alters the H-bond and water binding observed with RPV and the K101 
and E138 positions, respectively, as is seen with compound 11 (560). M230 is located in the 
primer grip region of RT and stabilizes primer residues by forming a hydrogen bond between the 
amino acid and a phosphate of the primer strand (565). Modeling of compound 13 and RT could 
show if the drug-enzyme interaction disrupts the primer bond or if M230I sterically hinders the 
binding of compound 13. Modeling can be used to predict drug-RT interactions, the mechanisms 
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of resistance, and identify alternative DRMs to guide the refinement of more analogs; however, 
crystal structures of compound 13 bound to WT and mutant RT are needed to truly understand 
the inhibitory effects of compound 13 and how the DRMs reduce compound 13 efficacy. 
Overall, our data show that the RPV analogs 7 and 11 do not select different DRMs than 
RPV. The resistance phenotypes of known RPV-associated DRMs of these compounds are 
similar to RPV as well, results that are supported by our collaborators (560). Yet, compound 13 
selected a novel combination of DRMs in HIV-1. The selection of two resistance mutations, one 
inside the NNRTI-binding pocket (M230I) and one outside (G112D), suggests that compound 13 
is causing a conformational shift in RT that is unique to this molecule. Nevertheless, 
G112D/M230I confers resistance to all clinically approved NNRTIs but results in 
hypersusceptibility to NRTIs and a pyrophosphate analog. Compound 13 is not an ideal 
candidate for further development as ART or PrEP because of NNRTI cross-resistance. 
However, biochemical and modeling experiments to better understand the mechanisms of 
resistance and hypersusceptibility conferred by G112D and M230I are the next step in 
understanding the unique effect that compound 13 has on RT and how the structure can be best 
used to design new drugs that do not select cross-resistant DRMs.  
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6.0  FINAL DISCUSSION AND IMPLICATIONS FOR PUBLIC HEALTH 
The global response to the HIV-1 pandemic is one of the most organized and well-funded efforts 
to control a human disease; however, 30 years after the discovery of the virus, there is no vaccine 
or cure. Until a vaccine is approved for public use, PrEP with antiretroviral drugs is an effective 
method to reduce HIV-1 incidences in populations at high-risk of being infected with the virus. 
Daily oral Truvada is currently the only PrEP regimen available for prescription, but its global 
availability is limited to less than 12 countries at the time of this writing. Despite significant 
reductions in HIV-1 infections by Truvada in multiple clinical trials, the biggest barrier to PrEP 
efficacy is adherence. Alternative PrEP modalities that address adherence include intercourse-
dependent oral Truvada or microbicide gels, IVRs, and long-acting injectables. Intercourse-
dependent PrEP and IVRs have shown success in clinical trials, but these options are user-driven 
and adherence cannot be guaranteed. In contrast, long-acting injectable PrEP would guarantee 
adherence but the ability of such a strategy to prevent HIV-1 transmission has not been tested in 
clinical trials.  
RPV LA is the long-acting injectable formulation of the NNRTI RPV and is safe in 
humans and a single dose can provide concentrations above a theoretical protective concentration 
for at least one month post-dosing. However, the current paradigm of using antiretroviral drugs 
approved for both ART and PrEP has two issues that should be addressed for every PrEP 
modality. The first issue is selection of drug resistance in individuals who receive PrEP when 
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already HIV-1+ or in those who experience a breakthrough infection while on PrEP. The second 
issue is the ability of PrEP to prevent transmission of drug-resistant HIV-1. Thus, the overall 
concern is an increase in newly infected individuals with drug-resistant HIV-1. Importantly, 
certain mutations lead to cross-resistance to some or all drugs of the same class (16), thus ART 
options could be reduced in newly infected individuals should they acquire a virus with DRMs. 
There is no ethical way to directly study these scenarios in humans; nevertheless, we used two 
distinct animal models to address two questions in regard to RPV LA as PrEP and its role in 
resistance selection. One, would RPV LA monotherapy select for DRMs in macaques infected 
with RT-SHIV (Chapter 3); and two, can RPV LA prevent mucosal transmission of drug-
resistant HIV-1 in humanized mice (Chapter 4)? The success of PrEP in clinical trials likely 
guarantees its eventual global use, thus questions of drug resistance and PrEP efficacy are 
valuable to study in pre-clinical models prior to large-scale human trials and widespread clinical 
approval. The public health significance of this dissertation work is the development of pre-
clinical animal models to assess the potential consequences of RPV LA use in scenarios that 
have occurred in clinical trials with Truvada (318-320) and how drug resistance affects PrEP 
efficacy. Testing these questions in animal models provides a better understanding of RPV LA 
PrEP, and the results can be used to inform future study designs with the drug. 
 Due to cross-resistance between NNRTIs (265) and growing global coverage of ART, the 
utility of NNRTIs is diminishing because of increases in NNRTI-resistance prevalence and 
transmission (285, 352, 353). Thus, new antiretroviral drugs to expand options for ART and 
PrEP are needed. These novel drugs should be active against drug-resistant HIV-1, have novel 
mechanisms of actions, and should not select cross-resistant mutations (or preferably no 
resistance at all). We were provided with analogs of RPV that are active against known drug-
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resistant HIV-1 molecular clones (543). Our objective was to determine the resistance genotype 
and phenotype of HIV-1 selected in the presence of the analogs as a way to understand the 
mechanism of action of the compounds (Chapter 5). Mutations that develop under drug selection 
and confer resistance in a virus can indicate where the inhibitors bind to suppress the HIV-1 
replication cycle. The public health significance of this study is a better understanding of novel 
compounds that can be used to focus the design of new antiretroviral compounds for control of 
the HIV-1 pandemic. 
6.1 RPV LA MONOTHERAPY DOES NOT READILY SELECT FOR RESISTANCE 
MUTATIONS IN RT-SHIV-INFECTED MACAQUES 
The goal of this aim was to address the concern that RPV LA could select for drug resistance 
should individuals receive the drug after becoming infected with HIV-1. In this situation RPV 
becomes monotherapy, which is a strategy no longer in practice due to rapid selection of drug-
resistant HIV-1 (268-270, 272). In successful Truvada clinical trials, 17 individuals were found 
retrospectively to be infected with HIV-1 before receiving PrEP, and five of them (29.4%) 
developed DRMs (318-320). Although providing PrEP to HIV-1+ participants was rare, these 
findings confirm that PrEP can select drug resistance in persons with undetected HIV-1 
infection, hence the need to test DRM selection in a monotherapy setting for RPV LA and any 
other PrEP strategy. 
Contrary to earlier studies in macaques infected with RT-SHIV and treated with EFV or 
NVP monotherapy (389, 465-467), RPV LA monotherapy did not select DRMs at a high or 
consistent frequency. Two different RPV-associated resistance mutations were detected at a 
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lower than expected frequency in RT-SHIV isolated from plasma samples of two macaques. No 
DRMs were observed in virus isolated from ileum or axillary LN tissues of the same macaques, 
in which drug concentrations were >4-fold higher than in plasma. However, one of 66 
participants in a Phase I clinical trial of RPV LA became infected with HIV-1 after receiving a 
single 300 mg dose of RPV LA (338). This person developed detectable levels of HIV-1 with a 
RPV-resistant mutation in plasma when drug concentrations were around the PAEC90 for RPV 
(351). In humans, low concentrations of RPV can be detected in plasma and tissues for up to 160 
days after a single dose of RPV LA (338, 348). During viral rebound, drug concentrations in our 
macaques were similar to concentrations reported in the infected person, but resistance selection 
did not occur in our animals. While our dosing strategy reflected drug concentrations reported in 
humans, the long tail that hovers around the PAEC90 value may be the ideal situation for 
resistance selection in humans but not in macaques. Our data support that selection of drug 
resistance by RPV LA monotherapy may be rare in pigtailed macaques infected with RT-SHIV. 
While our results are based on a population of two animals, single-genome sequencing of HIV-1 
RNA isolated from plasma of BLT mice treated with RPV LA PrEP showed similar low 
frequencies of DRMs  (Chapter 4), furthering supporting our macaque results. Nonetheless, the 
experiment could be repeated with a larger cohort of macaques to show consistency with the 
RPV LA/RT-SHIV model and eliminate idiosyncrasies of the two animals that may have 
affected the results.  
Our data support that RPV LA monotherapy does not easily select for resistance 
mutations in RT-SHIV-infected macaques or HIV-1-infected humanized mice. Similar to RT-
SHIV, we had difficulty selecting for RPV resistance in HIV-1-infected cells in vitro (Chapter 
5). RPV concentrations >100-fold the in vitro EC50 were needed to select for mutant viruses with 
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single low-level DRMs. Overall, our data support that low concentrations of RPV do not readily 
select DRMs in RT-SHIV (or HIV-1); thus, RPV LA may not significantly increase the 
prevalence of DRMs if approved for widespread prophylactic use. However, the contrasting 
outcomes between our two macaques on RPV LA monotherapy and one individual on RPV LA 
with a breakthrough infection should be further studied to better understand the consequences of 
RPV LA use.  
6.2 RPV LA CAN INHIBIT DRUG-RESISTANT HIV-1 TRANSMISSION IN BLT 
MICE BUT NOT AT BIOLOGICALLY RELEVANT DRUG CONCENTRATIONS  
The goal of this aim was to determine the efficacy of RPV LA to inhibit mucosal transmission of 
WT and drug-resistant HIV-1. RPV LA has been shown to be safe and tolerable in multiple 
clinical trials and provide drug concentrations above a theoretical protective PAEC90 value for at 
least a month post-dosing (338, 340, 348). To date, only one study has tested the ability of RPV 
LA to inhibit mucosal transmission of HIV-1 infection. Kovarova et al. showed that a single 
dose of RPV LA protected 13/16 (81%) mice from vaginal infection after challenge with WT 
transmitted/founder isolates of HIV-1 (501). However, the RPV LA dose used in this study 
resulted in sustained plasma RPV concentrations for 28 days post-injection approximately 6-fold 
higher than peak concentrations reported in humans (six days post-injection) who received a 
single 1,200 mg dose of RPV LA (338) and tissue RPV concentrations were not measured. In 
contrast, we performed PK analysis of RPV LA in plasma and mucosal tissues and found that a 
150 mg/kg IM dose of RPV LA in BLT mice recapitulated RPV concentrations reported in 
humans, thus providing a more biologically relevant model for efficacy studies.  
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We found that biologically relevant concentrations of RPV did not significantly inhibit 
vaginal transmission of WT or low-level resistant HIV-1. However, we then challenged mice 
when plasma and vaginal tissue RPV concentrations were approximately 8-fold higher than 
concentrations reported in humans, similar to Kovarova et al. (501). With this dosing strategy, 
we observed total protection from vaginal infection by low-level resistant HIV-1 (Y181C), 
demonstrating that RPV LA can inhibit vaginal transmission of virus with a DRM. This is an 
encouraging result, as most known RPV-associated DRMs confer low-level resistance to the 
drug, similar to Y181C (265). However, we did not observe statistically significant protection 
from WT or high-resistant HIV-1. We believe the lack of protection to WT HIV-1 is due to the 
high replication rate of the lab-adapted challenge strain. It is possible that the use of 
transmitted/founder HIV-1 isolates and a different titer method by Kovarova et al. (501) resulted 
in a significant difference between the challenge inoculums used between our studies. It is 
possible the modest replication defect conferred by Y181C in our challenge stock created a virus 
with similar replication capacity to the WT viruses used by Kovarova et al. (501), hence the 
similar protective results. In vitro infectivity and replication assays could directly assess the 
dissimilarities between our lab-adapted and the transmitted/founder challenge stocks used in the 
experiments. While our study was designed to analyze specific mutations within RT, we plan to 
use clinical WT and drug-resistant HIV-1 isolates in future experiments to determine what 
concentrations of RPV LA should be achieved to inhibit mucosal transmission. The use of 
clinical isolates would allow us to elucidate the effect of RPV LA concentrations on transmission 
of biologically relevant viruses; however, the use of clinical isolates introduces the issue of 
mutations outside of RT and heterogeneous populations that could influence results by affecting 
infectivity and replication capacity. Therefore, cloning the RT region, and perhaps the Env 
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region, from clinical viruses into a molecular clone of HIV-1 with consistent replication is being 
considered to reduce such confounding factors. Regardless, in vitro infectivity and replication 
will be measured to normalize challenge doses. 
Although RPV LA did not provide the level of protection against WT HIV-1 that we had 
hypothesized, detection of plasma viremia was delayed in two WT-infected mice challenged at 
high RPV concentrations. This indicates that RPV LA had a suppressive but not protective effect 
on early virus replication. We could utilize animals with this “smoldering” infection to identify 
sanctuary sites and track initial HIV-1 spread through visualization techniques such as 
bioluminescence or PET imaging, similar to what has been performed with SIV in mice (571) 
and macaques (572). Although we have PK data for mucosal tissues, there could be an uneven 
temporal distribution of active RPV that would allow sanctuary sites to form and be maintained 
until systemic drug concentrations decline to allow viral circulation. Imaging studies combined 
with PK analyses could elucidate the specific location(s) of low-level virus replication and 
determine what drug concentrations are needed to prevent mucosal transmission. For example, if 
we identify a specific tissue as a sanctuary site, we could then perform a dose response study 
with RPV LA until we find the drug concentration that prevents such sites from forming. It is 
also possible that virus is shielded from RPV by immune cell interactions, such as capture by 
dendritic cells (573), and ex vivo immunofluorescence assays could identify the cell populations 
and tissue locations responsible for such a phenomenon. This information could guide future 
RPV LA or PrEP designs to account for dosing, improved systemic drug dissemination, and 
specific cell/tissue drug targeting. Work has begun on the development of infectious and 
replication competent reporter viruses that produce nano-luciferase or infrared fluorescent 
protein for in vivo imaging of active virus replication sites.  
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Despite breakthrough infection in the majority of mice challenged at day 7 post-RPV LA 
dosing, no DRMs were detected in plasma virus by population sequencing. Subsequent single- 
genome sequencing of a larger group of infected mice revealed a low prevalence of NRTI- and 
NNRTI-associated DRMs in both untreated and RPV LA-treated animals. The low frequency of 
DRMs bolsters our results from Chapter 3 that RPV LA does not readily select for drug 
resistance but is contradictory to the infection of a participant in the SSAT 040 trial (351). 
Although we did not perform PK analysis beyond week 1 post-RPV LA injection, it is likely that 
RPV in our mice would still be detectable at concentrations similar to the infected human 
through the end of our study.  
It is also possible that physiological differences between humans and mice, such as 
metabolism or protein binding, account for the discrepancy in protective efficacy and resistance 
selection. To accurately test this, we would need to perform an equilibrium dialysis assay to 
determine the amount of free, active RPV in mice and humans in relevant tissue compartments; 
however, this would be costly and technically challenging. Alternatively we could perform drug 
susceptibility assays in the presence mouse plasma to calculate a PAEC90 to better predict 
protective RPV concentrations in mice. Based on our PK data, we could adjust dosing strategies 
to define protective levels of RPV or determine suboptimal concentrations that would be more 
likely to select for resistance. Thus, longitudinal studies with different doses of RPV LA or 
challenges at different time points may better reveal the effect of RPV on resistance selection 
and further refine the BLT model for RPV LA and future PrEP studies.  
Combined with results from human tissue explant models (348, 349), our preliminary 
data comparing vaginal or rectal transmission of WT HIV-1 in RPV LA-treated mice indicate 
that the drug at current proposed dosing regimens may be more effective at preventing rectal 
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rather than vaginal HIV-1 transmission. However, we need more animals to provide statistical 
power to the analysis. Even if RPV LA is more appropriate for prevention of rectal infection, we 
still want to know what concentrations of RPV are protective. To determine these protective 
concentrations in vivo, we could take plasma samples on the day of challenge for 
pharmacodynamic analysis to establish a protective correlation between plasma and mucosal 
tissue drug concentrations. This could determine a protective threshold for RPV, as was done for 
CAB LA in macaques (484). However, it may be worth utilizing the RT-SHIV macaque model 
for such a study if we first addressed the metabolism of RPV as discussed in the previous 
section. Using macaques would allow for larger plasma volumes for more sensitive virus 
detection and mucosal tissue biopsies to correlate actual RPV concentrations at the site of 
infection. Knowing what concentrations of RPV are necessary for effective HIV-1 inhibition at 
mucosal sites would provide a better understanding of RPV tissue deposition, guide dosing 
strategies, and could influence selection of the target populations in future RPV LA trials. 
Overall, our data indicate that RPV LA can be effective at preventing low-level drug-
resistant (2-fold) HIV-1 infection in BLT mice, but not at concentrations observed in human 
women and not against HIV-1 with higher RPV resistance (27-fold). It will be important to 
determine an accurate in vivo protective concentration of RPV in plasma and mucosal tissues, 
rather than relying on a theoretical PAEC90 based on in vitro data. With a more accurate in vivo 
protective value and clinical HIV-1 isolates, we could design challenge and resistance selection 
experiments that closely recapitulate human exposure events and provide results that could shape 
RPV LA dosing recommendations and clinical trial design. 
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6.3 A RPV ANALOG SELECTS FOR A NOVEL COMBINATION OF MUTATIONS 
IN HIV-1 REVERSE TRANSCRIPTASE 
The goal of this work was to determine the resistance profile of three analogs of RPV. By 
knowing what DRMs these compounds select, we may be able to predict where they bind and 
how they inhibit HIV-1 replication. The flexible chemical structure of RPV allows it to adjust to 
mutations in RT (288) and is credited with the low-level resistance conferred by many DRMs 
(265). Therefore, the structure of RPV was altered to create analogs that potentially select novel 
DRMs in HIV-1 while maintaining the safety and potency associated with RPV (543). Utilizing 
in vitro assays, we determined the resistance genotype and phenotype of HIV-1 exposed to the 
RPV analogs and found that one selected a novel combination of RT mutations that conferred 
resistance to NNRTIs, but was hypersusceptible to NRTIs.  
While two of the analogs selected RPV-associated DRMs with similar resistance 
genotypes and phenotypes as RPV, compound 13 selected for the combination of G112D and 
M230I mutations in RT. This is unique as currently approved NNRTIs typically select single 
amino acid changes. The presence of both RT mutations in HIV-1 enhanced replication capacity 
and NNRTI-resistance compared to virus with either mutation alone. Interestingly, the G112D 
mutation conferred resistance to the NRTI FTC, no resistance to NNRTIs, and 
hypersusceptibility to the NRTI AZT and the pyrophosphate analog PFA. Selection of G112D is 
unique since all DRMs associated with FDA-approved NNRTIs exist near or within the NNRTI-
binding pocket, but G112D is near the D110 catalytic domain of the polymerase active site. This 
indicates that the structure of compound 13 may be binding RT in a novel manner and exerting 
pressure on RT outside of the canonical NNRTI-binding region. While the M230I mutation is 
considered part of the NNRTI-binding pocket and conferred cross-resistance to clinically 
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relevant NNRTIs, this mutation also conferred hypersusceptibility to the NRTIs we tested, which 
may explain why M230I is not prevalent in sequences cataloged in the HIV Drug Resistance 
Database (266). To further elucidate the inhibitory mechanism of compound 13, we could test 
compound 13 against a larger panel of RT inhibitor-resistant HIV-1 clones to predict amino acid 
positions in which the compound may interact with the viral enzyme.   
Because G112D and M230I exist in different motifs of RT, it would be fascinating to 
know how they alter RT structure to preserve enzyme functionality in the presence of NNRTIs. 
RT polymerization assays have confirmed a processing defect in RT with the M230I mutation, 
while G112D alone does little to effect enzyme function. Polymerization assays in the presence 
of RT inhibitors are planned to confirm our resistance phenotype results. Because compound 13 
affects NRTI susceptibility, dNTP incorporation assays could also be performed to determine the 
effect of the mutations on selectivity and incorporation. This would provide evidence to the 
mechanism of resistance or hypersusceptibility to NRTIs and PFA. Since the chemical structures 
of compound 13 and RPV are similar, we hypothesize that compound 13 targets the NNRTI-
binding pocket, and in silico modeling of compound 13, using a RPV-RT crystal structure as a 
template, could predict potential sites of interaction (and DRMs) between RT and compound 13. 
Drug-RT interactions could be tested phenotypically as mentioned in the previous paragraph. 
This assumes that compound 13 behaves in a similar manner as RPV, which may not be the case 
given the selection of G112D. To truly understand how the compound binds, crystal structures of 
compound 13 bound to a WT and G112D/M230I mutant RT should be solved. Crystallographic 
structures would reveal how compound 13 and RT truly interact, complement results of drug 
susceptibility analyses, and refine in silico modeling for future analogs.  
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Although compound 13 selected for a novel combination of resistance mutations in HIV-
1, suggesting a higher genetic barrier to resistance than RPV and the other analogs, the pair of 
mutations conferred cross-resistance to all clinically prescribed NNRTIs. This cross-resistance 
makes compound 13 unsuitable to move forward for clinical development. However, the 
selection of two mutations, one outside of the NNRTI-binding pocket, is unique and suggests 
that compound 13 is binding in a manner distinct from other NNRTIs, particularly RPV. Thus, 
compound 13 could serve as the backbone for development of a novel NNRTI or a new class of 
RT inhibitors that could eventually become approved antiretroviral drugs for ART or PrEP. 
6.4 CONCLUSION 
The unifying theme of this dissertation is the study of the effects of HIV-1 resistance on the 
FDA-approved drug RPV in regard to its use as a long-acting PrEP agent or as the backbone for 
novel antiretroviral compounds. We used animal models to address concerns of resistance 
selection as a result of RPV LA use and the ability of the formulation to prevent transmission of 
drug-resistant HIV-1. Our data indicate that RPV LA when administered as PrEP or 
monotherapy, an unintended consequence of its prophylactic use, does not readily select a viral 
population with high levels or consistent DRMs. This is an encouraging finding as selection for 
drug resistance should be negligent in compounds proposed for PrEP use. Also, our humanized 
mouse model shows that RPV LA can prevent vaginal infection of HIV-1 with a low-level RPV 
resistance mutation, suggesting the prophylactic formulation should be effective in areas with 
circulating drug-resistant HIV-1, particularly Y181C the second most prevalent transmitted 
NNRTI-resistant mutation. However, our data also indicate that RPV LA may not prevent 
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infection with viruses containing transmitted DRMs that confer higher levels of resistance (e.g. 
Y181V), thus the prevalence of certain DRMs in an area should be considered before 
administering RPV LA. More importantly, our results show that biologically relevant 
concentrations of RPV in humans do not translate to protection in humanized mice and 
protective concentrations between mucosal compartments may be significantly different. While 
drug metabolism differences between humans and mice may account for this discrepancy, we 
suggest tempering expectations that the current RPV LA dosing strategy in humans should be 
effective at significantly protecting at-risk populations from HIV-1 infection. Instead, 
pharmacodynamic studies should be performed to better define an in vivo protective 
concentration of RPV prior to efficacy trials.  
Finally, we determined the resistance profile of three RPV analogs to find where they 
interact with RT and if they could be of use as future ART or PrEP drugs. One of the compounds 
selected a novel combination of mutations not associated with other RT inhibitors; however, the 
two mutations together conferred cross-resistance to FDA-approved NNRTIs suggesting the 
compound targets the NNRTI-binding pocket in a way unique from the approved drugs. This 
suggests the structure of the compound could be further modified to create a new NNRTI or even 
a novel class of RT inhibitors with a distinct resistance profile. While more research should be 
performed to better understand RPV, the data presented in this dissertation demonstrates the 
utility of RPV for PrEP and as a step toward future anti-HIV-1 drugs.  
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APPENDIX: ABBREVIATIONS PRESENTED WITHIN THE WORK 
AIDS – acquired immunodeficiency syndrome  
AAALAC – American Association of Accreditation of Laboratory Animal Care  
APOBEC3 – apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3  
ART – antiretroviral therapy  
BLT – bone marrow, liver, thymus 
CAB – cabotegravir 
CAB LA – long-acting cabotegravir 
CCR5 – C-C chemokine receptor type 5 
CD3 – cluster of differentiation 3 
CD4 – cluster of differentiation 4 
CD8 – cluster of differentiation 8 
CD34 – cluster of differentiation 34 
CD45 – cluster of differentiation 45 
cDMEM – complete Dulbecco’s modified Eagle’s medium 
cDNA – complementary deoxyribonucleic acid 
CPE – cytopathic effect  
CRF – circulating recombinant form 
CXCR4 – C-X-C chemokine receptor type 4 
DAP – dapivirine  
DMEM – Dulbecco’s modified Eagle’s medium 
DNA – deoxyribonucleic acid 
dNTP – deoxynucleoside triphosphate 
DMPA – depot medroxyprogesterone 
DRM – drug resistant mutation 
EC50 – effective concentration to prevent 50% infection 
EC90 – effective concentration to prevent 90% infection 
EFV – efavirenz 
Env – HIV-1 envelope protein 
ETR – etravirine 
FBS – fetal bovine serum 
FDA – Food and Drug Administration 
FTC – emtricitabine 
GALT – gut-associated lymphoid tissue 
HIV-1 – human immunodeficiency virus type 1 
HSV-2 – herpes simplex virus type 2 
IACUC – Institutional Animal Care and Use Committee  
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IL-2 – interleukin-2 
IM – intramuscular 
IU – infectious units 
IV – intravenous 
IVR – intravaginal ring 
LC-MS/MS – liquid chromatograph-tandem mass spectrometry  
LN – lymph node 
MOI – multiplicity of infection 
mRNA – messenger RNA 
MSM – men who have sex with men 
MVC – maraviroc 
NIH – National Institute of Health 
NK – natural killer 
NNRTI – non-nucleoside reverse transcriptase inhibitor 
NRTI –nucleoside reverse transcriptase inhibitor 
NSG – NOD-Prkdcscid IL2rgTm1Wjl 
NVP – nevirapine 
PAEC90 – protein-adjusted effective concentration to prevent 90% of infections 
PBMC – peripheral blood mononuclear cells 
PBS – phosphate buffered saline 
PFA – foscarnet 
PIC – pre-integration complex 
PK – pharmacokinetic 
PrEP – pre-exposure prophylaxis 
QC – quality control 
qRT-PCR – quantitative reverse transcriptase PCR 
RAL – raltegravir 
RLU – relative light unit 
RNA – ribonucleic acid 
RPV – rilpivirine 
RPV LA – long-acting rilpivirine 
RT – reverse transcriptase 
Pol II – human RNA polymerase II 
scid – Severe combined immunodeficiency 
SHIV – simian-human immunodeficiency virus 
siRNA – small interfering ribonucleic acid 
SIV – simian immunodeficiency virus 
T-20 – enfuvirtide 
TAR – transactivation-response 
TFV – tenofovir 
US – United States 
vDNA – viral deoxyribonucleic acid 
vRNA – viral ribonucleic acid 
WHO – World Health Organization 
WT – wild-type 
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